Sentence,class,file
http://dx.doi.org/10.1111/j.1574- 6968.2011.02221.x .,Non-OADS,/arxiv_data1/oa_pdf/02/fe/mBio.01697-14.PMC4196230.pdf
25:859 – 868. http://dx.doi.org/10.1093/molbev/msn027 .,Non-OADS,/arxiv_data1/oa_pdf/02/fe/mBio.01697-14.PMC4196230.pdf
http://dx.doi.org/10.1126/science.1167140 .,Non-OADS,/arxiv_data1/oa_pdf/02/fe/mBio.01697-14.PMC4196230.pdf
http://dx.doi.org/ 10.1101/gr.1358104 .,Non-OADS,/arxiv_data1/oa_pdf/02/fe/mBio.01697-14.PMC4196230.pdf
31:857– 871. http://dx.doi.org/10.1093/molbev/msu004 .,Non-OADS,/arxiv_data1/oa_pdf/02/fe/mBio.01697-14.PMC4196230.pdf
http://dx.doi.org/ 10.1093/bioinformatics/btp393 .,Non-OADS,/arxiv_data1/oa_pdf/02/fe/mBio.01697-14.PMC4196230.pdf
Bioinformatics23:673– 679. http://dx.doi.org/10.1093/bioinformatics/btm009 .,OADS,/arxiv_data1/oa_pdf/02/fe/mBio.01697-14.PMC4196230.pdf
http://dx.doi.org/10.1093/nar/gkt090 .,Non-OADS,/arxiv_data1/oa_pdf/02/fe/mBio.01697-14.PMC4196230.pdf
Science 278: 631– 637. http://dx.doi.org/10.1126/ science.278.5338.631 .,Non-OADS,/arxiv_data1/oa_pdf/02/fe/mBio.01697-14.PMC4196230.pdf
http://dx.doi.org/10.1101/ gr.092759.109 .,Non-OADS,/arxiv_data1/oa_pdf/02/fe/mBio.01697-14.PMC4196230.pdf
http://dx.doi.org/10.1093/bioinformatics/btl446 .,Non-OADS,/arxiv_data1/oa_pdf/02/fe/mBio.01697-14.PMC4196230.pdf
http://dx.doi.org/10.1093/ molbev/mst059 .,Non-OADS,/arxiv_data1/oa_pdf/02/fe/mBio.01697-14.PMC4196230.pdf
http://dx.doi.org/10.1093/molbev/mst010 .,OADS,/arxiv_data1/oa_pdf/02/fe/mBio.01697-14.PMC4196230.pdf
http://dx.doi.org/ 10.1177/1094342013495095 .,Non-OADS,/arxiv_data1/oa_pdf/02/fe/mBio.01697-14.PMC4196230.pdf
http://dx.doi.org/10.1093/nar/gkq291 .,Non-OADS,/arxiv_data1/oa_pdf/02/fe/mBio.01697-14.PMC4196230.pdf
http://dx.doi.org/10.1016/0378- 1119(84)90111-2 .,OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/10.1007/BF00337820 .,Non-OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
Plasmid 17:37– 45. http://dx.doi.org/10.1016/0147-619X(87)90006-0 .,OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/ 10.1016/0147-619X(88)90028-5 .,OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
15:5479. http://dx.doi.org/10.1093/nar/15.13.5479 .,Non-OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/10.1089/mdr.2010.0042 .,OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/10.1128/AAC.47.1.342-349.2003 .,Non-OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/10.1016/0378- 1119(94)00905-8 .,OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/ 10.1089/mdr.2011.0037 .,Non-OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/10.1128/AAC.01407-08 .,Non-OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/10.1093/jac/dkh251 .,Non-OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
55:453– 454. http://dx.doi.org/10.1128/ AAC.00866-10 .,Non-OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/10.1111/j.1348-0421.1994.tb01741.x .,Non-OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/10.1128/AAC.49.8.3541-3543.2005 .,Non-OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/10.1093/jac/ dks459 .,Non-OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/ 10.1099/mic.0.27773-0 .,Non-OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/10.1146/annurev.genet.42.110807.091656 .,Non-OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/10.1128/AAC.01502-06 .,Non-OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
58:669 – 672. http://dx.doi.org/10.1093/jac/dkl302 .,Non-OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/10.1111/1574-6968.12084 .,Non-OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/10.1128/mBio.00915-14 .,Non-OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
198: 84 – 89. http://dx.doi.org/10.1007/BF00328705 .,Non-OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/10.1007/BF00425660 .,Non-OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
Plasmid 14: 80 – 89. http://dx.doi.org/10.1016/0147-619X(85)90034-4 .,OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/10.1016/0378-1119(83)90137-3 .,OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/10.1111/1574-6976.12067 .,Non-OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
http://dx.doi.org/10.1016/ 0378-1119(89)90160-1 .,OADS,/arxiv_data1/oa_pdf/8f/be/mBio.01801-14.PMC4196232.pdf
ACKNOWLEDGMENTS This work was supported by a grant from the Deutsche Forschungsge- meinschaft (DFG) ( http://www.dfg.de ) to G.H.,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
from the German Ministry for Education and Research (BMBF)( http://www.bmbf.de/ ; Medizinische Infektionsgenomik BMBF 0315834 A).,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1371/ journal.pntd.0000460 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1016/S0966-842X(97)01061-5 .,OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1016/ j.chom.2008.05.018 .,OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1242/jcs.00695 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1016/j.celrep.2013.04.027 .,OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1038/ nrm3284 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/ 10.1073/pnas.1314138111 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1083/jcb.200804023 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1038/nbt.1611 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1016/ j.micinf.2014.02.008 .,OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1515/BC.2011.081 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/ 10.1016/j.cub.2007.08.042 .,OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
Cell3:791– 802. http://dx.doi.org/10.1016/S1534-5807(02)00366-0 .,OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1111/j.1438- 8677.2008.00165.x .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1074/jbc.M804962200 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1083/ jcb.200710039 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1038/nature07578 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
Methods5:605– 607. http://dx.doi.org/10.1038/nmeth.1220 .,OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1111/j.1462- 5822.2010.01465.x .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
Haemost.106:475– 483. http://dx.doi.org/10.1160/TH11-05-0305 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1038/sj.onc.1208101 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
Cell 13:677– 690. http://dx.doi.org/10.1016/j.devcel.2007.09.001 .,OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1016/S1534-5807(02)00371-4 .,OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1128/ MCB.05734-11 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1016/ S0960-9822(00)80115-3 .39.,OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1016/j.jmb.2010.10.002 .,OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1128/IAI.01340-09 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1242/jcs.02351 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/ 10.1111/cmi.12256 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1083/ jcb.201006031 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1074/ jbc.M501573200 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
Mol.Cancer 9:164. http://dx.doi.org/10.1186/1476-4598-9-164 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
18:7174. http://dx.doi.org/10.1093/nar/18.23.7174 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1126/science.1106823 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
Cell 16:4648 – 4659. http://dx.doi.org/10.1091/ mbc.E05-03-0267 .,OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/ 10.1038/sj.leu.2405039 .,Non-OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
8:68 – 82. http://dx.doi.org/ 10.1016/j.molonc.2013.09.003 .Volceanov et al.,OADS,/arxiv_data1/oa_pdf/e1/17/mBio.01802-14.PMC4196233.pdf
http://dx.doi.org/10.1016/j.tvjl.2007.01.014 .,OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
53:27.http://dx.doi.org/ 10.1186/1751-0147-53-27 .,Non-OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
153: 59 – 66. http://dx.doi.org/10.1016/ j.vetmic.2011.04.005 .,OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1128/JB.01807-07 .,Non-OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
183: 4451– 4458. http://dx.doi.org/10.1128/JB.183.15.4451- 4458.2001 .,Non-OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1371/ journal.ppat.1001210 .,Non-OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1016/0378-1135(93)90133-R .,OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1016/0378-1135(96)00054-5 .,OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1016/j.vetmic.2012.09.028 .,OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/ 10.1128/JCM.03485-13 .,Non-OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1038/nbt1302 .,Non-OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1016/ j.vetmic.2012.12.020 .,OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
56:29.http://dx.doi.org/10.1186/ 1751-0147-56-29 .,Non-OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
BMCGenomics 12:402. http://dx.doi.org/10.1186/1471-2164-12-402 .,OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/ 10.1093/molbev/msj030 .,Non-OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1016/j.vetmic.2013.11.013 .,OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1099/ 13500872-141-9-2081 .,Non-OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1099/00221287-137-9-2117 .,Non-OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/ 10.1016/0378-1119(95)00315-W .,OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1016/j.vetmic.2006.04.018 .,OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1016/ j.anaerobe.2009.02.005 .,OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
Rev.64:412– 434. http://dx.doi.org/10.1128/MMBR.64.2.412-434.2000 .,Non-OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/ 10.1111/j.1574-6976.2010.00231.x .,Non-OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1111/j.1365- 2958.1995.mmi_17010183.x .,Non-OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1016/ j.vetmic.2010.06.024 .,OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1016/S0378- 1135(98)00206-5 .,OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/ 10.1111/j.1365-2958.1991.tb00726.x .,Non-OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1371/journal.pone.0047932 .,Non-OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1016/j.vaccine.2013.01.043 .,OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1111/j.1574- 6968.1998.tb13344.x .,Non-OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1371/journal.pcbi.1000386 .,Non-OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1086/519795 .,Non-OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1093/molbev/msr121 .,Non-OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
215: 403– 410. http://dx.doi.org/ 10.1016/S0022-2836(05)80360-2 .Comparative Genomics of D. nodosus September/October 2014 Volume 5 Issue 5 e01821-14®mbio.asm.org 11,OADS,/arxiv_data1/oa_pdf/55/77/mBio.01821-14.PMC4196234.pdf
http://dx.doi.org/10.1016/S0924 -8579(10)70003-0 .,OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
6:29 – 40. http://dx.doi.org/10.1038/nrd2201 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1126/science.1176667 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
70:461– 477. http://dx.doi.org/10.1021/ np068054v .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://www.who.int/foodborne_disease/resistance/antimicrobials_human.pdf .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1016/0006-291X(78)91493 -6.,OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1016/j.jmb.2004.08.097 .,OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
6:244. http://dx.doi.org/10.1038/nchembio0310-244a .,OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1038/35030019 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1093/nar/gki862 .,OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1002/ cbic.200300657 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
346:467– 475. http://dx.doi.org/10.1016/j.jmb.2004.11.073 .,OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1128/AAC.49.12.5112-5118.2005 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1128/ AAC.50.4.1489-1496.2006 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1093/emboj/18.11.3133 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1093/embo-reports/kve062 .,OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
35: 6086 – 6093. http://dx.doi.org/10.1093/nar/gkm658 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1261/rna.805208 .,OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1002/ijch.201000003 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1159/000013861 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
7:5. http://dx.doi.org/10.1186/1472 -6815-7-5 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1038/ng0793-289 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1086/381133 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/ 10.1073/pnas.0707265105 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1073/ pnas.0811258106 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1074/jbc.M113.533588 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
54:4636 – 4642. http://dx.doi.org/10.1128/AAC.00572-10 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/ 10.1002/anie.200500903 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1021/ml200202y .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
105: 477– 498. http://dx.doi.org/ 10.1021/cr0301088 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1002/cbic.200900779 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1523/JNEUROSCI.3430-12.2013 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
5:3112. http://dx.doi.org/ 10.1038/ncomms4112 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/ 10.1002/hlca.200890167 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1038/nrd3845 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1021/ja000575w .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
http://dx.doi.org/10.1021/ja0543144 .,Non-OADS,/arxiv_data1/oa_pdf/fe/3e/mBio.01827-14.PMC4196235.pdf
7:429 – 431. http://dx.doi.org/10.1038/ ncb1243 .,Non-OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
http://dx.doi.org/10.1371/journal.ppat.0020085 .,Non-OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
http://dx.doi.org/ 10.1038/ncb2364 .,Non-OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
14:693– 697. http://dx.doi.org/10.1038/nrm3681 .,Non-OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
http://dx.doi.org/10.4161/nucl.25960 .,Non-OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
CellRes.120:451– 455. http://dx.doi.org/10.1016/0014-4827(79)90412-9 .,OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
http://dx.doi.org/10.1152/ajpcell.00066.2006 .,OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
http://dx.doi.org/10.1074/jbc.M109.063768 .,Non-OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
http://dx.doi.org/ 10.1073/pnas.1103411108 .,Non-OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
http://dx.doi.org/10.1128/JVI.02124-07 .,Non-OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
http://dx.doi.org/10.1371/ journal.pone.0040585 .,Non-OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
Methods5:605– 607. http://dx.doi.org/10.1038/nmeth.1220 .,OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
http://dx.doi.org/ 10.1038/nmeth0310-168 .,Non-OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
http://dx.doi.org/10.1111/j.1365-2818.2009.03300.x .,Non-OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
http://dx.doi.org/10.1074/ jbc.275.7.5163 .,Non-OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
http://dx.doi.org/10.1074/ jbc.M206393200 .,Non-OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
http://dx.doi.org/10.1091/mbc.E12-09-0685 .,Non-OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
Science 314: 464 – 467. http://dx.doi.org/10.1126/science.1133348 .,Non-OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
Methods 6:317. http://dx.doi.org/10.1038/nmeth0509-317 .,OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
http://dx.doi.org/10.1007/ s00418-013-1151-4 .,Non-OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
http://dx.doi.org/10.1073/ pnas.1103411108 .,Non-OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
Methods9:676 – 682. http://dx.doi.org/10.1038/nmeth.2019 .F-Actin Is Not Involved in Nuclear Capsid Motility September/October 2014 Volume 5 Issue 5 e01909-14®mbio.asm.org 9,Non-OADS,/arxiv_data1/oa_pdf/f0/da/mBio.01909-14.PMC4196236.pdf
http://dx.doi.org/10.1128/CMR.00111-13 .,Non-OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.1080/17453670902805064 .,Non-OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.1038/nrmicro1384 .,OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.1086/656047 .,OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.1128/ IAI.70.10.5428-5437.2002 .,Non-OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.1128/JB.187.9.2967 -2973.2005 .,Non-OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.1099/jmm.0.009720-0 .,Non-OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.1099/jmm.0.066068-0 .,Non-OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.1086/507633 .,Non-OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.1016/ j.diagmicrobio.2012.06.029 .,OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.1086/516962 .,Non-OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.1128/JCM.01562-09 .,Non-OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.1007/s11999-011-2102-9 .,Non-OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.1093/cid/cis803 .,OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
39:603– 608. http://dx.doi.org/10.1093/jac/39.5.603 .,Non-OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.1128/JCM.01510-06 .,Non-OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.1093/cid/cit270 .,OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.1086/515238 .,Non-OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.1128/ AAC.49.3.1216-1219.2005 .,Non-OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.1128/AAC.44.6.1616 -1623.2000 .,Non-OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.2147/CLEP.S29025 .,Non-OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
357: 654 – 663. http://dx.doi.org/10.1056/ NEJMoa061588 .,Non-OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/ 10.1016/j.jse.2011.06.016 .,OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
188:687– 693. http://dx.doi.org/ 10.1128/JB.188.2.687-693.2006 .,Non-OADS,/arxiv_data1/oa_pdf/2f/2d/mBio.01910-14.PMC4196237.pdf
http://dx.doi.org/10.1371/ journal.ppat.1002158 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1093/ jac/dkp256 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/ 10.1093/jac/dkp101 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1128/ AAC.01707-08 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1038/335351a0 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
12:53. http://dx.doi.org/10.1186/1471-2180-12-53 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.2165/11533040 -000000000-00000 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1016/j.ijmm.2013.02.008 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1111/ j.1600-0463.2008.00922.x .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
67:74 – 83. http://dx.doi.org/ 10.1093/jac/dkr405 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1093/jac/dkt044 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1111/j.1462-2920.2006.01091.x .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1016/j.tim.2006.02.006 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
35:790 – 819. http://dx.doi.org/10.1111/ j.1574-6976.2011.00273.x .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/ 10.1016/j.envres.2012.01.002 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1021/cr00094a002 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1016/S0883-2927(02)00018-5 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1021/es026219q .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1016/S0048-9697(03)00052-4 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1080/10915810305087 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1016/j.resconrec.2005.03.002 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1196/annals.1454.049 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1128/AEM.02979-05 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
Antibiotics in the aquatic environment—a review— part I. Chemosphere 75:417– 434. http://dx.doi.org/10.1016/ j.chemosphere.2008.11.086 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
Chemosphere 75:435– 441. http://dx.doi.org/10.1016/ j.chemosphere.2008.12.006 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
Health Perspect.121:878 – 885. http://dx.doi.org/10.1289/ehp.1206446 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1016/j.jhazmat.2007.07.008 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
27:80 – 86. http://dx.doi.org/10.1897/07-080.1 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1016/j.chemosphere.2010.10.026 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1093/cid/cit355 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
41:613– 619. http://dx.doi.org/10.1016/j.watres.2006.11.014 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/ 10.1371/journal.pone.0028674 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1016/ 0022-2836(80)90065-0 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1146/ annurev.ge.14.120180.000353 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1016/0022-2836(91)90878 -A.,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1128/JB.188.2.507-514.2006 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/ 10.1016/j.chemosphere.2011.03.022 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
367: 481– 497. http://dx.doi.org/ 10.1016/j.scitotenv.2006.04.002 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/ 10.1007/s11270-010-0412-2 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1016/ j.envpol.2011.12.034 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1007/BF02380485 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
Arsenic in ground water of the United States: occurrence and geochemistry.Ground Water 38:589 – 604. http://dx.doi.org/10.1111/j.1745 -6584.2000.tb00251.x .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
Nature 395:338. http://dx.doi.org/10.1038/26387 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/ 10.1126/science.1076978 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1038/333134a0 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1016/0883-2927(95)00084-4 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
ACSNano 5:8950 – 8957. http://dx.doi.org/10.1021/nn2031319 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1016/ j.scitotenv.2005.11.029 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1016/ j.envpol.2005.09.004 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1007/s10653-009-9259-0 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1016/j.envint.2010.10.012 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1016/j.microc.2009.09.014 .75.,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/ 10.1016/j.scitotenv.2011.04.020 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1016/j.chemosphere.2004.07.017 .,OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/ 10.1093/nar/25.6.1203 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
3:4. http://dx.doi.org/10.1186/1754-1611-3-4 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1146/ annurev.es.21.110190.002105 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/ 10.1073/pnas.37.3.146 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1186/gb-2009-10-10-r118 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
http://dx.doi.org/10.1093/molbev/msu111 .Selection at Low Levels of Antibiotics and Metals September/October 2014 Volume 5 Issue 5 e01918-14®mbio.asm.org 9,Non-OADS,/arxiv_data1/oa_pdf/8a/b3/mBio.01918-14.PMC4196238.pdf
"All 4,217 sequence-veriﬁed genes of M. tuberculosis in a mammalian expression vector, pANT7_GST, were obtained fromDNASU (http://dnasu.org/DNASU/), including 3,816 clones from strainH37Rv and 401 clones from strain CDC1551.",OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/ 10.1101/gad.1299905 .,Non-OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.4161/cib.3.6.12756 .,Non-OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/ 10.1371/journal.pone.0011113 .,Non-OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
Cell 7:58 – 67. http://dx.doi.org/10.1128/EC.00370 -07.,OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.1172/JCI44261 .,Non-OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
J. Proteomics 106C: 46 – 60. http://dx.doi.org/ 10.1016/j.jprot.2014.04.023 .,OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/ 10.1016/j.immuni.2010.09.015 .,OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.1016/j.vaccine.2009.10.014 .,OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.1371/journal.pone.0015692 .,Non-OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
76:4554 – 4563. http://dx.doi.org/10.1128/IAI.00532-08 .,Non-OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
Vaccine 29:6236 – 6241. http://dx.doi.org/10.1016/ j.vaccine.2011.06.077 .,Non-OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.1126/science.1097639 .,Non-OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.1146/annurev.immunol.19.1.93 .,Non-OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.4049/jimmunol.173.4.2660 .,OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.1128/IAI.01311-09 .,Non-OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.1084/ jem.20021911 .,Non-OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.1016/j.vaccine.2011.06.001 .,OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
77:472– 484. http://dx.doi.org/10.1128/IAI.01139-08 .,Non-OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
190:4092– 4102. http://dx.doi.org/ 10.4049/jimmunol.1200742 .,Non-OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.1016/j.chom.2013.02.009 .,OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
93:448 – 455. http://dx.doi.org/10.1016/ j.tube.2013.03.001 .,OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.1038/nrmicro2321 .,OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
13:843– 850. http://dx.doi.org/ 10.1038/nm1592 .,OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.1084/jem.20052433 .,Non-OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
77: 622– 631. http://dx.doi.org/10.1128/IAI.00685-08 .,Non-OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.1038/nm.2285 .,OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
181: 4955– 4964. http://dx.doi.org/10.4049/jimmunol.181.7.4955 .,Non-OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.1038/nm.2420 .,OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.1046/ j.1365-2567.1997.00358.x .,Non-OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
79:663– 673. http://dx.doi.org/10.1128/IAI.00806-10 .,Non-OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.1016/j.vaccine.2011.11.055 .,OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.1002/pmic.200900840 .,Non-OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.1016/j.immuni.2005.12.001 .,OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/10.1016/j.mimet.2006.05.016 .,OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
http://dx.doi.org/ 10.1021/pr100686b .Prados-Rosales et al.,OADS,/arxiv_data1/oa_pdf/c3/0e/mBio.01921-14.PMC4196239.pdf
"Available from: http://www.medicaid.nv.gov/Downloads/provider/web_announcement_468_20120425.pdf [Accessed January 14, 2013].",OADS,/arxiv_data1/oa_pdf/20/19/TORJ-8-54.PMC4196249.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/ 3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/20/19/TORJ-8-54.PMC4196249.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/ 3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/07/75/TORJ-8-69.PMC4196250.pdf
"Avail- able at http://image.guardian.co.uk/sys-files/Society/documents/  2004/02/12/Bennett.pdf  [46] Gaskin CJ, Elsom SJ, Happel B.",Non-OADS,/arxiv_data1/oa_pdf/cd/2a/CPEMH-10-94.PMC4196251.pdf
Available from: http://dx.doi.org/10.1016/j.clml.,OADS,/arxiv_data1/oa_pdf/a7/95/JOMFP-18-152.PMC4196279.pdf
Start a QR-code reading software (see list of free applications from http://tinyurl.com/ yzlh2tc) and point the camera to the QR-code printed in the journal.,Non-OADS,/arxiv_data1/oa_pdf/c9/5b/JOMFP-18-155.PMC4196280.pdf
See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3ysr3me for the free  applications.,Non-OADS,/arxiv_data1/oa_pdf/c9/5b/JOMFP-18-155.PMC4196280.pdf
The  application can be downloaded from https://market.android.com/details?id=comm.app.medknow.,Non-OADS,/arxiv_data1/oa_pdf/dd/bf/JOMFP-18-183.PMC4196284.pdf
The application can be downloaded from http://itunes.apple.com/us/app/medknow-journals/ id458064375?ls=1&mt=8.,Non-OADS,/arxiv_data1/oa_pdf/52/e3/JOMFP-18-189.PMC4196285.pdf
Internet J Dent Sci 2009;7 (2): http://ispub.com/ IJDS/7/2/7150.,Non-OADS,/arxiv_data1/oa_pdf/28/0a/JOMFP-18-201.PMC4196287.pdf
Available from: http://coffeetea.about.,Non-OADS,/arxiv_data1/oa_pdf/28/0a/JOMFP-18-201.PMC4196287.pdf
Available from:  http://ezinearticles.com/?chicory-a-healthy-coffee-substitute  and id=4522093 [Last accessed on 2010 Sept 12].,Non-OADS,/arxiv_data1/oa_pdf/28/0a/JOMFP-18-201.PMC4196287.pdf
Available	 from:	http://herbs.ygoy.com/2009/05/20/benefits‑of‑chicory/[Last	 accessed	on	 2010 Sept 12].,Non-OADS,/arxiv_data1/oa_pdf/28/0a/JOMFP-18-201.PMC4196287.pdf
Available from: http://www.herbs2000.com/ herbs/herbs_chicory.htm [Last accessed on 2010 Sept 12].,Non-OADS,/arxiv_data1/oa_pdf/28/0a/JOMFP-18-201.PMC4196287.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/28/0a/JOMFP-18-201.PMC4196287.pdf
"[29,30]  There are currently 1872 precursor and 2578 mature human  miRNA sequences listed in the miRNA registry (Sanger  miRBase release 20; http://www.mirbase.org/).",Non-OADS,/arxiv_data1/oa_pdf/6b/5b/JOMFP-18-229.PMC4196292.pdf
Available from:  http://chromagar.com [Last accessed on 13 May 2013].,Non-OADS,/arxiv_data1/oa_pdf/0c/11/JOMFP-18-235.PMC4196293.pdf
Available from: http://doctorfungus.org/the fungi  rhodotorula- mucilaginosa.htm [Last accessed on 12 Feb 2013].,Non-OADS,/arxiv_data1/oa_pdf/0c/11/JOMFP-18-235.PMC4196293.pdf
Available  from: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3634b1a_tab4d.,Non-OADS,/arxiv_data1/oa_pdf/0b/8c/SJG-20-267.PMC4196340.pdf
"FDA Talk Paper: FDA Warns Against Women Using  Unapproved Drug, Domperidone, to increase milk production available  from: http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ ucm173886.htm, 2004.",Non-OADS,/arxiv_data1/oa_pdf/0b/8c/SJG-20-267.PMC4196340.pdf
"Available from: http://www.hc‑sc.gc.ca/dhp‑mps/medeff/advisories‑avis/ index‑eng.php, 2012.",Non-OADS,/arxiv_data1/oa_pdf/0b/8c/SJG-20-267.PMC4196340.pdf
"Available from:  http://www.sfda.gov.sa: 80/ar/drug/circulations/DocLib/35586.pdf, 2014.",OADS,/arxiv_data1/oa_pdf/0b/8c/SJG-20-267.PMC4196340.pdf
Available from: http://globocan.iarc.fr/Pages/fact_ sheets_cancer.aspx?cancer=stomach) World Health Organization.,Non-OADS,/arxiv_data1/oa_pdf/85/ef/SJG-20-309.PMC4196347.pdf
Available from:  http://www.dnaindia.com/health/report‑stomach‑   cancer‑second‑biggest‑killer‑in‑india‑1670749).,Non-OADS,/arxiv_data1/oa_pdf/85/ef/SJG-20-309.PMC4196347.pdf
Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.,Non-OADS,/arxiv_data1/oa_pdf/07/82/SJG-20-315.PMC4196348.pdf
Available from: http://www.census.,OADS,/arxiv_data1/oa_pdf/27/17/JLP-6-102.PMC4196356.pdf
Available from: http://www.qimaging.com/support/pdfs/he_technote.,OADS,/arxiv_data1/oa_pdf/22/36/JLP-6-84.PMC4196369.pdf
Available from:  http://www.cdc.gov/niosh/75‑168.html.,OADS,/arxiv_data1/oa_pdf/22/36/JLP-6-84.PMC4196369.pdf
Available from: http://www.en.wikipedia.org/wiki/Detergent.,Non-OADS,/arxiv_data1/oa_pdf/22/36/JLP-6-84.PMC4196369.pdf
Available from: http://www.technogreen.,Non-OADS,/arxiv_data1/oa_pdf/22/36/JLP-6-84.PMC4196369.pdf
Available from: http://www.ihcworld.,Non-OADS,/arxiv_data1/oa_pdf/22/36/JLP-6-84.PMC4196369.pdf
Available  from: http://www.dako.com/08066_12may10_webchapter  13.pdf.,Non-OADS,/arxiv_data1/oa_pdf/22/36/JLP-6-84.PMC4196369.pdf
Available  from: http://www.ihcworld.com/royellis/problems/problem25.htm.,Non-OADS,/arxiv_data1/oa_pdf/22/36/JLP-6-84.PMC4196369.pdf
Available from: http://antimicrobianos.com.ar/ATB/wp‑content/ uploads/2012/11/M100S22E.pdf  [Last assessed on 2014 May 15].,Non-OADS,/arxiv_data1/oa_pdf/8d/12/JLP-6-91.PMC4196370.pdf
"G&I    Genomics & InformaticseISSN 2234-0742 Genomics Inform  2014;12(3):105-113 http://dx.doi.org/10.5808/GI.2014.12.3.105 REVIEW ARTICLE Received July 29, 2014; Revised August 11, 2014; Accepted August 14, 2014 *Corresponding author:  Tel: +1-225-578-7692, Fax: +1-225-578-2597, E-mail: jkim@lsu.edu Copyright © 2014 by the Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Regulation and Function  of the Peg3 Imprinted Domain Hongzhi He, Joomyeong Kim* Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803,USA A subset of mammalian genes differ functionally between tw o alleles due to genomic imprinting, and seven such genes  (Peg3, Usp29, APeg3, Zfp264, Zim1, Zim2, Zim3 ) are localized within the 500-kb genomic interval of the human and mouse  genomes, constituting the Peg3 imprinted domain.",Non-OADS,/arxiv_data1/oa_pdf/e7/18/gni-12-105.PMC4196374.pdf
http://dx.doi.org/10.1038/onc.2014.38.,Non-OADS,/arxiv_data1/oa_pdf/e7/18/gni-12-105.PMC4196374.pdf
"G&I    Genomics & InformaticseISSN 2234-0742 Genomics Inform  2014;12(3):114-120 http://dx.doi.org/10.5808/GI.2014.12.3.114 ORIGINAL ARTICLE Received July 30, 2014; Revised August 14, 2014; Accepted August 19, 2014 *Corresponding author:  Tel: +82-54-279-2350, Fax: +82-54-279-8179, E-mail: tyroh@postech.edu Copyright © 2014 by the Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).A Follow-up Association Study of Genetic Variants for  Bone Mineral Density in a Korean Population Seokjin Ham1, Tae-Young Roh1,2* 1Department of Life Sciences, POSTECH, Pohang 790-784, Korea,  2Division of Integrative Biosciences and Biotechnology, POSTECH, Pohang 790-784, Korea Bone mineral density (BMD) is one of the quantitative traits th at are genetically inherited and affected by various factors.",Non-OADS,/arxiv_data1/oa_pdf/b8/f4/gni-12-114.PMC4196375.pdf
"G&I    Genomics & InformaticseISSN 2234-0742 Genomics Inform  2014;12(3):121-126 http://dx.doi.org/10.5808/GI.2014.12.3.121 ORIGINAL ARTICLE Received June 30, 2014; Revised July 18, 2014; Accepted July 20, 2014 *Corresponding author:  Tel: +82-53-580-3843, Fax: +82-53-580-3788, E-mail: wonki@dsmc.or.kr Copyright © 2014 by the Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Genome-Wide Association Study of  Medication Adherence in Chronic Diseases  in the Korean Population Incheol Seo, Seong-Il Suh, Min-Ho Suh, Won-Ki Baek* Department of Microbiology, Keimyung University School of Medicine, Daegu 704-701, Korea Medication adherence is generally defined as the extent of voluntary cooperation of a patient in taking medicine as  prescribed.",Non-OADS,/arxiv_data1/oa_pdf/94/e2/gni-12-121.PMC4196376.pdf
Available from: http://www.who.,Non-OADS,/arxiv_data1/oa_pdf/94/e2/gni-12-121.PMC4196376.pdf
Available from: http://cran.r-project.org/web/pack- ages/qqman/.,Non-OADS,/arxiv_data1/oa_pdf/94/e2/gni-12-121.PMC4196376.pdf
"3, 2014G&I    Genomics & InformaticseISSN 2234-0742 Genomics Inform  2014;12(3):127-133 http://dx.doi.org/10.5808/GI.2014.12.3.127 ORIGINAL ARTICLE Received June 30, 2014; Revised August 6, 2014; Accepted August 12, 2014 *Corresponding author:  Tel: +82-41-550-3484, Fax: +82-41-550-1149, E-mail: sejongoh@dankook.ac.kr Copyright © 2014 by the Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Epidemiological and Genome-Wide Association Study  of Gastritis or Gastric Ulcer in Korean Populations Sumin Oh, Sejong Oh* Department of Nanobiomedical Science, Dankook University, Cheonan 330-714, Korea Gastritis is a major disease that has the potential to grow as gastric cancer.",Non-OADS,/arxiv_data1/oa_pdf/fd/e0/gni-12-127.PMC4196377.pdf
"4, 2012 *Corresponding author:  Tel: +82-2-2258-7343, Fax: +82-2-537-0572, E-maill: yejun@catholic.ac.kr Copyright © 2014 by the Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).G&I    Genomics & InformaticseISSN 2234-0742 Genomics Inform  2014;12(3):79 http://dx.doi.org/10.5808/GI.2014.12.3.79 EDITORIAL Editor’s Introduction to This Issue Yeun-Jun Chung* IRCGP , The Catholic University of Korea College of Medicine, Seoul 137-701, Korea Transposable elements (TEs) are genetic elements that  have the potential to move from one site to another in the  genome.",Non-OADS,/arxiv_data1/oa_pdf/5f/95/gni-12-79.PMC4196378.pdf
"G&I    Genomics & InformaticseISSN 2234-0742 Genomics Inform  2014;12(3):80-86 http://dx.doi.org/10.5808/GI.2014.12.3.80 REVIEW ARTICLE Received July 17, 2014; Revised August 18, 2014; Accepted August 19, 2014 *Corresponding author:  Tel: +82-2-880-1364, Fax: +82-2-880-1366, E-mail: kimbd@snu.ac.kr Copyright © 2014 by the Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Foldback Intercoil DNA and the Mechanism of  DNA Transposition Byung-Dong Kim1,2* 1Department of Plant Science, Seoul National University, Seoul 151-921, Korea, 2The Korean Academy of Science and Technology, Seongnam 463-808, Korea Foldback intercoil (FBI) DNA is formed by  the folding back at one point of a non-he lical parallel track of double-stranded DNA  at as sharp as 180° and the intertwining of two double helixes within each other’s major groove to form an intercoil with a  diameter of 2.2 nm.",Non-OADS,/arxiv_data1/oa_pdf/21/87/gni-12-80.PMC4196379.pdf
"G&I    Genomics & InformaticseISSN 2234-0742 Genomics Inform  2014;12(3):87-97 http://dx.doi.org/10.5808/GI.2014.12.3.87 REVIEW ARTICLE Received July 18, 2014; Revised August 18, 2014; Accepted August 22, 2014 *Corresponding author:  Tel: +82-33-250-6472, Fax: +82-33-259-5641, E-mail: kimnamsu@kangwon.ac.kr Copyright © 2014 by the Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Transposable Elements and Genome Size  Variations in Plants Sung-Il Lee, Nam-Soo Kim* Department of Molecular Bioscience, Kangwon National University, Chuncheon 200-701, Korea Although the number of protein-coding genes is not highly va riable between plant taxa, the DNA content in their genomes  is highly variable, by as much as 2,056- fold from a 1C amount of 0.0648 pg to 132.5 pg.",Non-OADS,/arxiv_data1/oa_pdf/08/b7/gni-12-87.PMC4196380.pdf
"Using Feulgen  microdensitometry or flow cytometry, C-value has been  measured in over 6,000 plant species and categorized in the  Kew Plant DNA C-value Databases (http://data.kew.org/ cvalues/) [1, 2].",OADS,/arxiv_data1/oa_pdf/08/b7/gni-12-87.PMC4196380.pdf
"The most frequent genome size of the sequenced plant  genomes is about 500 Mbp, which is similar to the average  genome size in the Kew Plant DNA C-value Database (http://data.kew.org/cvalues).",OADS,/arxiv_data1/oa_pdf/08/b7/gni-12-87.PMC4196380.pdf
Available from: http://data.kew.org/cvalues/.,OADS,/arxiv_data1/oa_pdf/08/b7/gni-12-87.PMC4196380.pdf
Plant  Genome 2013;6. http://dx.doi.org/10.3835/plantgenome2013.,OADS,/arxiv_data1/oa_pdf/08/b7/gni-12-87.PMC4196380.pdf
http://dx.doi.org/  10.1002/9780470015902.a0002014.pub2.,Non-OADS,/arxiv_data1/oa_pdf/08/b7/gni-12-87.PMC4196380.pdf
"G&I    Genomics & InformaticseISSN 2234-0742 Genomics Inform  2014;12(3):98-104 http://dx.doi.org/10.5808/GI.2014.12.3.98 REVIEW ARTICLE Received August 4, 2014; Revised August 14, 2014; Accepted August 18, 2014 *Corresponding author:  Tel: +82-51-510-2259, Fax: +82-51-581-2962, E-mail: khs307@pusan.ac.kr Copyright © 2014 by the Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).The Impact of Transposable Elements in Genome  Evolution and Genetic Instability and Their  Implications in Various Diseases Selvam Ayarpadikannan, Heui-Soo Kim* Department of Biological Sciences, College of Natural Sciences, Pusan National University, Busan 609-735, Korea Approximately 45% of the human genome is comprised of tran sposable elements (TEs).",Non-OADS,/arxiv_data1/oa_pdf/16/3a/gni-12-98.PMC4196381.pdf
" Annals of Surgical Treatment and Research 217pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.4.217 Annals of Surgical Treatment and ResearchTECHNICAL ADVANCE Successful laparoscopic reversal of gastric bypass in a  patient with malnutrition Ji Yeon Park, Yong Jin Kim Department of Surgery, Soonchunhyang University Seoul Hospital, Seoul, Korea INTRODUCTION Roux-en-Y gastric bypass (RYGB) is one of the most commonly  performed bariatric procedures around the world.",Non-OADS,/arxiv_data1/oa_pdf/1b/8d/astr-87-217.PMC4196428.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Roux-en-Y gastric bypass (RYGB) is one of the most commonly performed bariatric procedures around the world.",Non-OADS,/arxiv_data1/oa_pdf/1b/8d/astr-87-217.PMC4196428.pdf
" Annals of Surgical Treatment and Research 203pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.4.203 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE Factors influencing on difficulty with laparoscopic total  extraperitoneal repair according to learning period Byung Soo Park, Dong Yeon Ryu, Gyung Mo Son, Yong Hoon Cho Department of Surgery, Pusan National University Yangsan Hospital, Yangsan, Korea INTRODUCTION Inguinal hernia repair is one of the most common operations  around the world [1].",Non-OADS,/arxiv_data1/oa_pdf/3c/53/astr-87-203.PMC4196429.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Purpose:  Laparoscopic total extraperitoneal (TEP) repair of inguinal hernia is technically challenging enough to build high  barrier to entry.",Non-OADS,/arxiv_data1/oa_pdf/3c/53/astr-87-203.PMC4196429.pdf
" Annals of Surgical Treatment and Research 213pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.4.213 Annals of Surgical Treatment and ResearchCASE REPORT An accessory limb with an imperforate anus Kun-Bo Park, Yeon-Mee Kim1, Ji-Yong Park, Mi-Lim Chung2, Yu-Jin Jung2, So-Hyun Nam3 Departments of Orthopaedic Surgery, 1Pathology, 2Pediatrics, and 3Pediatric Surgery, Inje University Haeundae Paik Hospital,  Busan, Korea INTRODUCTION Congenital accessory limb is a very rare anomaly.",Non-OADS,/arxiv_data1/oa_pdf/d2/a8/astr-87-213.PMC4196430.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Congenital accessory limbs are very rare anomalies with many causative factors.",Non-OADS,/arxiv_data1/oa_pdf/d2/a8/astr-87-213.PMC4196430.pdf
180pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.4.180 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE Is retrieval of at least 15 lymph nodes sufficient  recommendation in early gastric cancer?,Non-OADS,/arxiv_data1/oa_pdf/90/d1/astr-87-180.PMC4196431.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Purpose:  The evaluation and extent of lymph node (LN) retrieval is clinically relevant for staging because lymphatic  invasion is the most common mechanism leading to up-staging of carcinoma.",Non-OADS,/arxiv_data1/oa_pdf/90/d1/astr-87-180.PMC4196431.pdf
Available from:  http://www.nccn.org.,Non-OADS,/arxiv_data1/oa_pdf/90/d1/astr-87-180.PMC4196431.pdf
" Annals of Surgical Treatment and Research 185pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.4.185 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE Caudal middle hepatic vein trunk preserved right lobe  graft in living donor liver transplantation Kwangho Yang1,2, Youngmok Park1, Kimyung Moon1, Jeho Ryu1, Chongwoo Chu1,2 1Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Pusan National University Yangsan  Hospital, Pusan National University School of Medicine, Yangsan, 2Research Institute for Convergence of Biomedical Science and  Technology, Pusan National University Yangsan Hospital, Yangsan, Korea INTRODUCTION As cadaveric organ shortage becomes a critical problem, living  donor liver transplantation (LDLT) is now widely performed  to expand the donor pool, especially in East Asia [1].",Non-OADS,/arxiv_data1/oa_pdf/8c/f5/astr-87-185.PMC4196432.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Purpose: Multiple segment 5 vein (V5) anastomoses are common and inevitable in living donor liver transplantation  (LDLT) using modified right lobe (MRL) graft.",Non-OADS,/arxiv_data1/oa_pdf/8c/f5/astr-87-185.PMC4196432.pdf
" Annals of Surgical Treatment and Research 209pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.4.209 Annals of Surgical Treatment and ResearchCASE REPORT Small bowel diverticulosis in patient with early gastric  cancer  Pyeong Su Kim, Eun-Joo Jung, Ho Yoon Bang Department of Surgery, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea INTRODUCTION Diverticula of the jejunum and ileum are rare in adults [1].",Non-OADS,/arxiv_data1/oa_pdf/80/28/astr-87-209.PMC4196433.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Jejunal and ileal diverticula are rare in adults.",Non-OADS,/arxiv_data1/oa_pdf/80/28/astr-87-209.PMC4196433.pdf
"174pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.4.174 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE BRAF mutation may predict higher necessity of  postoperative radioactive iodine ablation in papillary  thyroid cancer Sang-Ah Han*, Won Seo Park1,*, Jae-Hoon Jang, Sun-Young Min1, Jung Kyu Ryu2, Jeong-Yoon Song Department of Surgery, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul,  1Department of Surgery, Kyung Hee University School of Medicine, Seoul, 2Department of Radiology, Kyung Hee University  Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea INTRODUCTION The incidence of thyroid cancer has increased more than two  folds in the United States over the past three decades [1].",Non-OADS,/arxiv_data1/oa_pdf/f2/8d/astr-87-174.PMC4196434.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Purpose: The primary aim of the present study was to analyze the association between high-risk clinicopathologic  characteristics and the BRAFV600E mutation.",Non-OADS,/arxiv_data1/oa_pdf/f2/8d/astr-87-174.PMC4196434.pdf
Available from: http://www.cancer.go.kr.,Non-OADS,/arxiv_data1/oa_pdf/f2/8d/astr-87-174.PMC4196434.pdf
Avail- able from: http://seer.cancer.gov/csr/1975_  2009_pops09/.,Non-OADS,/arxiv_data1/oa_pdf/f2/8d/astr-87-174.PMC4196434.pdf
"192pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.4.192 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE Comparative results of conventional and eversion carotid  endarterectomy Jae Hoon Lee, Bo Yang Suh1 Division of Vascular and Endovascular Surgery, Department of Surgery, Catholic University of Daegu School of Medicine, Daegu,  1Division of Vascular Surgery, Department of Surgery, Yeungnam University College of Medicine, Daegu, Korea INTRODUCTION Carotid artery stenosis, the narrowing of the lumen of the  carotid artery, decreases blood flow to the brain and is known  to cause ischemic stroke [1,2].",Non-OADS,/arxiv_data1/oa_pdf/6d/e5/astr-87-192.PMC4196435.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Purpose:  Comparative results of conventional carotid endarterectomy (cCEA) and eversion carotid endarterectomy  (eCEA) have been reported in many studies.",Non-OADS,/arxiv_data1/oa_pdf/6d/e5/astr-87-192.PMC4196435.pdf
" Annals of Surgical Treatment and Research 167pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.4.167 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE Anticancer effect of silibinin on the xenograft model  using MDA-MB-468 breast cancer cells Won Ho Kil, Sang Min Kim, Jeong Eon Lee, Kyoung Sik Park1, Seok Jin Nam Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 1Department of Surgery,  Konkuk University School of Medicine, Seoul, Korea  INTRODUCTION While the traditional criteria for classification of breast  cancer were based on type of tumor, nuclear grade, tumor size,  and presence or absence of lymph node metastasis, breast  cancer has recently been classified into several subtypes based  on the molecular profiling according to the expression of mRNA.",Non-OADS,/arxiv_data1/oa_pdf/3a/d2/astr-87-167.PMC4196436.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Purpose: The aim of this study is to know whether silibinin has an anticancer effect on triple negative breast cancer  xenograft model using MDA-MB-468 cells.",Non-OADS,/arxiv_data1/oa_pdf/3a/d2/astr-87-167.PMC4196436.pdf
"222pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.4.222 Annals of Surgical Treatment and ResearchERRATUM ERRATUM: Correction of numbering used for citing Tables Evaluating the efficacy of the current diagnosis-related  group reimbursement system for laparoscopic  appendectomy at a single institute in Korea Ri Na Yoo, Chul-Woon Chung1, Jong-Woo Kim Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, 1Department of Surgery, International St.  Mary’s Hospital, Incheon, Korea On page 153 of this paper, the reference to “Table 7” in the  sixth paragraph of the left column should be corrected to “Table  9.”  “Table 7” at the bottom of this page should also be corrected  to “Table 9.”http://dx.doi.org/10.4174/astr.2014.87.3.148 Ann Surg Treat Res 2014;87(3):148-155 The related text should read as follows: The corrected sixth paragraph of the left column on page 153: “In fact, calculating the daily cost in each group from the  total amount divided by the total length of hospital stay (Table 1), the daily cost was the greatest in the patient group with the symptom duration less than 12 hours for both DRG reimbursement and total in-patient cost, shown in Table 9 .” Table 9.",Non-OADS,/arxiv_data1/oa_pdf/58/22/astr-87-222.PMC4196437.pdf
" Annals of Surgical Treatment and Research 197pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.4.197 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE Changes in suprarenal and infrarenal aortic angles after  endovascular aneurysm repair Ho Kyun Lee, Sang Young Chung, Jea Kyu Kim1, Sung Hee Yoo2, Soo Jin Na Choi Departments of Surgery and 1Radiology, Chonnam National University Medical School, Gwangju, 2Chonnam National University  Collage of Nursing, Gwangju, Korea INTRODUCTION Endovascular repair compares favorably to open aneurysm  repair with a significant reduction in morbidity, reduced blood  loss, shorter hospital stay, and earlier return to function [1].",Non-OADS,/arxiv_data1/oa_pdf/f9/4f/astr-87-197.PMC4196438.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Purpose: We investigated whether suprarenal and infrarenal aortic angles change after the endovascular aneurysm repair  (EVAR) procedure and during follow-up, and investigated the correlation between infrarenal aortic angle after EVAR and  type Ia endoleaks.",Non-OADS,/arxiv_data1/oa_pdf/f9/4f/astr-87-197.PMC4196438.pdf
4: 311-312 pISSN 2005-9159  eISSN 2093-0569http://dx.doi.org/10.3344/kjp.2014.27.4.311 |E d i t o r i a l| Guides for Pain Clinicians?,Non-OADS,/arxiv_data1/oa_pdf/b3/61/kjpain-27-311.PMC4196494.pdf
"4: 313-320 pISSN 2005-9159  eISSN 2093-0569http://dx.doi.org/10.3344/kjp.2014.27.4.313 | Review Article | Safe Sedation and Hypnosis using Dexmedetomidine for  Minimally Invasive Spine Surgery in a Prone Position Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University, Yangsan, Korea Kyung Hoon Kim Dexmedetomidine, an imidazoline compound, is a highly selective α2-adrenoceptor agonist with sympatholytic,  sedative, amnestic, and analgesic properties.",Non-OADS,/arxiv_data1/oa_pdf/26/8e/kjpain-27-313.PMC4196495.pdf
"4: 321-325 pISSN 2005-9159  eISSN 2093-0569 http://dx.doi.org/10.3344/kjp.2014.27.4.321 | Original Article | Anatomic Variations of Cervical and  High Thoracic Ligamentum Flavum  Departments of 1Anatomy, 2Anesthesiology and Pain Medicine,  Jeju National University, School of Medicine, Jeju, Korea  Sang Pil Yoon1, Hyun Jung Kim2, and Yun Suk Choi2 Background: Epidural blocks are widely used for the management of acute and chronic pain.",Non-OADS,/arxiv_data1/oa_pdf/1a/90/kjpain-27-321.PMC4196496.pdf
"4: 326-333 pISSN 2005-9159  eISSN 2093-0569http://dx.doi.org/10.3344/kjp.2014.27.4.326 | Original Article | Effects of Nefopam on Streptozotocin-Induced  Diabetic Neuropathic Pain in Rats Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul *Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea J a e  S i k  N a m ,  Y u  S e o n  C h e o n g ,  M y o n g  H w a n  K a r m ,  H o  S o o  A h n , Ji Hoon Sim, Jin Sun Kim*, Seong Soo Choi, and Jeong Gil Leem Background:  Nefopam is a centrally acting non-opioid analgesic agent.",Non-OADS,/arxiv_data1/oa_pdf/ae/cd/kjpain-27-326.PMC4196497.pdf
"4: 334-338 pISSN 2005-9159  eISSN 2093-0569http://dx.doi.org/10.3344/kjp.2014.27.4.334 | Original Article | The Effects of a Forceful Transforaminal Epidural Steroid  I n j e c t i o n  o n  R a d i c u l a r  P a i n :  A  P r e l i m i n a r y  S t u d y Department of Anesthesiology and Pain Medicine, School of Medicine, Ewha Womans University, Seoul, Korea Jong Min Byun, Hahck Soo Park, Jae Hee Woo, and Jin Kim Background:  Lumbar transforaminal epidural steroid injections (TFESIs) are performed to provide symptom relief in  patients with radicular pain.",Non-OADS,/arxiv_data1/oa_pdf/f5/be/kjpain-27-334.PMC4196498.pdf
4: 339-344 pISSN 2005-9159  eISSN 2093-0569 http://dx.doi.org/10.3344/kjp.2014.27.4.339 | Original Article | Do Severity Score and Skin Temperature Asymmetry  Correlate with the Subjective Pain Score in the Patients  with Complex Regional Pain Syndrome?,Non-OADS,/arxiv_data1/oa_pdf/1c/16/kjpain-27-339.PMC4196499.pdf
"4: 345-352 pISSN 2005-9159  eISSN 2093-0569http://dx.doi.org/10.3344/kjp.2014.27.4.345 | Original Article | Analgesia after Epidural Dexamethasone is Further Enhanced  by IV Dipyrone, but Not IV Parecoxibe Following  Minor Orthopedic Surgery Anesthesiology and Pain Management, School of Medicine of Ribeirão Preto, University of São Paulo, Brazil Gabriela R Lauretti, Claudia CF Righeti, and Antonio T Kitayama Background:  Epidural administration of dexamethasone has been suggested for pain control after minor orthopedic surgery.",Non-OADS,/arxiv_data1/oa_pdf/cb/07/kjpain-27-345.PMC4196500.pdf
"4: 353-359 pISSN 2005-9159  eISSN 2093-0569http://dx.doi.org/10.3344/kjp.2014.27.4.353 | Original Article | Correlation between Epidurographic Contrast Flow Patterns  and Clinical Effectiveness in Chronic Lumbar Discogenic  Radicular Pain Treated with Epidural Steroid  Injections Via Different Approaches Department of Anaesthesia, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar,  *Department of Anaesthesia, Post Graduate Institute of Medical Education and research, Chandigarh,  †Department of Radiodiagnosis and Imaging, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, India Ruchi Gupta, Saru Singh, Sukhdeep Kaur*, Kulvinder Singh†, and Kuljeet Aujla Background:  Epidural steroid injections are an accepted procedure for the conservative management of chronic backache  caused by lumbar disc pathology.",Non-OADS,/arxiv_data1/oa_pdf/8c/fc/kjpain-27-353.PMC4196501.pdf
"4: 360-364 pISSN 2005-9159  eISSN 2093-0569http://dx.doi.org/10.3344/kjp.2014.27.4.360 |C a s e  R e p o r t| Large Sized Common Iliac Artery Aneurysm with Thrombus  Developing a Diagnostic Confusion in a Patient with Sciatica Department of Neurosurgery, College of Medicine, Yonsei University Gangnam Severance Hospital, Seoul,  *Department of Neurosurgery, College of Medicine, Yeungnam University, Daegu, Korea Ik Chan Jeon, Sang Woo Kim*, and Young Jin Jung* The causes of sciatica are variable and include musculoskeletal, dermatologic, infectious, neoplastic, and  vascular disorders.",Non-OADS,/arxiv_data1/oa_pdf/8e/4f/kjpain-27-360.PMC4196502.pdf
"4: 365-366 pISSN 2005-9159  eISSN 2093-0569http://dx.doi.org/10.3344/kjp.2014.27.4.365 | Letters to Editor | Curcumin, COX-2, and Protein p300/CBP D e p a r t m e n t  o f  A n e s t h e s i o l o g y  a n d  P a i n  M e d i c i n e ,  C h o s u n  U n i v e r s i t y  S c h o o l  o f  M e d i c i n e ,  G w a n g j u ,  K o r e a Ki Tae Jung, and Kyung Joon Lim Received September 11, 2014.",Non-OADS,/arxiv_data1/oa_pdf/f9/5f/kjpain-27-365.PMC4196503.pdf
"http://informahealthcare.com/dre ISSN 0963-8288 print/ISSN 1464-5165 online Disabil Rehabil, 2014; 36(17): 1445–1451 !2014 Informa UK Ltd. DOI: 10.3109/09638288.2013.847123 RESEARCH PAPER Does the impact of osteoarthritis vary by age, gender and social deprivation?",Non-OADS,/arxiv_data1/oa_pdf/7e/e2/DRE-36-1445.PMC4196505.pdf
"Satorra and Bentler have developed a method for computing a scaled difference chi-square statistic [33].This was implemented using the Sbdiff.exe program developed by Prof. John Crawford, University of Aberdeen, (http://www.abdn.",OADS,/arxiv_data1/oa_pdf/7e/e2/DRE-36-1445.PMC4196505.pdf
"http://informahealthcare.com/amy ISSN: 1350-6129 (print), 1744-2818 (electronic) Amyloid, 2014; 21(3): 191–201 !2014 Informa UK Ltd. DOI: 10.3109/13506129.2014.937857 ORIGINAL ARTICLE Islet amyloid with macrophage migration correlates with augmented b-cell deficits in type 2 diabetic patients Kosuke Kamata, Hiroki Mizukami, Wataru Inaba, Kentaro Tsuboi, Yoshinori Tateishi, Taro Yoshida, and Soroku Yagihashi Department of Pathology and Molecular Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan Abstract Aims : Islet amyloid is a hallmark in type 2 diabetic subjects, but its implication in clinical features and development of islet pathology is still unclear.",Non-OADS,/arxiv_data1/oa_pdf/0f/32/AMY-21-191.PMC4196506.pdf
"http://informahealthcare.com/amy ISSN: 1350-6129 (print), 1744-2818 (electronic) Amyloid, 2014; 21(3): 175–184 !2014 Informa UK Ltd. DOI: 10.3109/13506129.2014.927759 ORIGINAL ARTICLE Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis Na´dia Pereira Gonc ¸alves1,2, Paulo Vieira3, and Maria Joa ˜o Saraiva1,2 1Department of Molecular Neurobiology, Institute for Molecular and Cell Biology, Rua do Campo Alegre, Porto, Portugal,2Instituto de Cie ˆncias Biome ´dicas de Abel Salazar (ICBAS), Universidade do Porto, Porto, Portugal, and3Unite ´du De ´veloppement des Lymphocytes, De ´partement d’Immunologie, Institut Pasteur, Paris, CEDEX, France Abstract Introduction: Inflammation is a key pathological hallmark of several neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease and familial amyloidotic polyneur- opathy (FAP).",Non-OADS,/arxiv_data1/oa_pdf/0b/e9/AMY-21-175.PMC4196507.pdf
Available from: http://amyloidosismutations.com ((c) 2010).,Non-OADS,/arxiv_data1/oa_pdf/0b/e9/AMY-21-175.PMC4196507.pdf
"Details of trial design, eligibility criteria and evaluations have been reported [2], and are briefl  y described in the Supplementary Methods section  to be found online at http://informahealthcare.com/doi/abs/10.3109/10428194.2013.866663.",Non-OADS,/arxiv_data1/oa_pdf/23/5a/LAL-55-2093.PMC4196520.pdf
"Effi  cacy and safety assessments   Measurement of cytogenetic and molecular response, defi  - nitions of disease progression and BCR – ABL1 mutational analysis have been previously described [2] and are outlined in the Supplementary Methods section to be found online at http://informahealthcare.com/doi/abs/10.3109/10428194.2013.866663.",Non-OADS,/arxiv_data1/oa_pdf/23/5a/LAL-55-2093.PMC4196520.pdf
"Dasatinib plasma concentra-tions in DASISION were pooled with data from seven other clinical studies (Supplementary Table I to be found online at http://informahealthcare.com/doi/abs/10.3109/10428194.2013.866663) for a population pharmacokinetic (PPK) analy-sis to characterize drug exposure and examine the potential eff ects of patient demographics and disease status [14,15].",OADS,/arxiv_data1/oa_pdf/23/5a/LAL-55-2093.PMC4196520.pdf
Baseline characteristics of randomized patients were gen- erally comparable between dasatinib- and imatinib-treated patients of the East Asian subpopulation (Supplementary Table II to be found online at http://informahealthcare.com/ doi/abs/10.3109/10428194.2013.866663).,Non-OADS,/arxiv_data1/oa_pdf/23/5a/LAL-55-2093.PMC4196520.pdf
Mean treatment duration and median dose  were similar for East Asian patients compared with non-East Asian patients (Table I and Supplementary Results to be found online at http://informahealthcare.com/doi/abs/10.3109/10428194.2013.866663).,Non-OADS,/arxiv_data1/oa_pdf/23/5a/LAL-55-2093.PMC4196520.pdf
"Effi  cacy   As in non-East Asian patients, East Asian patients had  higher cytogenetic and molecular response rates and faster molecular responses with dasatinib compared with imatinib (Figure 1 and Supplementary Results to be found online at http://informahealthcare.com/doi/abs/10.3109/10428194.2013.866663).",Non-OADS,/arxiv_data1/oa_pdf/23/5a/LAL-55-2093.PMC4196520.pdf
"At 24 months, both East Asian and non-East Asian  patients had high rates of PFS (dasatinib: 98% vs. 92% for East Asian vs. non-East Asian; imatinib: 98% vs. 91%) and OS (dasatinib: 98% vs. 94%; imatinib: 98% vs. 95%), as well as similar rates of transformation to accelerated phase/blast phase (AP/BP) CML (Supplementary Results to be found online at http://informahealthcare.com/doi/abs/10.3109/10428194.2013.866663).",Non-OADS,/arxiv_data1/oa_pdf/23/5a/LAL-55-2093.PMC4196520.pdf
Safety   Drug-related AEs with dasatinib and imatinib in the East Asian  and non-East Asian subpopulations were primarily grade 1/2 (Supplementary Table III to be found online at http://informahealthcare.com/doi/abs/10.3109/10428194.2013.866663).,Non-OADS,/arxiv_data1/oa_pdf/23/5a/LAL-55-2093.PMC4196520.pdf
"As detailed in the Supplementary Results to be found  online at http://informahealthcare.com/doi/abs/10.3109/ 10428194.2013.866663, trends in non-hematologic AEs occurring in    /H11350    10% of patients were similar for East Asian  patients and non-East Asian patients in terms of comparisons  between imatinib and dasatinib and time to onset (Figure 2 and Supplementary Table III to be found online at http:// informahealthcare.com/doi/abs/10.3109/10428194.2013.",Non-OADS,/arxiv_data1/oa_pdf/23/5a/LAL-55-2093.PMC4196520.pdf
"When incidences of non-hematologic AEs occurring  in    /H11350    10% of patients were compared for East Asian versus non- East Asian patients, overall fl  uid retention, rash, nausea and  fatigue showed a trend for higher rates in East Asian patients  regardless of treatment (Figure 2 and Supplementary Table III  to be found online at http://informahealthcare.com/doi/abs/10.3109/10428194.2013.866663).",Non-OADS,/arxiv_data1/oa_pdf/23/5a/LAL-55-2093.PMC4196520.pdf
"In the dasatinib arm, increased incidence of fl  uid  retention among East Asian patients over non-East Asian patients (39% vs. 18%) was due to a higher incidence of superfi  cial edema (17% vs. 9%) and pleural eff  usion (24%  vs. 10%), as well as other types of fl  uid-related events (see  footnote in Supplementary Table III to be found online at  http://informahealthcare.co m/doi/abs/10.3109/10428194.",Non-OADS,/arxiv_data1/oa_pdf/23/5a/LAL-55-2093.PMC4196520.pdf
"Grade 3/4 laboratory abnormalities (Supplementary  Table III to be found online at http://informahealthcare.com/doi/abs/10.3109/10428194.2013.866663) occurring in the East Asian subpopulation also occurred in non-East Asian patients, and included decreased phosphate, the most common grade 3/4 laboratory abnormality seen in non-East Asian patients (for both dasatinib and imatinib).",Non-OADS,/arxiv_data1/oa_pdf/23/5a/LAL-55-2093.PMC4196520.pdf
866663) and for the East Asian subpopulation (Supplemen-tary Figure 2 to be found on at http://informahealthcare.com/doi/abs/10.3109/10428194.2013.866663).,Non-OADS,/arxiv_data1/oa_pdf/23/5a/LAL-55-2093.PMC4196520.pdf
"In DASISION, peripheral blood samples from 235 patients  within the dasatinib arm were collected for PK analysis, of which 59 were from the East Asian subpopulation (Figure 3 and Supplementary Table IV to be found online at http://informahealthcare.com/doi/abs/10.3109/10428194.2013.866663).",Non-OADS,/arxiv_data1/oa_pdf/23/5a/LAL-55-2093.PMC4196520.pdf
"Furthermore, exposure parameters did not show a correla-tion with body weight (Supplementary Figures 1 and 2 to be found online at http://informahealthcare.com/doi/abs/10.3109/10428194.2013.866663).",Non-OADS,/arxiv_data1/oa_pdf/23/5a/LAL-55-2093.PMC4196520.pdf
Available from:   http://www.migrationinformation.org/feature/display.cfm?ID    /H11005    733        Sheiner   LB  .,OADS,/arxiv_data1/oa_pdf/23/5a/LAL-55-2093.PMC4196520.pdf
"Available from:   http://www.sprycel.jp/investigation.html#03        Kantarjian   HM ,  Shah   NP  ,  Cortes   JE ,  et   al  .",OADS,/arxiv_data1/oa_pdf/23/5a/LAL-55-2093.PMC4196520.pdf
"Available from:   http://seer.cancer.gov/csr/1975_2007/        Ng   KP  ,  Hillmer   AM ,  Chuah   CT  ,  et   al  .",OADS,/arxiv_data1/oa_pdf/23/5a/LAL-55-2093.PMC4196520.pdf
TaqMan    ®   -based qRT-PCR (Applied Biosystems) was sub- sequently performed on selected differentially expressed  genes within signaling pathways identiﬁ  ed by pathway anal- ysis as dysregulated in schizophrenia and several randomly  chosen genes (Supplementary Table 1; available online at  http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918).,OADS,/arxiv_data1/oa_pdf/f6/03/NEG-28-053.PMC4196521.pdf
miRNA proﬁ  l- ing was conducted according to manufacturer ’ s speci-ﬁ cations (Supplementary Methods 1 available online at  http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918).,Non-OADS,/arxiv_data1/oa_pdf/f6/03/NEG-28-053.PMC4196521.pdf
Microarray data have been deposited into the Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/projects/geo/; accession number GSE37981).,OADS,/arxiv_data1/oa_pdf/f6/03/NEG-28-053.PMC4196521.pdf
Varying the stringency criteria of fold-change and  FDR-adjusted p-value resulted in several lists of differen-tially expressed genes (Supplementary T able 2 available  online at http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918).,Non-OADS,/arxiv_data1/oa_pdf/f6/03/NEG-28-053.PMC4196521.pdf
A complete list of these genes is shown in Supplementary Table 3 available online at  http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918.,Non-OADS,/arxiv_data1/oa_pdf/f6/03/NEG-28-053.PMC4196521.pdf
HPRT expression level also did  not differ between schizophrenia and normal control groups (Supplementary Figure 1 av ailable online at  http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918).,Non-OADS,/arxiv_data1/oa_pdf/f6/03/NEG-28-053.PMC4196521.pdf
"A representative correlation with  SMAD4   (signal  via the mothers against decapentaplegic homologs 4), the key transcription factor upon which TGF- β  and BMP sig- naling cascades converge, is depicted in Supplementary Figure 2 av ailable online at http://informahealthcare.com/ doi/abs/10.3109/01677063.2014.882918.",Non-OADS,/arxiv_data1/oa_pdf/f6/03/NEG-28-053.PMC4196521.pdf
"Both the TFG- β  and BMP canonical pathways  propagate their signal via SMADs (Shi  &  Massague, 2003) (Figures 3 and Supplementary Figure 3 available  online at http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918) and we found that  SMAD4   and   SMAD5   were up-regulated in schizophrenia.",OADS,/arxiv_data1/oa_pdf/f6/03/NEG-28-053.PMC4196521.pdf
The speciﬁ  c genes that were found by microar- ray to be differentially expressed in schizophrenia and are also the predicted targets of the differentially expressed miRNAs are shown in Supplementary Table 4 available  online at http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918.,Non-OADS,/arxiv_data1/oa_pdf/f6/03/NEG-28-053.PMC4196521.pdf
"In fact, we found that the mRNA for the gene that encodes the 65-kDa isoform of the GABA-synthesizing enzyme glutamic acid decarboxylase ( GAD2  ) was sig- niﬁ cantly down-regulated by 1.9-fold in the schizophre- nia subjects (Supplementary Table 3 available online at  http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918).",Non-OADS,/arxiv_data1/oa_pdf/f6/03/NEG-28-053.PMC4196521.pdf
"http://informahealthcare.com/plt ISSN: 0953-7104 (print), 1369-1635 (electronic) Platelets, 2014; 25(6): 461–462 !2014 Informa UK Ltd. DOI: 10.3109/09537104.2013.830709 CASE REPORT Atypical erythrocytes and platelets in a patient with a pro-thrombin mutation Etheresia Pretorius, Natasha Vermeulen, & Janette Bester Department of Physiology, Faculty of Health Sciences, University of Pretoria, Arcadia, South Africa Abstract Prothrombin mutation G20210A, anti-phospholipid syndrome as well as iron overload has previously been shown to cause thrombotic events.",Non-OADS,/arxiv_data1/oa_pdf/a3/1a/PLT-25-461.PMC4196522.pdf
"http://informahealthcare.com/jas ISSN: 0277-0903 (print), 1532-4303 (electronic) J Asthma, 2014; 51(8): 814–824 !2014 Informa Healthcare USA, Inc. DOI: 10.3109/02770903.2014.913619 WORK RELATED ASTHMA Occupations with an increased prevalence of self-reported asthma in Indian adults Sutapa Agrawal, PhD1, Neil Pearce, PhD, DSc, FRSNZ, FMedSci2,3, Christopher Millett, PhD1,4, S.V.",Non-OADS,/arxiv_data1/oa_pdf/47/8e/JAS-51-814.PMC4196548.pdf
[Accessed 24 November 2013] Available at http://dget.nic.in/nco/jobdescription/welcome.html9.,Non-OADS,/arxiv_data1/oa_pdf/47/8e/JAS-51-814.PMC4196548.pdf
"Nine to 27 days after tumor cell injection,  animals were randomized into groups and treatment began in accordance with the study protocols for the individual experiments (Supplementary Table I to be found online at  http://informahealthcare.com/doi/abs/10.3109/10428194.",Non-OADS,/arxiv_data1/oa_pdf/5d/14/LAL-55-2151.PMC4196549.pdf
"]), both antibodies induced complete tumor remis - sion, but obinutuzumab (GA101) showed an earlier onset of tumor regression (Supplementary Figure 1 to be found   online at http://informahealthcare.com/doi/abs/10.3109/10428194.2013.856008).",Non-OADS,/arxiv_data1/oa_pdf/5d/14/LAL-55-2151.PMC4196549.pdf
"The efficacious  dose of obinutuzumab (GA101) was reached, with 10 mg/kg corresponding to trough serum levels of approximately   100 mg/mL; however, with doses of obinutuzumab (GA101)   100 mg/kg corresponding to trough serum levels of   500–700 mg/mL, the efficacy in terms of kinetics of tumor regre- ssion could still be slightly enhanced (Supplementary Figures 2 and 3 to be found online at http://informahealthcare.com/ doi/abs/10.3109/10428194.2013.856008).",Non-OADS,/arxiv_data1/oa_pdf/5d/14/LAL-55-2151.PMC4196549.pdf
"Available from: http://www.nccn.org/ Tilly H, Zelenetz A.",Non-OADS,/arxiv_data1/oa_pdf/5d/14/LAL-55-2151.PMC4196549.pdf
[Also see our digest video of this operation to conﬁrm a STAMP plate-guided Bonebridge implan- tation: http://www.shinshu-u.ac.jp/faculty/medicine/chair/ent/BB-STAMP.mp4].,Non-OADS,/arxiv_data1/oa_pdf/c6/02/OTO-134-1042.PMC4196550.pdf
Available from: http://www.fredskorpset.no/en.,OADS,/arxiv_data1/oa_pdf/0d/ef/EJP-16-130.PMC4196551.pdf
"During the interview, the patients and healthcare  professionals tested the technique, a communication system for mobile phones, CQ, Circadian Questions, developed by 21st Century Mobile AB (http://www.cqmobil.se), in a test run, answering mock questions on a mobile phone brought by the study team.",Non-OADS,/arxiv_data1/oa_pdf/dc/a2/BLO-23-288.PMC4196574.pdf
"http://www.who.int/chp/knowledge/publications/adher- ence_report/en/index.html        Munger   MA ,  Van Tassel   BW ,  LaFleur   J  .",OADS,/arxiv_data1/oa_pdf/dc/a2/BLO-23-288.PMC4196574.pdf
"http://www.wma.net/en/30publications/10policies/b3/ index.html        Docteur   E ,  Coulter   A  .",Non-OADS,/arxiv_data1/oa_pdf/dc/a2/BLO-23-288.PMC4196574.pdf
"Methods   A communication system for mobile phones, Circa- dian Questions (CQ), developed by 21st Century Mobile AB (http://www.cqmobil.se), was adapted for use in this study.",OADS,/arxiv_data1/oa_pdf/32/ba/BLO-23-296.PMC4196575.pdf
"http://www.who.int/chp/knowledge/publications/ adherence_report/en/index.html        Antikainen   RL ,  Kastarinen   MJ ,  Jousilahti   P ,  Peltonen   M , 4.",OADS,/arxiv_data1/oa_pdf/32/ba/BLO-23-296.PMC4196575.pdf
2010 ;  60:e476 –  e488 [cited 29 Nov 2010] ;  Available from: http://www.ncbi.,OADS,/arxiv_data1/oa_pdf/32/ba/BLO-23-296.PMC4196575.pdf
Health Qual Life Outcomes  [doi:10.1186/1477-7525-7-3] 2009;7:3 [cited 23 Jan 2009] ;   Available from: http://www.hqlo.com/content/7/1/3.,Non-OADS,/arxiv_data1/oa_pdf/32/ba/BLO-23-296.PMC4196575.pdf
"Available at :  http://www.cdc.gov/nchs/data/databriefs/db107.pdf        Beatty   PC  ,  Willis   GB  .",OADS,/arxiv_data1/oa_pdf/32/ba/BLO-23-296.PMC4196575.pdf
"http://www.wma.net/en/30publications/10policies/b3/ index.html        Conrad   FG ,  Blair   J  .",Non-OADS,/arxiv_data1/oa_pdf/32/ba/BLO-23-296.PMC4196575.pdf
"According to the registry, 87% of all HIV-positive patients in Sweden were receiving ART in 2012 (http://infcare.com/hiv/sv/resultat/2012-arsrapport/, in Swedish).",Non-OADS,/arxiv_data1/oa_pdf/1d/51/INF-46-673.PMC4196576.pdf
"Data from InfCare HIV show that all-cause mortality among HIV patients in Sweden is cur-rently lower than 1% annually (http://infcare.com/hiv/sv/resultat/2012-arsrapport/, in Swedish).",Non-OADS,/arxiv_data1/oa_pdf/1d/51/INF-46-673.PMC4196576.pdf
Available at:  http://folkhalsomyndigheten.se/documents/ projektwebbar/rav/rekommendationer/profylax-behandling-graviditet-hiv1-infekterade-kvinnor.pdf   Lippincott Williams:  Wilkins.,Non-OADS,/arxiv_data1/oa_pdf/1d/51/INF-46-673.PMC4196576.pdf
"http://informahealthcare.com/enz ISSN: 1475-6366 (print), 1475-6374 (electronic) J Enzyme Inhib Med Chem, 2014; 29(5): 663–669 !2014 Informa UK Ltd. DOI: 10.3109/14756366.2013.837901 ORIGINAL ARTICLE Inhibition of anthrax lethal factor by curcumin and chemically modified curcumin derivatives Anthony C. Antonelli1, Yu Zhang2, Lorne M. Golub3, Francis Johnson1,2,4,5, and Sanford R. Simon1,6 1Department of Pathology,2Department of Chemistry,3Department of Oral Biology & Pathology,4Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, USA,5Chem-Master International, Inc., Stony Brook, NY, USA, and6Department of Biochemistry & Cell Biology, Stony Brook University, Stony Brook, NY, USA Abstract Curcumin (diferuloylmethane), the active ingredient in the eastern spice turmeric ( Curcuma longa ), has been shown to inhibit the activities of numerous enzymes and signaling molecules involved in cancer, bacterial and viral infections and inflammatory diseases.",Non-OADS,/arxiv_data1/oa_pdf/98/88/ENZ-29-663.PMC4196590.pdf
BLAST (http://blast.ncbi.nlm.nih.gov/ Blast.cgi) analyses of the two miRNA genes which har-boured nucleotide variants ( miR-1-2    –  NR_029662.1  and  miR-133a-2    –  NR_029676.1) identiﬁ  ed several  similar sequences in a number of species.,OADS,/arxiv_data1/oa_pdf/19/b9/CLB-74-485.PMC4196592.pdf
"RNAfold Web- server (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi) was used to compute the minimum free energy (MFE), the partition function, the matrix of base pairing prob-abilities, and the centroid structure [50].",OADS,/arxiv_data1/oa_pdf/19/b9/CLB-74-485.PMC4196592.pdf
"Statistical analysis   Tests for allele frequencies, heterozygosity values,  genic differentiation and Hardy-Weinberg equilib-rium were carried out using the exact tests of GenePop on the web (http://genepop.curtin.edu.au/).",OADS,/arxiv_data1/oa_pdf/19/b9/CLB-74-485.PMC4196592.pdf
"Available from: http://www.mirbase.org/ [18]  cgi-bin/mirna_summary.pl?org=hsa       Bentwich   I ,  Avniel   A ,  Karov   Y ,  Aharonov   R ,  Gilad   S ,  Barad  [19]   O ,  Barzilai   A ,  Einat   P ,  Einav   U ,  Meiri   E ,  Sharon   E ,  Spector    Y ,  Bentwich   Z  .",Non-OADS,/arxiv_data1/oa_pdf/19/b9/CLB-74-485.PMC4196592.pdf
"March 7, 2013 Available from http://www.socialstyrelsen.se/nationellariktlinjerforstrokesjukvard.",Non-OADS,/arxiv_data1/oa_pdf/fd/76/OCC-21-377.PMC4196634.pdf
2004. cited 2011 November 15 Available from http://www.socialstyrel- sen.se/publikationer2004/2004-123-40.,Non-OADS,/arxiv_data1/oa_pdf/fd/76/OCC-21-377.PMC4196634.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e5/fe/ppa-8-1337.PMC4196787.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpPatient Preference and Adherence 2014:8 1337–1346Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1337OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S6774 2Willingness to pay for ovulation induction  treatment in case of WhO ii anovulation: a study  using the contingent valuation method Thomas g Poder1 Jie he2 catherine simard3 Jean-charles Pasquier4 1UeTM is and crchUs, chUs,   sherbrooke, Qc , canada;   2Department of economics, greDi,   University of sherbrooke, Qc ,   canada; 3Department of Obstetrics  and gynecology, ch of chicoutimi,   affiliated to chUs, Qc , canada;   4Department of Obstetrics and  gynecology, chUs, sherbrooke,    Qc, canadaObjective:  To measure the willingness to pay (WTP) of women aged 18–45 years to receive  drug treatment for ovulation induction (ie, the social value of normal cycles of ovulation for a  woman of childbearing age) in order to feed the debate about the funding of fertility cares.",Non-OADS,/arxiv_data1/oa_pdf/e5/fe/ppa-8-1337.PMC4196787.pdf
"These feelings can  become overwhelming at times and it follows inexorably the emergence of stress.correspondence: Thomas g Poder Unité eTMis, hôpital hôtel-Dieu, chU  de sherbrooke, 580, rue Bowen sud,  sherbrooke, Qc J1g 2e8, canada Fax +1 819 829 3247 email tpoder.chus@ssss.gouv.qc.c a Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2014 Volume: 8 Running head verso: Poder et al Running head recto: WTP for ovulation induction treatment  DOI: http://dx.doi.org/10.2147/PPA.S67742",Non-OADS,/arxiv_data1/oa_pdf/e5/fe/ppa-8-1337.PMC4196787.pdf
Available from: http://www.darrp.noaa.gov/ library/pdf/cvblue.pdf.,Non-OADS,/arxiv_data1/oa_pdf/e5/fe/ppa-8-1337.PMC4196787.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/e5/fe/ppa-8-1337.PMC4196787.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/3c/88/ott-7-1733.PMC4196788.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncoTargets and Therapy 2014:7 1733–1742OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1733Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S6669 2Overexpression of eTV4 protein in triple-negative  breast cancer is associated with a higher risk   of distant metastasis Zhong-Yu Yuan1–3,* Ting Dai1,2,* shu-sen Wang1–3 rou-Jun Peng1–3 Xing-hua li1,2 Tao Qin1–3 li-Bing song1,2 Xi Wang1,2,4 1state Key laboratory of Oncology  in south china, guangzhou, People’s  republic of china; 2collaborative  innovation center for cancer  Medicine, guangzhou, People’s  republic of china; 3Department  of Medical Oncology, sun Yat- sen  University cancer center, guangzhou,   People’s republic of china;   4Department of Breast Oncology,    sun Yat- sen University cancer   center, guangzhou, People’s   republic of china *These authors contributed equally   to this work correspondence: Zhong-Yu Yuan   Department of Medical Oncology,   sun Yat-sen University cancer center,   651 Dongfeng road east,   guangzhou 510060, People’s republic   of china   T el +86 20 8734 3794   Fax +86 20 8734 3535   email yuanzhygz@163.co m    Xi Wang   Department of Breast Oncology,   sun Yat-sen University cancer center,   guangzhou 510060, People’s republic   of china   T el +86 20 8734 3333   Fax +86 20 8734 3171   email wangxi@sysucc.org.c nBackground:  Patients with triple-negative breast cancer (TNBC) present a higher probability  of distant metastasis and lack of effective targeted therapy.",Non-OADS,/arxiv_data1/oa_pdf/3c/88/ott-7-1733.PMC4196788.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/3c/88/ott-7-1733.PMC4196788.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/3c/88/ott-7-1733.PMC4196788.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e2/74/ott-7-1753.PMC4196789.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncoTargets and Therapy 2014:7 1753–1759OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1753ORIGINAL RESEARCHopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OTT .S6666 7Expression of YY1 correlates with progression  and metastasis in esophageal squamous cell  carcinomas Judong Luo1,* Xin Jiang1,* LiLi Cao2,* Kejun Dai1 Shuyu Zhang3,4 Xin Ge3,4 Xifa Zhou1 Xujing Lu1 1Department of Radiotherapy,   Changzhou Tumor Hospital, Soochow  University, Changzhou, People’s Republic  of China;  2Department of Molecular  Radiobiology, Research Institute  for Radiation Biology and Medicine,   Hiroshima University, Hiroshima, Japan;   3School of Radiation Medicine and  Protection and Jiangsu Provincial Key  Laboratory of Radiation Medicine and  Protection,  4Collaborative Innovation  Center of Radiation Medicine of Jiangsu  Higher Education Institutions and School  for Radiological and Interdisciplinary  Sciences (RAD-X), Soochow University,   Suzhou, People’s Republic of China *These authors contributed equally   to this work Correspondence: Xifa Zhou   1 Huaide North Road, Zhonglou District,  Department of Radiotherapy, Changzhou  Tumor Hospital, Soochow University,  Changzhou 213001, People’s Republic of  China   Tel +86 519 8686 8265  Fax +86 519 8686 8265  Email  83559808@qq.co m    Xujing Lu   1 Huaide North Road, Zhonglou District,  Department of Radiotherapy, Changzhou  Tumor Hospital, Soochow University,  Changzhou 213001, People’s Republic of  China   Tel +86 519 8686 8265  Fax +86 519 8686 8265  Email luxujing68@aliyun.co mObjective:  Esophageal squamous cell carcinoma (ESCC) is one of the deadliest cancers  worldwide.",Non-OADS,/arxiv_data1/oa_pdf/e2/74/ott-7-1753.PMC4196789.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/e2/74/ott-7-1753.PMC4196789.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/e2/74/ott-7-1753.PMC4196789.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/dc/95/tacg-7-177.PMC4196791.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pThe Application of Clinical Genetics 2014:7 177–182The Application of Clinical Genetics Dove press submit your manuscript | www.dovepress.co m Dove press  177CAse Repo RTopen access to scientific and medical research open Access Full T ext Article http: //dx.doi.org/10.2147/TACG.S6428 0A novel nonsense mutation of the KAL1 gene  (p.Trp204*) in Kallmann syndrome Antonette souto el Husny1 Milene Raiol-Moraes1 Milena Coelho Fernandes- Caldato2,3 Ândrea Ribeiro-dos-santos1 1Laboratory of Human and Medical  Genetics, Federal University of pará,  2João de Barros Barreto University  Hospital, Federal University of pará,  3University Center of pará, CesUp A,   Belém, pará, Brazil Correspondence: Antonette souto el  Husny   Universidade Federal do pará – UFpA,  Laboratório de Genética Humana e  Médica, Av Augusto Corrêa,  01 –   Guamá, Cep:  66075-110, Belém,   pará, Brasil   Tel +55 91 3201 7843  email a.elhusny@gmail.co mObjective:  To describe a novel KAL1  mutation in patients affected by Kallmann syndrome.",Non-OADS,/arxiv_data1/oa_pdf/dc/95/tacg-7-177.PMC4196791.pdf
"The Application of Clinical Genetics Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/the-application-of-clinical-genetics-journa lThe Application of Clinical Genetics is an international, peer-reviewed  open access journal that welcomes laboratory and clinical findings in  the field of human genetics.",Non-OADS,/arxiv_data1/oa_pdf/dc/95/tacg-7-177.PMC4196791.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/dc/95/tacg-7-177.PMC4196791.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/16/f6/ott-7-1761.PMC4196792.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncoTargets and Therapy 2014:7 1761–1768OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1761Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S6877 3crenolanib, a PDgFr inhibitor, suppresses   lung cancer cell proliferation and inhibits   tumor growth in vivo Ping Wang1 liqiang song2 hui ge1 Pule Jin1 Yifang Jiang1 Wenxia hu1 nan geng1 1Department of respiratory  Medicine, Fourth hospital of hebei  Medical University, shijiazhuang,   hebei, People’s republic of china;   2Department of Pathology, school of  Basic Medical sciences, Peking Union  Medical college, Beijing, People’s  republic of china correspondence: Ping Wang   12 Jiankang rd, Qiaodong, shijiazhuang,   hebei 050011, People’s republic of china   Tel +86 139 3113 0696   email pingwang1393@gmail.co mAbstract:  Platelet-derived growth factor (PDGF) and its receptors (PDGFR), including  PDGFR α and PDGFR β, play important roles in tumorigenesis, tumor progression, and the  regulation of stromal cell function.",Non-OADS,/arxiv_data1/oa_pdf/16/f6/ott-7-1761.PMC4196792.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/16/f6/ott-7-1761.PMC4196792.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/16/f6/ott-7-1761.PMC4196792.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/b9/40/ott-7-1769.PMC4196793.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncoTargets and Therapy 2014:7 1769–1775OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1769Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S6961 8conventional fractionated helical tomotherapy  for patients with small to medium hepatocellular  carcinomas without portal vein tumor thrombosis Jinhong Jung Moonkyoo Kong seong eon hong Department of radiation Oncology,   Kyung hee University Medical center,   Kyung hee University school of  Medicine, seoul, republic of Korea correspondence: Moonkyoo Kong   Department of radiation Oncology,   Kyung hee University Medical center,   Kyung hee University school   of Medicine, 23 Kyungheedae-gil,   Dongdaemoongu, seoul, 130-702,   republic of Korea   Tel +82 2958 8661   Fax +82 2958 9469   email kongmoonkyoo@khu.ac.k rBackground:  The purpose of this study was to evaluate clinical outcomes of conventional  fractionated helical tomotherapy in patients with small to medium hepatocellular carcinomas  (HCCs) without portal vein tumor thrombosis.",Non-OADS,/arxiv_data1/oa_pdf/b9/40/ott-7-1769.PMC4196793.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/b9/40/ott-7-1769.PMC4196793.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/b9/40/ott-7-1769.PMC4196793.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d2/17/ott-7-1717.PMC4196794.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncoTargets and Therapy 2014:7 1717–1722OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1717Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S6738 0Brentuximab vedotin for relapsed or refractory  cD30+ hodgkin lymphoma: a multicenter   analysis from asia Qing-Ming Yang1,* Jung Y ong hong2,* Y oung hyeh Ko3 shek-Ying lin4 Wing-Yan au4 Moon Ki choi5 silvia Park6 seok Jin Kim6 Won seog Kim6 1The First affiliated hospital of the  People’s liberation army general  hospital, Beijing, People’s republic  of china; 2Department of internal  Medicine, chung- ang University  college of Medicine, 3Department of  Pathology, samsung Medical center,   sungkyunkwan University school of  Medicine, seoul, Korea; 4Blood-Med  clinic, hong Kong, People’s republic  of china; 5Divisions of hematology  and Medical Oncology, Department  of internal Medicine, seoul national  University Bundang hospital, seoul  national University college of  Medicine, gyeonggi-do, Korea;   6Division of hematology-Oncology,   Department of Medicine, samsung  Medical center, sungkyunkwan  University school of Medicine,    seoul, Korea *Qing-Ming Yang and Jung Y ong hong  contributed equally to this work correspondence: Won seog Kim   Division of hematology-Oncology,   Department of Medicine,   samsung Medical center,   sungkyunkwan University school   of Medicine, 50 irwon-dong   gangnam-gu, seoul, 135-710, Korea   Tel +82 2 3410 6548   Fax +82 2 3410 1754   email wskimsmc@skku.ed uIntroduction:  Brentuximab vedotin (SGN-35), an anti-cluster of differentiation (CD)-30 anti - body conjugated to the anti-tubulin agent monomethyl auristatin E, has demonstrated promising  efficacy and tolerability in relapsed and heavily treated Hodgkin lymphoma (HL).",Non-OADS,/arxiv_data1/oa_pdf/d2/17/ott-7-1717.PMC4196794.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/d2/17/ott-7-1717.PMC4196794.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/d2/17/ott-7-1717.PMC4196794.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/bd/2d/ott-7-1743.PMC4196795.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncoTargets and Therapy 2014:7 1743–1752OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1743Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S6965 7Prognostic value of preoperative inflammatory  markers in chinese patients with breast cancer Minya Yao1 Yu liu1 hailong Jin2 Xiaojiao liu1 Kezhen lv1 haiyan Wei1 chengyong Du1 shuqian Wang1 Bajin Wei1 Peifen Fu1 1Department of Breast center,   2gastrointestinal surgery, First  affiliated hospital, college of  Medicine, Zhejiang University,   hangzhou, Zhejiang Province,    People’s republic of china correspondence: Peifen Fu   Breast Center of the First Affiliated   hospital, college of Medicine,   Zhejiang University, 79 Qingchun road,   hangzhou, 310003, Zhejiang Province,   People’s republic of china   Tel +86 571 87235125   Fax +86 571 87235125   email fupeifen@hotmail.co mAbstract:  Cancer-associated inflammation is a key determinant of disease progression and  survival in most cancers.",Non-OADS,/arxiv_data1/oa_pdf/bd/2d/ott-7-1743.PMC4196795.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/bd/2d/ott-7-1743.PMC4196795.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/bd/2d/ott-7-1743.PMC4196795.pdf
Available at: http://www.neighbourhood.,Non-OADS,/arxiv_data1/oa_pdf/e4/28/mlr-52-935.PMC4196797.pdf
Avai lable at: http://www.R-project.org/.,Non-OADS,/arxiv_data1/oa_pdf/8b/d9/mlr-52-975.PMC4196798.pdf
2011.http://CRAN.R-project.org/package=lme4.,Non-OADS,/arxiv_data1/oa_pdf/8b/d9/mlr-52-975.PMC4196798.pdf
Available at: http://www.cdc.gov/niosh/topics/workschedules/.,Non-OADS,/arxiv_data1/oa_pdf/8b/d9/mlr-52-975.PMC4196798.pdf
Available at http://commons.esc.edu/spss/).,Non-OADS,/arxiv_data1/oa_pdf/85/7b/ejanet-31-611.PMC4196799.pdf
"For statistical analysis we used SPSS version 20 (IBM Cor- poration, Armonk, New York, USA) or the online calcu- lators http://www.openepi.com (including the Fisher’s exact test) and http://vassarstats.net (including the Kappa test).",OADS,/arxiv_data1/oa_pdf/85/7b/ejanet-31-611.PMC4196799.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/31/e8/tcrm-10-759.PMC4196840.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpTherapeutics and Clinical Risk Management 2014:10 759–762Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  759Case Repo RTopen access to scientific and medical research open access Full T ext article http: //dx.doi.org/10.2147/TCRM.S6729 9a fatal case of Trichosporon asahii  fungemia   and pneumonia in a kidney transplant   recipient during caspofungin treatment Mei-fang Yang1,2 Hai-nv Gao1,2 Lan-juan Li1,2 1state Key Laboratory for Diagnosis  and Treatment of Infectious Diseases,   The First affiliated Hospital, school  of Medicine, Zhejiang University;   2Collaborative Innovation Center for  Diagnosis and Treatment of Infectious  Diseases, Hangzhou, people’s Republic  of China Correspondence: Lan-juan Li   state Key Laboratory for Diagnosis and  Treatment of Infectious Diseases,   The First Affiliated Hospital School   of Medicine, Zhejiang University,   79 Qingchun Road, Hangzhou 310003,  people’s Republic of China   Tel +861 390 651 4210   email ljli@zju.edu.c nAbstract:  Trichosporon asahii  is an emerging opportunistic pathogen that is life-threatening  particularly for immunosuppressed patients.",Non-OADS,/arxiv_data1/oa_pdf/31/e8/tcrm-10-759.PMC4196840.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/31/e8/tcrm-10-759.PMC4196840.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/31/e8/tcrm-10-759.PMC4196840.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/7c/34/vhrm-10-577.PMC4196841.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pVascular Health and Risk Management 2014:10 577–584Vascular Health and Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  577ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/VHRM.S4447 1endothelial function testing and cardiovascular  disease: focus on peripheral arterial tonometry Rosa Maria Bruno1 T ommaso Gori2 Lorenzo Ghiadoni3 1institute of Clinical Physiology CNR,   Pisa, italy; 2Department of Medicine  ii, University Medical Center of the  Johannes Gutenberg-University Mainz,   Mainz, Germany;  3Department of  Clinical and experimental Medicine,   University of Pisa, Pisa, italy Correspondence: Rosa Maria Bruno   institute of Clinical Physiology CNR,   Via Moruzzi  1, 56125 Pisa, italy   Tel +39 05 0315 2377  Fax +39 05 0315 2355  email rosam.bruno@gmail.co mAbstract:  During recent decades, a number of methods have been developed to assess  endothelial function, contributing to a better understanding of the pathophysiology of cardio - vascular disease.",Non-OADS,/arxiv_data1/oa_pdf/7c/34/vhrm-10-577.PMC4196841.pdf
"Vascular Health and Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/vascular-health-and-risk-management-journa lVascular Health and Risk Management is an international, peer- reviewed journal of therapeutics and risk management, focusing on  concise rapid reporting of clinical studies on the processes involved  in the maintenance of vascular health; the monitoring, prevention and  treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes.",Non-OADS,/arxiv_data1/oa_pdf/7c/34/vhrm-10-577.PMC4196841.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/7c/34/vhrm-10-577.PMC4196841.pdf
Two months after publication it is  available to the public under an Attribution–Noncommercial–Share Alike 3.0  Unported Creative Commons License (http://creativecommons.org/licenses/by- nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/20/78/3095.PMC4196862.pdf
Two months after publication it is avail - able to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/98/e8/3105.PMC4196863.pdf
Two months after publication it is avail - able to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/2f/d5/3119.PMC4196864.pdf
Two months after publication  it is available to the public under an Attribution–Noncommercial–Share Alike 3.0  Unported Creative Commons License (http://creativecommons.org/licenses/ by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/1c/96/3133.PMC4196865.pdf
Two months after publication it is avail - able to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/f4/f9/3147.PMC4196866.pdf
Mutations are described  at http://flybase.org.,Non-OADS,/arxiv_data1/oa_pdf/f4/f9/3147.PMC4196866.pdf
Two months after publication it is available  to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/b0/58/3166.PMC4196867.pdf
Two months after publication it is avail - able to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/f8/92/3178.PMC4196868.pdf
Two months after publication it is avail - able to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/da/b5/3210.PMC4196870.pdf
"The plasmids pLPBLP , pDEX-NLS-cre,  pDV-CYFP-CTAP , pDM326, and pDXA-MCS-YFP were obtained  through the Dicty Stock Center (http://dictybase.org/).",OADS,/arxiv_data1/oa_pdf/da/b5/3210.PMC4196870.pdf
Two months after publication it is available  to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/a9/50/3222.PMC4196871.pdf
Two months after publi - cation it is available to the public under an Attribution–Noncommercial–Share  Alike 3.0 Unported Creative Commons License (http://creativecommons.org/ licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/40/00/3234.PMC4196872.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/da/41/opth-8-1993.PMC4196883.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2014:8 1993–1999Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1993Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S6938 8Challenges for the cataract surgeon treating  people with dementia: a qualitative study  exploring anesthetic choices Joanna Mary Jefferis1–3 Michael Patrick Clarke1,3 John-Paul Taylor2 Katie rhian Brittain4 1newcastle eye Centre, royal Victoria  infirmary, 2institute for ageing and  health, 3institute of neurosciences,   4institute of health and society,   newcastle University, newcastle  upon Tyne, UKBackground:  In light of the growing number of people with dementia and age-related cataract,  as well as changing anesthetic practices for cataract surgery, this study aimed to explore the  experiences of cataract surgeons in managing patients with dementia and making anesthetic  decisions.",Non-OADS,/arxiv_data1/oa_pdf/da/41/opth-8-1993.PMC4196883.pdf
"However, there is a trend away from  using sharp needle blocks and a growth in the number of people using purely topical  anesthetic.13 Along with this, there has been a diminishing role for the ophthalmic Correspondence: Joanna Mary Jefferis Clinical ageing research Unit, Campus  for ageing and Vitality, newcastle  University, newcastle upon Tyne,  ne4 5Pl, UK Tel +44 191 248 1297 Fax +44 191 248 1250 email j oanna.jefferis@ncl.ac.u k Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2014 Volume: 8 Running head verso: Jefferis et al Running head recto: Challenges treating people with dementia DOI: http://dx.doi.org/10.2147/OPTH.S69388",Non-OADS,/arxiv_data1/oa_pdf/da/41/opth-8-1993.PMC4196883.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/da/41/opth-8-1993.PMC4196883.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/da/41/opth-8-1993.PMC4196883.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/40/a0/dddt-8-1555.PMC4196884.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpDrug Design, Development and Therapy 2014:8 1555–1561Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1555Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/DDDT .S3655 6Clinical utility and development of the fluticasone/ formoterol combination formulation (Flutiform®)  for the treatment of asthma Ricardo Antonio Tan1 Jonathan Corren2 1California Allergy and Asthma  Medical Group, 2David Geffen School  of Medicine at UCLA, Los Angeles,   CA, USA Correspondence: Jonathan Corren   Allergy Medical Clinic   10780 Santa Monica Blvd.,   Suite 280, Los Angeles,   CA 90025, USA   email jcorren@ucla.ed uAbstract:  Pharmacologic treatment of asthma should be done with a stepwise approach  recommended in treatment guidelines.",Non-OADS,/arxiv_data1/oa_pdf/40/a0/dddt-8-1555.PMC4196884.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/40/a0/dddt-8-1555.PMC4196884.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/40/a0/dddt-8-1555.PMC4196884.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a5/8d/dddt-8-1695.PMC4196885.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pDrug Design, Development and Therapy 2014:8 1695–1708Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1695Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S6481 4effects of immunosuppressive treatment   on protein expression in rat kidney Karolina Kędzierska1 Katarzyna Sporniak-T utak2 Krzysztof Sindrewicz2 Joanna Bober3 Leszek Domański1 Mirosław Parafiniuk4 Elżbieta Urasińska5 Andrzej Ciechanowicz6 Maciej Domański1 T omasz Smektała2 Marek Masiuk5 Wiesław Skrzypczak6 Małgorzata Ożgo6 Joanna Kabat-Koperska1 Kazimierz Ciechanowski1 1Department of n ephrology,   Transplantology, and internal  Medicine,  2Department of Dental  surgery,  3Department of Medical  chemistry,  4Department of  Forensic Medicine,  5Department  of Pathomorphology, Pomeranian  Medical University,  6Department  of Physiology, Cytobiology, and  Proteomics, West Pomeranian  University of T echnology, Szczecin,   Poland Correspondence: Karolina Kędzierska   Department of nephrology,   Transplantology and internal Medicine,   Powstańców Wlkp  72, 70-111 Szczecin,   Pomeranian Medical University, Poland   Tel +48 91 466 11 96  Fax +48 91 466 11 96  email karolina.kedzierska@interia.p lAbstract:  The structural proteins of renal tubular epithelial cells may become a target for  the toxic metabolites of immunosuppressants.",Non-OADS,/arxiv_data1/oa_pdf/a5/8d/dddt-8-1695.PMC4196885.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/a5/8d/dddt-8-1695.PMC4196885.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/8d/dddt-8-1695.PMC4196885.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/dc/85/ndt-10-1879.PMC4196886.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2014:10 1879–1886Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1879OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S6803 9hamza Mohammad abdulghani1 Mohammad irshad1 Mohammed a al Zunitan1,2 ali a al sulihem1,2 Muhammed a al Dehaim1,2 Waleed a al esefir1,2 abdulaziz M al rabiah1,2 rashid N Kameshki1,2 Nourah abdullah alrowais2 abdulaziz sebiany3 shafiul haque1 1Department of Medical education, college  of Medicine, King saud University, riyadh,  saudi arabia; 2Department of Family and  community Medicine, King saud University,  riyadh, saudi arabia; 3Department of Family  and community Medicine, University  of Dammam, Dammam, saudi arabia correspondence: hamza Mohammad  abdulghani Department of Medical education, college  of Medicine, King saud University, PO Box  230155, riyadh 11321, saudi arabia Tel +966 11 469 9177 Fax +966 11 467 1967 email hamzaabg@gmail.co m Prevalence of stress in junior doctors during  their internship training: a cross-sectional study  of three saudi medical colleges’ hospitals Background:  Medical science is perceived as a stressful educational career, and medical stu - dents experience monstrous stress during their undergraduate studies, internship, and residency  training, which affects their cognitive function, practical life, and patient care.",Non-OADS,/arxiv_data1/oa_pdf/dc/85/ndt-10-1879.PMC4196886.pdf
"The internship is a kind of experiential learning during which recent gradu - ates take the opportunity to apply acquired knowledge and skills from their medical  school training to real-world situations, and it provides an opportunity for medical  graduates to integrate and consolidate their thinking and actions.1–3 Also, it bridges  the gap between the medical school and being board eligible for medical specialty Journal name: Neuropsychiatric Disease and Treatment Journal Designation: Original Research Y ear: 2014 Volume: 10 Running head verso: Abdulghani et al Running head recto: Stress in junior doctors during their training DOI: http://dx.doi.org/10.2147/NDT.S68039 Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/dc/85/ndt-10-1879.PMC4196886.pdf
Or use: http://dvpr.es/WXgLO TVideo abstract,Non-OADS,/arxiv_data1/oa_pdf/dc/85/ndt-10-1879.PMC4196886.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/dc/85/ndt-10-1879.PMC4196886.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.Dove pres s Neuropsychiatric Disease and Treatment 2014:10submit your manuscript | www.dovepress.co m Dove press Dove press 1886abdulghani et al 22.,Non-OADS,/arxiv_data1/oa_pdf/dc/85/ndt-10-1879.PMC4196886.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a5/e5/opth-8-1967.PMC4196887.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2014:8 1967–1985Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1967Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OPTH.S5916 2Latanoprost in the treatment of glaucoma Albert Alm Department of Neuroscience,   Ophthalmology, University Hospital,   Uppsala, Sweden Correspondence: Albert Alm   Department of Neuroscience  (Ophthalmology), Uppsala University  Biomedical Centre, Husargarten 3,   Se-751 24, Uppsala, Sweden   Tel +46 186 115 135   email albert.alm@akademiska.s eAbstract:  Prostaglandins are approved by the European Glaucoma Society guidelines as first- line treatment for glaucoma.",Non-OADS,/arxiv_data1/oa_pdf/a5/e5/opth-8-1967.PMC4196887.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/a5/e5/opth-8-1967.PMC4196887.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/e5/opth-8-1967.PMC4196887.pdf
"Predetermined Glial Cell Fate As already mentioned above, our pre - vious work on embryonic peripheral glial cells (ePG) suggested a predetermined cell fate of each ePG with respect to ori - gin, marker gene expression, migratory Tracing cells throughout development Insights into single glial cell differentiation Christian von Hilchen and Benjamin Altenhein* Institute of Genetics; University of Mainz; Mainz, Germany Keywords:  peripheral glia, peripheral  nervous system, Flybow, hypertrophy,  hyperplasia *Correspondence to: Benjamin Altenhein; Email:  balt@uni-mainz.de Submitted: 02/26/2014; Revised: 04/08/2014; Accepted: 04/11/2014; Published Online: 04/25/2014http://dx.doi.org/10.4161/fly.28855 Extra view to: von Hilchen CM, Bustos AE,  Giangrande A, Technau GM, Altenhein B. Predetermined embryonic glial cells form the distinct glial sheaths of the Drosophila peripheral nervous system.",Non-OADS,/arxiv_data1/oa_pdf/20/f8/fly-8-86.PMC4197020.pdf
Development 2013; 140:3657-68; PMID:23903191 ;   http://dx.doi.org/10.1242/dev.093245,OADS,/arxiv_data1/oa_pdf/20/f8/fly-8-86.PMC4197020.pdf
Dev Biol 1997; 189:186-204; PMID:9299113 ;  http://dx.doi.org/10.1006/dbio.1997.8660 4.,Non-OADS,/arxiv_data1/oa_pdf/20/f8/fly-8-86.PMC4197020.pdf
Mech Dev 2008; 125:542- 57; PMID:18296030 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/20/f8/fly-8-86.PMC4197020.pdf
Mech Dev 2008; 125:337- 52; PMID:18077143 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/20/f8/fly-8-86.PMC4197020.pdf
J Neurosci  2006; 26:3319-29;  PMID:16554482 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/20/f8/fly-8-86.PMC4197020.pdf
J Neurosci  2008; 28:587-97;  PMID:18199760 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/20/f8/fly-8-86.PMC4197020.pdf
Nat Methods 2011; 8:260- 6; PMID:21297619 ; http://dx.doi.org/10.1038/ nmeth.1567 9.,OADS,/arxiv_data1/oa_pdf/20/f8/fly-8-86.PMC4197020.pdf
Cell 2005; 123:145- 56; PMID:16213219 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/20/f8/fly-8-86.PMC4197020.pdf
Glia 2008; 56:1518- 31; PMID:18803315 ; http://dx.doi.org/10.1002/ glia.20778 11.,Non-OADS,/arxiv_data1/oa_pdf/20/f8/fly-8-86.PMC4197020.pdf
Genes Dev 2012; 26:31- 6; PMID:22215808 ; http://dx.doi.org/10.1101/ gad.177436.111 12.,OADS,/arxiv_data1/oa_pdf/20/f8/fly-8-86.PMC4197020.pdf
J Neurosci  2007; 27:279-88;  PMID:17215387 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/20/f8/fly-8-86.PMC4197020.pdf
PLoS One  2011; 6:e28106;  PMID:22132223 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/20/f8/fly-8-86.PMC4197020.pdf
Development 2012; 139:2763- 72; PMID:22745312 ; http://dx.doi.org/10.1242/ dev.074179,OADS,/arxiv_data1/oa_pdf/20/f8/fly-8-86.PMC4197020.pdf
"The Mind neuron is a single Fruitless isoforms and target genes specify the sexually dimorphic  nervous system underlying Drosophila  reproductive behavior Tetsuya Nojima*, Megan C Neville, and Stephen F Goodwin Department of Physiology, Anatomy and Genetics; University of Oxford; Oxford, UK Keywords:  sexual behavior, courtship,  sexual dimorphism, fruitless , transcription  factor, DamID, nervous system  development *Correspondence to: Tetsuya Nojima;   Email: tetsuya.nojima@dpag.ox.ac.uk Submitted: 03/25/2014Revised: 04/29/2014Accepted: 05/06/2014Published Online: 05/09/2014http://dx.doi.org/10.4161/fly.29132 Extra View to: Neville MC, Nojima T, Ashley E,  Parker DJ, Walker J, Southall T, Van de Sande B, Marques AC, Fischer B, Brand AH, et al.",Non-OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Curr Biol 2014; 24:229-41; PMID:24440396; http://dx.doi.org/10.1016/j.cub.2013.11.035,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Behav  Genet 1978; 8:125-41; PMID:99136 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Proc Natl Acad Sci U S A 1996; 93:9687-92; PMID:8790392 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Cell  1996; 87:1079-89;  PMID:8978612 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Curr Biol 2006; 16:R766-76;  PMID:16950103 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Cell 2005; 121:785- 94; PMID :15935764 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Curr Biol  2007; 17:1473-8;  PMID:17716899 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Cell  1984; 36:775-82;  PMID:6421491 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Cell 1986; 45:505-13;  PMID:3085954 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Nat Cell Biol 2000; 2:500-6; PMID:10934470 ;  http://dx.doi.org/10.1038/35019537 11.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Curr Biol  2006; 16:1063-76;  PMID:16753560 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Curr Biol 2010; 20:836- 40; PMID:20399094 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
J Neurobiol 2000; 43:404-26; PMID:10861565 ; http://dx.doi.org/10.1002/1097- 4695(20000615)43:4<404::AID-NEU8>3.0.CO;2-D 14.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Nature 2005; 438:229-33;  PMID:16281036 ; http://dx.doi.org/10.1038/ nature04229 15.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Neuron 2008; 59:759-69; PMID:18786359 ;  http://dx.doi.org/10.1016/j.neuron.2008.06.007 16.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Curr Biol  2010; 20:1589-601;  PMID:20832311 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Curr Biol  2010; 20:1602-14;  PMID:20832315 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Neuron 2011; 69:509- 22; PMID :21315261 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
J Neurobiol 2001; 47:121-49; PMID:11291102 ; http://dx.doi.org/10.1002/ neu.1021 24.,Non-OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Curr Biol 2014; 24:229- 41; PMID:24440396 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Curr Biol 2014; 24:242-51; PMID:24440391 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Nature 1967; 215:669-71; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Anim Behav 1976; 24:622-5; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Mol Biol Evol 2009; 26:1557-69; PMID:19349644 ;  http://dx.doi.org/10.1093/molbev/msp06734.,Non-OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
"Heredity (Edinb) 2014; 112:300-6; PMID:24149653 ; http://dx.doi.org/10.1038/ hdy.2013.106 35. van Steensel B, Henikoff S. Identification of in vivo DNA targets of chromatin proteins using  tethered dam methyltransferase.",OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Nat Biotechnol  2000; 18:424-8;  PMID:10748524 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
BMC Genomics  2013; 14:659;  PMID:24074028 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Mol Biol Rep 1994; 20:97-107;  PMID:7536299 ; http://dx.doi.org/10.1007/ BF00996358 38.,Non-OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Proc Natl Acad Sci U S A  2008; 105:9715-20;  PMID:18621688 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Cell Rep 2012; 2:991- 1001;  PMID:23063364 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Cell 2000; 101:671-84; PMID:10892653 ; http://dx.doi.org/10.1016/ S0092-8674(00)80878-8 42 .,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Neuron  2004; 42:77-88;  PMID:15066266 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Cell 1987; 48:975-88; PMID:3548998 ;  http://dx.doi.org/10.1016/0092-8674(87)90706-9 45.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
Cell 2005; 121:795-807;  PMID :15935765 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/25/84/fly-8-95.PMC4197022.pdf
e-mail: b.bakhshi@modares.ac.ir ©2014 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/9d/27/jvms-76-1195.PMC4197144.pdf
e-mail: nobhoshi@kobe-u.ac.jp ©2014 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/44/33/jvms-76-1201.PMC4197145.pdf
e-mail: s.pavone@izsum.it ©2014 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/82/86/jvms-76-1209.PMC4197146.pdf
©2014 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/36/7d/jvms-76-1213.PMC4197147.pdf
e-mail:	hsst56@vet.osakafu-u.ac.jp ©2014	The	Japanese	Society	of	 Veterinary	Science This	is	an	open-access	 article	distributed 	under	the	terms	of	the	Creative	 Commons	 Attribution	 Non-Commercial	 No	Derivatives	 (by-nc-nd)	 License	<http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/fb/fe/jvms-76-1219.PMC4197148.pdf
e-mail: k-sato@yamaguchi-u.ac.jp ©2014 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/51/b7/jvms-76-1225.PMC4197149.pdf
©2014 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/b9/28/jvms-76-1231.PMC4197150.pdf
e-mail: t.ohama@yamaguchi-u.ac.jp ©2014 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/12/b5/jvms-76-1235.PMC4197151.pdf
e-mail: satohi@ims.u-tokyo.ac.jp ©2014 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/42/e5/jvms-76-1241.PMC4197152.pdf
e-mail: huenishi@affrc.go.jp ©2014 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/15/b4/jvms-76-1249.PMC4197153.pdf
e-mail: atakashi@gifu-u.ac.jp ©2014 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/bc/f1/jvms-76-1257.PMC4197154.pdf
©2014 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/98/fe/jvms-76-1261.PMC4197155.pdf
e-mail: harasawa@iwate-u.ac.jp ©2014 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/00/55/jvms-76-1267.PMC4197156.pdf
e-mail: niwa@epizoo.equinst.go.jp ©2014 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/80/47/jvms-76-1271.PMC4197157.pdf
e-mail: takehara@cc.tuat.ac.jp ©2014	The	Japanese	Society	of	 Veterinary	Science This	is	an	open-access	 article	distributed 	under	the	terms	of	the	Creative	 Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License	<http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/9b/a5/jvms-76-1277.PMC4197158.pdf
Lancet	 online	Feb	5.	http://dx.doi.org/	 10.1016/ S0140- 6736(14)60111–2.,OADS,/arxiv_data1/oa_pdf/9b/a5/jvms-76-1277.PMC4197158.pdf
http://www.oie.int/ fileadmin/Home/eng/Animal_Health_in_the_World/docs/pdf/ Global_Strategy_fulldoc.pdf.,Non-OADS,/arxiv_data1/oa_pdf/9b/a5/jvms-76-1277.PMC4197158.pdf
e-mail: atakashi@gifu-u.ac.jp ©2014 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/1e/ff/jvms-76-1281.PMC4197159.pdf
e-mail: yanai@gifu-u.ac.jp ©2014	The	Japanese	Society	of	 Veterinary	Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/3b/39/jvms-76-1285.PMC4197160.pdf
2006; Available from: http://ec.europa.eu/environment/nature/nature_conserva-tion/focus_wild_birds/avian_influenza/index_en.htm.,Non-OADS,/arxiv_data1/oa_pdf/3b/39/jvms-76-1285.PMC4197160.pdf
e-mail: matsuu@vet.kagoshima-u.ac.jp ©2014 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/a9/b1/jvms-76-1291.PMC4197161.pdf
e-mail: mtchiou@mail.npust.edu.tw ©2014 The Japanese Society of  Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/0d/94/jvms-76-1297.PMC4197162.pdf
e-mail: yanai@gifu-u.ac.jp ©2014 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/6e/39/jvms-76-1301.PMC4197163.pdf
e-mail: amontoya@dpat.ulpgc.es ©2014 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/db/b4/jvms-76-1305.PMC4197164.pdf
"), Available from http://www.ema.europa.eu.",Non-OADS,/arxiv_data1/oa_pdf/db/b4/jvms-76-1305.PMC4197164.pdf
e-mail: hfukushi@gifu-u.ac.jp ©2014 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/43/45/jvms-76-1309.PMC4197165.pdf
e-mail: inokuma@obihiro.ac.jp ©2014 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.,Non-OADS,/arxiv_data1/oa_pdf/c2/4c/jvms-76-1313.PMC4197166.pdf
"Sequence data of the PCR products were analyzed for  homology with registered sequences using the standard nucleotide BLAST program (National Center for Biotech- nology Information, http://blast.ncbi.nlm.nih.gov/Blast.cgi).",OADS,/arxiv_data1/oa_pdf/c2/4c/jvms-76-1313.PMC4197166.pdf
"Phylogenetic  analyses were performed by using an unrooted maximum- likelihood method (HKY model) with ClustalW2 (EMBL- EBI, https://www.ebi.ac.uk/Tools/msa/ clustalw2/) and the  PhyML version 3.0 program [4] (http://www.atgc-montpel- lier.fr/ phyml/).",OADS,/arxiv_data1/oa_pdf/c2/4c/jvms-76-1313.PMC4197166.pdf
http://taxonomy.zoology.,Non-OADS,/arxiv_data1/oa_pdf/c2/4c/jvms-76-1313.PMC4197166.pdf
"Copyright © 2014 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2014.20.3.223 Clinical and Molecular Hepatology 2014;20:223-227 Review INTRODUCTION  Hepatitis B virus (HBV) infection is prevalent in Asia, Africa,  Southern Europe and Latin America, where the prevalence of HB - sAg in the general population ranges from 2% to 20%.1 The long- term outcomes of chronic HBV infection vary widely.",Non-OADS,/arxiv_data1/oa_pdf/4e/0c/cmh-20-223.PMC4197169.pdf
"224 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.223of HBV carriers have been identified.4,5 Among these viral factors,  baseline serum HBV-DNA level is the main driving force for cirrho - sis and HCC development in adult HBV carriers.6 Recently, quanti - tative hepatitis B surface antigen (qHBsAg) has been increasingly  recognized to be a biomarker to predict both favorable and ad - verse outcomes of HBV carriers.7,8 In this review, qualitative and  quantitative HBV factors affecting disease progression  and the risk  stratification for disease progression in Asian HBV carriers will be  discussed.",Non-OADS,/arxiv_data1/oa_pdf/4e/0c/cmh-20-223.PMC4197169.pdf
Risk stratification for HBV infection http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.223sAg and liver disease progression.,Non-OADS,/arxiv_data1/oa_pdf/4e/0c/cmh-20-223.PMC4197169.pdf
"226 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.223multivariate analysis, age, male gender, and liver stiffness values  were independent predictors of HCC, whereas HBV-DNA level >  20,000 IU/L showed borderline statistical significance.",OADS,/arxiv_data1/oa_pdf/4e/0c/cmh-20-223.PMC4197169.pdf
Risk stratification for HBV infection http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.223oxidative stress and DNA damage.,Non-OADS,/arxiv_data1/oa_pdf/4e/0c/cmh-20-223.PMC4197169.pdf
"Copyright © 2014 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Copyright © 2014 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2014.20.3.228 Clinical and Molecular Hepatology 2014;20:228-236 Review INTRODUCTION  Liver fibrosis represents a pervasive wound-healing response,  driven primarily by the development of inflammation in response  to parenchymal acute or chronic injury.1 Liver fibrosis may be rep - resented by variable clinical manifestations, which are determined  by the type and extent of liver damage, the underlying liver dis - ease and the capacity of the whole body to respond.",Non-OADS,/arxiv_data1/oa_pdf/b1/ce/cmh-20-228.PMC4197170.pdf
"Fibrosis progression in CHB/CHC http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.228tive probability of developing cirrhosis for patients with Metavir  stage F0 or F1 fibrosis at baseline was 0%, 11% and 11% at 5  years, 10 years and 15 years respectively.",Non-OADS,/arxiv_data1/oa_pdf/b1/ce/cmh-20-228.PMC4197170.pdf
"230 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.228deficiency virus (HIV)-related immune deficiency modifies the nat - ural history of CHB with higher levels of HBV replication and a  lower rate of spontaneous HBeAg seroconversion, leading to a  more rapid liver fibrosis progression towards cirrhosis.23 Chronic  HDV infection leads to more severe liver disease than chronic HBV  mono-infection with an accelerated course of fibrosis progression,  an increased risk of hepatocellular carcinoma and early decom - pensation in the setting of established cirrhosis.24 Recipients with  graft occult HBV infection (O-HBV) and no O-HBV in the native  liver who received their grafts from donors aged above 40 years.25 Recent data from Chinese and Korean cohorts established that  metabolic syndrome is a risk factor of advanced liver fibrosis and  cirrhosis independent of viral factors in CHB.26,27 In a recent pro - spective cohort study of 663 CHB patients, new-onset metabolic  syndrome and some of its components (namely central obesity  and low high-density lipoprotein cholesterol) were found associat - ed with liver fibrosis progression (Fig.",Non-OADS,/arxiv_data1/oa_pdf/b1/ce/cmh-20-228.PMC4197170.pdf
Fibrosis progression in CHB/CHC http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.228It is a big challenge to use interferon-based antiviral therapy in  post-transplantation recurrent HCV infection because of its side  effects and concern on triggering rejection.41 Therefore its effects  on fibrosis progression have been little investigated.,Non-OADS,/arxiv_data1/oa_pdf/b1/ce/cmh-20-228.PMC4197170.pdf
"232 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.228tography (SWE, SuperSonic Imagine, Aix-en-Provence, France)  is an absolute quantification of tissue stiffness in terms of  pressure unit of kiloPascal (kPa) rather than producing semi- quantitative estimate corresponding to relative tissue strain.68  SWE was found more accurate than Fibroscan in liver fibrosis  ≥F2.69 All these imaging techniques were mostly assessed in a  cross-sectional fashion such that accuracy on applying them in  longitudinal fashion remains uncertain.",Non-OADS,/arxiv_data1/oa_pdf/b1/ce/cmh-20-228.PMC4197170.pdf
"Fibrosis progression in CHB/CHC http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.228biopsy, the imperfect gold standard of liver fibrosis assessment.",Non-OADS,/arxiv_data1/oa_pdf/b1/ce/cmh-20-228.PMC4197170.pdf
234 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.228progression in chronic hepatitis B patients positive for hepatitis B e  antigen: a prospective cohort study with paired transient elastogra - phy examination.,Non-OADS,/arxiv_data1/oa_pdf/b1/ce/cmh-20-228.PMC4197170.pdf
Fibrosis progression in CHB/CHC http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.22850.,Non-OADS,/arxiv_data1/oa_pdf/b1/ce/cmh-20-228.PMC4197170.pdf
"Fibro Touch web site,<http://www.fibrotouch.com/goods/producty - oushi1.aspx>.",Non-OADS,/arxiv_data1/oa_pdf/b1/ce/cmh-20-228.PMC4197170.pdf
236 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.228titis C. Gastroenterology 2005;128:343-350.,Non-OADS,/arxiv_data1/oa_pdf/b1/ce/cmh-20-228.PMC4197170.pdf
"Copyright © 2014 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2014.20.3.237 Clinical and Molecular Hepatology 2014;20:237-248 Review INTRODUCTION  A large number of drugs have deleterious effects on liver and  drug-induced liver injury (DILI) is a major clinical problem.",Non-OADS,/arxiv_data1/oa_pdf/54/af/cmh-20-237.PMC4197171.pdf
"238 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.237Elucidating the mechanisms of toxicity and probable susceptibil - ity factors which make patients vulnerable to DILI, will lead us to  the safer pharmaceuticals development and reducing adverse drug  reactions (ADRs).",Non-OADS,/arxiv_data1/oa_pdf/54/af/cmh-20-237.PMC4197171.pdf
Antithyroid drug-induced hepatotoxicity http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.237metabolizing enzymes between different individuals and its possi - ble impact on the hepatic injury induced by these drugs is dis - cussed here.,Non-OADS,/arxiv_data1/oa_pdf/54/af/cmh-20-237.PMC4197171.pdf
240 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.237injury induced by this antithyroid medication.,Non-OADS,/arxiv_data1/oa_pdf/54/af/cmh-20-237.PMC4197171.pdf
"Antithyroid drug-induced hepatotoxicity http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.237cess at least in part,72 one may argue that PTU might hasten liver  injury in these patients.",Non-OADS,/arxiv_data1/oa_pdf/54/af/cmh-20-237.PMC4197171.pdf
"242 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.237matter of clinicians’ personal preference, but different factors such  as patients’ age should be noticed.",Non-OADS,/arxiv_data1/oa_pdf/54/af/cmh-20-237.PMC4197171.pdf
Antithyroid drug-induced hepatotoxicity http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.237Underlying diseases Grave’s disease Several different disorders can cause hyperthyroidism.,Non-OADS,/arxiv_data1/oa_pdf/54/af/cmh-20-237.PMC4197171.pdf
"244 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.237over, elucidating the exact mechanism(s) of toxicity induced by  antithyroid medications will lead us to better management of  the developed hepatotoxic reactions.",Non-OADS,/arxiv_data1/oa_pdf/54/af/cmh-20-237.PMC4197171.pdf
Antithyroid drug-induced hepatotoxicity http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.237  8.,Non-OADS,/arxiv_data1/oa_pdf/54/af/cmh-20-237.PMC4197171.pdf
246 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.23743.,Non-OADS,/arxiv_data1/oa_pdf/54/af/cmh-20-237.PMC4197171.pdf
Antithyroid drug-induced hepatotoxicity http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.2372005;4:489-499.,Non-OADS,/arxiv_data1/oa_pdf/54/af/cmh-20-237.PMC4197171.pdf
248 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.237tions.,Non-OADS,/arxiv_data1/oa_pdf/54/af/cmh-20-237.PMC4197171.pdf
"Copyright © 2014 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728        eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2014.20.3.249 Clinical and Molecular Hepatology 2014;20:249-250 Editorial Occult hepatitis B virus (HBV) infection is defined as presence of  HBV DNA in the liver regardless of serum HBV DNA detectability  in HBsAg-negative patients.1 Occult HBV infection is not uncom - mon in Korea because the prevalence of occult HBV infection de - pends on the HBsAg carrier rate.2 The underlying mechanisms for  occult HBV infection is not fully understood yet, but both viral and  host factors are suggested to contribute to the suppressed viral  replication / secretion status.2,3 In this issue, Kim et al reported the pattern of HBs gene muta - tion in Korean patients with occult HBV infection.4 In this study,  HBV S gene was PCR-amplified and sequenced from serum and/ or tissue samples of chronic hepatitis B patients who lost se - rum HBsAg during follow-up.",Non-OADS,/arxiv_data1/oa_pdf/f0/f4/cmh-20-249.PMC4197172.pdf
250 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.249Conflicts of Interest The authors have no conflicts to disclose.,Non-OADS,/arxiv_data1/oa_pdf/f0/f4/cmh-20-249.PMC4197172.pdf
"Copyright © 2014 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2014.20.3.251 Clinical and Molecular Hepatology 2014;20:251-260 Original Article Corresponding author :  Sang Hoon Ahn Department of Internal Medicine, Yonsei University College of Medicine,  250 Seongsanno, Seodaemun-gu, Seoul 120-752, Korea  Tel: +82-2-2228-1992, Fax: +82-2-393-6884  E-mail: ahnsh@yuhs.ac Co-Corresponding author :  Kyun-Hwan Kim Department of Pharmacology, School of Medicine, Konkuk University, 1 Hwayang-dong, Gwangjin-gu, Seoul 143-701, Korea,  Tel: +82-2-2030-7833, Fax: +82-2-2049-6192  E-mail: khkim10@kku.ac.krAbbreviations:   HBV, hepatitis B virus; MHR, major hydrophilic region; HBsAg, hepatitis B  surface antigen; ccc DNA, covalently closed circular DNA Received :  Jun.",Non-OADS,/arxiv_data1/oa_pdf/e8/75/cmh-20-251.PMC4197173.pdf
"252 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.251in about 30-35% of serum samples and 40-50% of liver samples  from HBsAg-negative chronic hepatitis and persistence of HBsAg- negative infection is related with liver pathogenesis.1-8 Transmis - sion of HBV infection from such “occult” carriers has also been  documented, although infrequently.4  Many studies have attempted to determine the molecular fea - tures of HBV persistence in HBsAg-negative patients.",Non-OADS,/arxiv_data1/oa_pdf/e8/75/cmh-20-251.PMC4197173.pdf
HBsAg loss in Korean patients http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.251primer sets used were sense: 5’-TCGGAATTCTCAAATG - TATACCCAAAGACAAAAGAA-3’ and antisense: 5’-GGTAAGCT - TATGGAGAACACAACATCAGGA-3’.,Non-OADS,/arxiv_data1/oa_pdf/e8/75/cmh-20-251.PMC4197173.pdf
254 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.251and use of excess amount of template DNA.,Non-OADS,/arxiv_data1/oa_pdf/e8/75/cmh-20-251.PMC4197173.pdf
"HBsAg loss in Korean patients http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.251Relationship between spontaneous HBsAg loss and  HBV subtypes in Korea Previous reports demonstrated subtype adr (genotype C) as the  dominant HBV in Korea, accounting for more than 90 % of infec - tion.23-24 To establish the association between spontaneous HBsAg  loss and viral genotypes, the HBV subtype and genotype in each  patient was deduced from the sequence profile in the MHR region as described.25 The HBV genotypes were also verified by phyloge - netic analysis21 (Fig.",OADS,/arxiv_data1/oa_pdf/e8/75/cmh-20-251.PMC4197173.pdf
"256 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.251difference in the distribution of HBV genotypes in Korea, we  cloned and sequenced the whole surface gene from 28 HBsAg- positive patients enrolled in our hospital.",OADS,/arxiv_data1/oa_pdf/e8/75/cmh-20-251.PMC4197173.pdf
HBsAg loss in Korean patients http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.251tage against genotype C at the HBsAg negative stage of infection.,Non-OADS,/arxiv_data1/oa_pdf/e8/75/cmh-20-251.PMC4197173.pdf
258 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.251DNA which corresponds to 0.6 to 8.0 copies of ccc DNA per cell  (Table 3).,OADS,/arxiv_data1/oa_pdf/e8/75/cmh-20-251.PMC4197173.pdf
HBsAg loss in Korean patients http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.251point mutations in the MHR region36 and W172stop corresponding  to the multidrug-resistant rtA181T mutation in polymerase37 im- pair the secretion of both virions and HBsAg.,Non-OADS,/arxiv_data1/oa_pdf/e8/75/cmh-20-251.PMC4197173.pdf
260 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.251lently closed circular viral DNA in hepadnavirus-infected cells.,Non-OADS,/arxiv_data1/oa_pdf/e8/75/cmh-20-251.PMC4197173.pdf
"Copyright © 2014 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2014.20.3.261 Clinical and Molecular Hepatology 2014;20:261-266 Original Article Corresponding author :  Jun Yong Park Department of Internal Medicine, Yonsei University College of Medicine 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea Tel: 82-2-2228-1994, Fax:82-2-365-2125 E-mail: DRPJY@yuhs.acAbbreviations:   TDF, tenofovir disoproxil  fumarate; CHB, chronic hepatitis B; LAM,  lamivudine; CVR, complete virological response; HCC, hepatocellular  carcinoma; HBV, hepatitis B virus; AST, aspartate aminotransferase; ALT,  alanine aminotransferase Received :  Jul.",Non-OADS,/arxiv_data1/oa_pdf/01/be/cmh-20-261.PMC4197174.pdf
"262 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.261studies regarding hig h rate of HBV polymerase gene  mutation  and LAM drug resistance during drug administration were report - ed, ranging from 14-32% after 1 year, and 60-70% on 5 year  treatment,2 which can cause serious clinical consequences.3-5  Thus, increasing evidence supports the use of alternative antiviral  agents as the primary treatment option for CHB.6  Although preferred treatments may vary among countries and  regions, and are dependent on the HBV genotypes that are preva - lent in the region, p resent CHB treatment guidelines now recom - mend highly potent drugs, such as tenofovir disoproxil fumarate  (TDF), along with entecavir as first-line therapeutic agents.7,8 En- tecavir is an effective monotherapy in treatment-naïve patients  that has a low resistance rate (1.2%), with up to 6 years of treat - ment.9,10 TDF has provided potent, long-term suppression of HBV  replication for up to 5 years with no evidence of resistance based  on international, multicenter phase III studies.11 However, these  clinical trials focused mainly on genotype A and D. Data concern - ing CHB patients with genotype C, which is known to infect al - most all HBV patients in Korea (>95%), are lacking.12 In addition,  currently available data derived from these clinical trials often dif - fer from those of real-world clinical practice including heteroge - neous patients with other conditions.",Non-OADS,/arxiv_data1/oa_pdf/01/be/cmh-20-261.PMC4197174.pdf
"Efficacy of a 12-month tenofovir treatment http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.261RESULTS Baseline characteristics A total of 1487 patients started TDF between December 2012  and December 2013 at the Severance Hospital, Yonsei University  College of Medicine.",Non-OADS,/arxiv_data1/oa_pdf/01/be/cmh-20-261.PMC4197174.pdf
264 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.261tance.,Non-OADS,/arxiv_data1/oa_pdf/01/be/cmh-20-261.PMC4197174.pdf
"Efficacy of a 12-month tenofovir treatment http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.261phasize a reduced HBV DNA titer as a better indication of treat - ment response, since it is associated with a decreased risk of  development of liver cirrhosis or HCC as well as other liver-related  events.14,15 An ideal drug for treating CHB has superior efficacy  and lower risk of resistance and adverse effects.",Non-OADS,/arxiv_data1/oa_pdf/01/be/cmh-20-261.PMC4197174.pdf
266 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.261REFERENCES   1.,Non-OADS,/arxiv_data1/oa_pdf/01/be/cmh-20-261.PMC4197174.pdf
"Copyright © 2014 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2014.20.3.267 Clinical and Molecular Hepatology 2014;20:267-273 Original Article Corresponding author :  Hyun Woong Lee Department of Internal Medicine, Chung-Ang University College of  Medicine, 84 Heukseok-ro, Dongjak-Ku, Seoul 156-755, Korea Tel: +82-2-6299-1417, Fax: +82-2-6299-1137 E-mail: lhwdoc@hanmail.netAbbreviations:   ADV, adefovir; ALT, alanine aminotransferase; CHB, chronic hepatitis B;  ETV, entecavir; HBeAg, hepatitis B virus e antigen; HBV, hepatitis B virus;  LAM, lamivudine; LAM-r CHB, lamivudine-resistant chronic hepatitis B;  TDF, tenofovir Received :  Jun.",Non-OADS,/arxiv_data1/oa_pdf/21/26/cmh-20-267.PMC4197175.pdf
"268 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.267effects on HBV polymerase/reverse transcriptase activity, but no  direct effects on covalently closed circular DNA (cccDNA) synthe - sis; thus, prolonged therapy is usually required to ensure main - tained or sustained HBV suppression.4 In the early period, LAM was the first drug to be approved for  treatment of CHB.4,5 Worldwide studies of LAM in patients with  CHB have demonstrated good efficacy based on improved hepatic  histology, Hepatitis B virus e antigen (HBeAg) seroconversion.6,7  However, long term use of LAM leads to emergence of a resistant  HBV (YMDD) mutant.",Non-OADS,/arxiv_data1/oa_pdf/21/26/cmh-20-267.PMC4197175.pdf
Long termoutcome ofrescue treatment  http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.267Student’s t-test for continuous variables.,Non-OADS,/arxiv_data1/oa_pdf/21/26/cmh-20-267.PMC4197175.pdf
"270 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.267follow-up period, the cumulative rate of HBV-DNA undetectability  was significantly higher in ADV combination group ( P=0.016).",OADS,/arxiv_data1/oa_pdf/21/26/cmh-20-267.PMC4197175.pdf
"Long termoutcome ofrescue treatment  http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.267The cumulative virologic breakthrough rates at 1, 2, 3, 4, 5 and 6  years in each group were 0%, 9.3%, 11.1%, 14.4%, 14.4% and  14.4%, vs 4.2%, 21.6%, 40.0%, 55.6%, 61.1% and 71.9%, re - spectively (Fig.",Non-OADS,/arxiv_data1/oa_pdf/21/26/cmh-20-267.PMC4197175.pdf
"272 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.267ADV-resistance mutations are infrequent in combination therapy  with LAM.21-23 In addition, ADV has a cost benefit in its long-term  experience and safety.",Non-OADS,/arxiv_data1/oa_pdf/21/26/cmh-20-267.PMC4197175.pdf
Long termoutcome ofrescue treatment  http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.267for lamivudine-resistant chronic hepatitis B: a systematic review and  meta-analysis.,Non-OADS,/arxiv_data1/oa_pdf/21/26/cmh-20-267.PMC4197175.pdf
"Copyright © 2014 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2014.20.3.274 Clinical and Molecular Hepatology 2014;20:274-282 Original Article Corresponding author :  Jeong Han Kim Digestive Disease Center, Department of Internal Medicine, Konkuk  University School of Medicine, Konkuk University Medical Center, 120-1  Neungdong-ro, Gwangjin-gu, Seoul 143-729, Korea Tel: +82-2-2030-7764, Fax: +82-2-2030-5029 E-mail: 93haan@hanmail.netAbbreviations:   HBsAg, hepatitis B surface antigen; CHB, chronic hepatitis B; LMV,  lamivudine; ADV, adefovir; VR, virological response; ETV, entecavir;  PCR, polymerase chain reaction; ALT, alanine aminotransferase, HBeAg,  hepatitis B 'e' antigen; RFMP , restriction fragment mass polymorphism Received :  Jul.",Non-OADS,/arxiv_data1/oa_pdf/fe/0c/cmh-20-274.PMC4197176.pdf
"HBsAg in CHB patients treated with LMV-ADV combination http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.274(ETV) treatment.3-5 However, these studies involved treatment-na - ïve patients with CHB.",Non-OADS,/arxiv_data1/oa_pdf/fe/0c/cmh-20-274.PMC4197176.pdf
276 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.274Table 1.,Non-OADS,/arxiv_data1/oa_pdf/fe/0c/cmh-20-274.PMC4197176.pdf
"HBsAg in CHB patients treated with LMV-ADV combination http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.274and HBeAg negative patients (r=0.498, P=P0.022) (Fig.",Non-OADS,/arxiv_data1/oa_pdf/fe/0c/cmh-20-274.PMC4197176.pdf
"278 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.274also significantly lower in patients with VR at 6 months (2.6 vs. 4.7  Log10 IU/mL, P<0.001), 1 year (2.4 vs. 4.3 Log10 IU/mL, P<0.001)  and 2 year (1.2 vs. 3.7 Log10 IU/mL, P<0.001).",Non-OADS,/arxiv_data1/oa_pdf/fe/0c/cmh-20-274.PMC4197176.pdf
"HBsAg in CHB patients treated with LMV-ADV combination http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.274DISCUSSION CHB is an important cause of mortality and morbidity world -wide, accounting for up to 1 million deaths annually.8 HBV infec - tion is also the one of the most common etiology of chronic liver  disease in Korea.9 Although the prevalence of chronic HBV infec -33.13.23.33.43.53.63.73.83.94 Baseline 6 month 1 year 2 year 3 yearHBsAg (Log 10IU/mL)HBsAg level VR+  VR- P=0.002 P=0.004 P=0.008 P=0.020 P=0.07200.10.20.30.40.50.60.7 6 month 1 year 2 year 3 yearHBsAg (Log 10IU/mL)Reduction of HBsAg level from baseline VR+  VR- P=0.479 P=0.247 P=0.556 P=0.384 0123456789 Baseline 6 month 1 year 2 year 3 yearHBsAg (Log 10IU/mL)HBV DNA level VR+  VR- P<0.001 P<0.001 P<0.001 P<0.001 P=0.02601234567 6 month 1 year 2 year 3 yearHBsAg (Log 10IU/mL)Reduction of HBV DNA level from baseline VR+  VR- P=0.013 P=0.004 P=0.006 P=0.001 Figure 2 .",Non-OADS,/arxiv_data1/oa_pdf/fe/0c/cmh-20-274.PMC4197176.pdf
"280 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.274tion is decreasing, this plays a major role in the etiology of liver  cirrhosis and hepatocellular carcinoma in Korea.10  HBsAg has been the hallmark of HBV infection since the 1960s.11  Several studies have shown a clear correlation between serum  HBsAg level and covalently closed circular DNA (cccDNA)12-14 Stud - ies using newly available automated quantitative assays have  shown that serum levels of HBsAg are inversely proportional to  the immune response against HBV, i.e., greater the immune re - sponse, lower the HBsAg level.15 Furthermore, several studies have  shown that the decrease in serum HBsAg levels during pegylated  interferon treatment mimics that in intrahepatic cccDNA, suggest - ing that a decrease in the serum HBsAg level is associated with  the induction of an effective immune response.16-18 In contrast,  treatment with nucleoside analogs may induce a marked decrease  in HBV DNA levels; however, their effect on the serum level of HB - sAg is limited, and the decrease in the HBsAg level during treat - ment is slower than the decrease in HBV DNA.3,19-21 Therefore, the  clinical use of monitoring HBsAg levels in nucleoside analogs  treatment for CHB patients is limited.15 Several studies show a cor - relation between the HBsAg level and treatment response during  nucleoside analog treatment; however, these studies are limited by their small sample size.3-5 To our knowledge, the present study  is the first to evaluate the possibility of a correlation between HB - sAg levels and treatment response during rescue therapy for LMV- resistant CHB patients.",Non-OADS,/arxiv_data1/oa_pdf/fe/0c/cmh-20-274.PMC4197176.pdf
HBsAg in CHB patients treated with LMV-ADV combination http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.274ranted in such cases.,Non-OADS,/arxiv_data1/oa_pdf/fe/0c/cmh-20-274.PMC4197176.pdf
282 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.274rum hepatitis B surface antigen quantitation can reflect hepatitis B  virus in the liver and predict treatment response.,Non-OADS,/arxiv_data1/oa_pdf/fe/0c/cmh-20-274.PMC4197176.pdf
"Copyright © 2014 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2014.20.3.283 Clinical and Molecular Hepatology 2014;20:283-290 Original Article Corresponding author :  Dongmo Je Division of Gastroenterology, Department of Medicine, Samsung Medical  Center, Sungkyunkwan University School of Medicine, Irwon-ro 81,  Gangnam-gu, Seoul 135-710, Korea.",Non-OADS,/arxiv_data1/oa_pdf/42/9b/cmh-20-283.PMC4197177.pdf
"284 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.283decompression, or transjugular intrahepatic portosystemic shunts  can decrease portal hypertension, and esophageal variceal liga - tion (EVL) can treat the varices directly.4 It is recommended that nonselective beta-blockers are consid - ered for patients with small varices which have never bled but  have a high risk of bleeding (Child-Pugh class B, C or red color  signs on endoscopy), and nonselective beta-blockers or EVL are  considered for preventing the first bleeding occurrence in patients  with large varices (F2 or F3).2,5 EVL has been shown to be safe and  more effective than propranolol for the primary prevention of  esophageal variceal bleeding.6,7 Theoretically, direct obliteration of  varices by EVL in combination with reduction of portal pressure by  propranolol would be more effective synergistically than either  therapy applied alone.",Non-OADS,/arxiv_data1/oa_pdf/42/9b/cmh-20-283.PMC4197177.pdf
Primary prophylaxis of variceal bleeding http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.283ing; Cox regression model for predicting mortality.,Non-OADS,/arxiv_data1/oa_pdf/42/9b/cmh-20-283.PMC4197177.pdf
"286 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.283in Gr2 ( P=0.04), indicating that the patients with EVL plus pro - pranolol had a lower probability of variceal bleeding compared to  propranolol alone (Fig.",Non-OADS,/arxiv_data1/oa_pdf/42/9b/cmh-20-283.PMC4197177.pdf
Primary prophylaxis of variceal bleeding http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.283Mortality There were 20 deaths in Gr1 (6.1%) and 12 deaths in Gr2  (6.9%).,Non-OADS,/arxiv_data1/oa_pdf/42/9b/cmh-20-283.PMC4197177.pdf
288 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.283the mortality rate by treating the varices directly.6-9 The aim of the  present study was to investigate the efficacy and longterm out -come of EVL plus propranolol in comparison with propranolol  alone for the primary prophylaxis of esophageal variceal bleeding.,Non-OADS,/arxiv_data1/oa_pdf/42/9b/cmh-20-283.PMC4197177.pdf
Primary prophylaxis of variceal bleeding http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.283the bleeding control rate of Gr1 might be inferior to Gr2.,Non-OADS,/arxiv_data1/oa_pdf/42/9b/cmh-20-283.PMC4197177.pdf
290 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.283Conflicts of Interest The authors have no conflicts to disclose.,Non-OADS,/arxiv_data1/oa_pdf/42/9b/cmh-20-283.PMC4197177.pdf
"Copyright © 2014 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2014.20.3.291 Clinical and Molecular Hepatology 2014;20:291-299 Original Article Corresponding author :  Nam-Joon Yi Department of Surgery, Seoul National University College of Medicine,  101 Daehak-ro, Jongno-gu, Seoul 110-744, Korea  Tel: +82-2-2072-2990, Fax: +82-2-766-3975 E-mail: gsleenj@hanmail.netAbbreviations:   ACR, acute cellular rejection; Alc., alcoholic; AUC0 -12, area under the curve  from 0 to 1 2 hours; BUN, blood urea nitrogen; BWT, body weight; C0MPA,  plasma concentration of mycophenolic acid at pre-dosing; GFR, glomerular  filtration rate; GI, gastrointestinal; HBV, hepatitis B virus; HCC, hepatocellular  carcinoma; LC, liver cirrhosis; LDLT, living donor liver transplantation; LFT,  liver function tests; LT, liver transplantation; MELD, model for end-stage  liver disease; MMF, Mycophenolate mofetil; MPA, mycophenolic acid; POD,  postoperative days; RAI, rejection  activity index; TDM, therapeutic drug  monitoring; WBC, white blood cell Received :  Jun.",Non-OADS,/arxiv_data1/oa_pdf/f2/e2/cmh-20-291.PMC4197178.pdf
"292 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.291phenolic acid (MPA), the active metabolite.2-6 In a 2008 consensus meeting about MPA in Rome,7 the recom - mended initial daily dose of MMF was 3.0 g rather than 2.0 g with  cyclosporine in adult transplantations.",Non-OADS,/arxiv_data1/oa_pdf/f2/e2/cmh-20-291.PMC4197178.pdf
"Reduced dose of MMF with Tacrolimus in LDLT http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.291and at 1, 2, 4, 6, and 12 hours after the dose were obtained on  POD 7 and 14.",Non-OADS,/arxiv_data1/oa_pdf/f2/e2/cmh-20-291.PMC4197178.pdf
294 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.291Table 2.,Non-OADS,/arxiv_data1/oa_pdf/f2/e2/cmh-20-291.PMC4197178.pdf
"Reduced dose of MMF with Tacrolimus in LDLT http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.291Statistical analysis In the validating study, statistical analyses were performed using  SPSS version 19.0 (SPSS Inc., Illinois, USA).Continuous data were  presented as the mean ± standard deviation or medians, and cat - egorical parameters were presented as the number of cases with  percentage in parenthesis.",OADS,/arxiv_data1/oa_pdf/f2/e2/cmh-20-291.PMC4197178.pdf
296 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.291early post-LDLT.,Non-OADS,/arxiv_data1/oa_pdf/f2/e2/cmh-20-291.PMC4197178.pdf
Reduced dose of MMF with Tacrolimus in LDLT http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.291of MMF combined with tacrolimus in LDLT in Asian.,Non-OADS,/arxiv_data1/oa_pdf/f2/e2/cmh-20-291.PMC4197178.pdf
298 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.291Conflicts of Interest The authors have no conflicts to disclose.,Non-OADS,/arxiv_data1/oa_pdf/f2/e2/cmh-20-291.PMC4197178.pdf
Reduced dose of MMF with Tacrolimus in LDLT http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.29127.,Non-OADS,/arxiv_data1/oa_pdf/f2/e2/cmh-20-291.PMC4197178.pdf
"Copyright © 2014 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2014.20.3.300 Clinical and Molecular Hepatology 2014;20:300-305 Case Report INTRODUCTION  The first line therapeutic modality for non-surgical patients with  large and multifocal hepatocellular carcinoma (HCC) who do not  have vascular invasion or extrahepatic spread is transcatheter ar - terial chemoembolization (TACE).",Non-OADS,/arxiv_data1/oa_pdf/14/b4/cmh-20-300.PMC4197179.pdf
"Gastrectomy after radioembolization http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.300CASE A 67-year-old male, inactive hepatitis B virus (HBV) carrier  (HBeAg negative with undetectable serum HBV DNA level), was  admitted for further evaluation and treatment of hepatic masses.",Non-OADS,/arxiv_data1/oa_pdf/14/b4/cmh-20-300.PMC4197179.pdf
302 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.300view of the portal vein patency were done.,Non-OADS,/arxiv_data1/oa_pdf/14/b4/cmh-20-300.PMC4197179.pdf
Gastrectomy after radioembolization http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.300tient was readmitted due to severe abdominal pain four days after  discharge.,Non-OADS,/arxiv_data1/oa_pdf/14/b4/cmh-20-300.PMC4197179.pdf
304 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.300without HCC recurrence after 30 months of gastrectomy.,Non-OADS,/arxiv_data1/oa_pdf/14/b4/cmh-20-300.PMC4197179.pdf
Gastrectomy after radioembolization http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.300surface causing lack of response of acid suppression therapy  which acts primarily at the mucosa.3 Radiation enteritis is known  to be caused by excessive stimulation of transforming growth fac - tor (TGF)-β1 which leads to fibrosis and organ failure.,Non-OADS,/arxiv_data1/oa_pdf/14/b4/cmh-20-300.PMC4197179.pdf
"Copyright © 2014 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2014.20.3.306 Clinical and Molecular Hepatology 2014;20:306-309 Case Report INTRODUCTION  The coexistence hepatocellular carcinoma (HCC) and renal cell  carcinoma (RCC) is extremely rare, and only a few case reports  could be found in the literature.1  Radiofrequency ablation (RFA) has been shown to be safe and  successful for local tumor control in patients with HCC and is in - creasingly used for HCC patients.2-4 Currently, RFA and cryoabla - tion are considered alternatives to a partial nephrectomy in pa - tients unable to undergo surgery.5 These treatment options offer  several benefits compared to a nephrectomy, including a lower  complication rate, shorter hospital stay, less ischemic damage, and  the potential for outpatient management of the patient.5  We present a case of synchronous HCC and RCC treated with  RFA and a review of the literature.CASE REPORT A-53-year-old man visited our hospital with general weakness.",Non-OADS,/arxiv_data1/oa_pdf/95/0d/cmh-20-306.PMC4197180.pdf
Synchronous HCC and RCC treated with RFA http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.306of the liver and 1.9 cm hypervascular mass in left kidney.,Non-OADS,/arxiv_data1/oa_pdf/95/0d/cmh-20-306.PMC4197180.pdf
"308 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.306bolus of contrast material.9 The renal parenchyma enhances ho - mogeneously, allowing for the best opportunity for discrimination  between the normal renal medulla and masses.9 Most RCCs have  the tendency to show isointensity to hypointensity on T1 -weight - ed images and hyperintensity on T2-weighted images, although  large RCCs tend to show heterogeneous signal intensity reflecting  necrosis and hemorrhage.10 Our specific CT and MRI findings were  correctly indicated in the diagnostic criteria of the HCC and RCC.",Non-OADS,/arxiv_data1/oa_pdf/95/0d/cmh-20-306.PMC4197180.pdf
"Synchronous HCC and RCC treated with RFA http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.306TACE and RFA were shown to be as effective as a liver resection  for HCC in a recent study, with similar 1-, 3-, and 5-year overall  and recurrence-free survival rates.13 In cases of RCC, radical or partial nephrectomy is the standard  treatment for localized RCC.14 Since it was first applied in 1997, re - nal RFA has become increasingly more accepted during the past  few years.14 RFA has been used as a nephron sparing alternative  to a partial nephrectomy, with good early results.14 Recent report shows that RFA is an effective minimally invasive  therapy for the treatment of cT1a RCC, yielding equivalent long- term oncologic outcomes to nephron-sparing surgery.15 A charac - teristic of RFA is its cooling effect on the blood flow, which has a  considerable effect on the outcome of RFA treatment.16 The poten - tial advantages of RFA over surgery include: having minimal inva - siveness, avoiding damage to adjacent tissues, preserving the sur - rounding renal parenchyma, and reducing the complication rate,  resulting in a shorter hospital stay.17 But liver cirrhosis patients  have an inhibitive risk to perform either a biopsy of the RCC or its  resection.",Non-OADS,/arxiv_data1/oa_pdf/95/0d/cmh-20-306.PMC4197180.pdf
"Copyright © 2014 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728        eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2014.20.3.310 Clinical and Molecular Hepatology 2014;20:310-312 Letter to the Editor To the Editor, A 41-year-old man was admitted to our hospital for investiga - tion of a liver mass with extensive lymph node (LN) enlargement  that was detected during follow-up abdominal computed tomog - raphy (CT) for chronic viral hepatitis B.",Non-OADS,/arxiv_data1/oa_pdf/c9/38/cmh-20-310.PMC4197181.pdf
"Small HCC with an extensive lymph node metastasis   http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.310less than 2cm in diameter, is showing more than 50% of a 5-year  survival rate.4     Because LN metastasis of small HCC are very rare and good  prognosis, the clinical significance has not well investigated and  the relationship between the type of a primary HCC lesion and  type of accompanying lymph node metastasis has not been docu - mented.",Non-OADS,/arxiv_data1/oa_pdf/c9/38/cmh-20-310.PMC4197181.pdf
312 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.310Conflicts of Interest No potential conflict of interest relevant to this article was re - ported.,Non-OADS,/arxiv_data1/oa_pdf/c9/38/cmh-20-310.PMC4197181.pdf
"Copyright © 2014 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2014.20.3.313 Clinical and Molecular Hepatology 2014;20:313-316 Liver Pathology INTRODUCTION  The sarcomatoid variant of hepatocellular carcinoma (HCC) is a  rare histologic variant comprising malignant spindle cells and typical  HCC.",Non-OADS,/arxiv_data1/oa_pdf/01/bd/cmh-20-313.PMC4197182.pdf
314 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.313lating mass (Fig.,Non-OADS,/arxiv_data1/oa_pdf/01/bd/cmh-20-313.PMC4197182.pdf
"Sarcomatoid Hepatocellular carcinoma with mixed osteoclast-like giant cells and chondroid differentiation  http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.313having 10-25 small nuclei within the cytoplasm, the so-called os - teoclast-like giant cells (OGC) (Fig.",Non-OADS,/arxiv_data1/oa_pdf/01/bd/cmh-20-313.PMC4197182.pdf
"316 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.313compared with classical HCC, and there are no effective diagnos - tic tools except for tissue confirmation; thus, several studies have  recommended close follow-up and biopsy for tissue confirmation  when unusual or atypical features are found in radiological stud - ies.3,13,14  This case was histologically typical but interesting in that it had  two distinct tumor cell types on macro- and microscopic findings  with a transitional zone and spindle cell components that con - tained a unique combination of OGC and chondroid differentia - tion.",Non-OADS,/arxiv_data1/oa_pdf/01/bd/cmh-20-313.PMC4197182.pdf
"Copyright © 2014 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2014.20.3.317 Clinical and Molecular Hepatology 2014;20:317-326 Liver Imaging INTRODUCTION  It is important to recognize and understand the different chemo - therapeutic agents and how they affect the various organs.",Non-OADS,/arxiv_data1/oa_pdf/13/9b/cmh-20-317.PMC4197183.pdf
"318 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.317ing with DNA and RNA synthesis as well as cell division.2 These  include alkylating agents, anti-metabolites, anti-tumor antibiotics,  isomerase inhibitors, mitotic inhibitors.",Non-OADS,/arxiv_data1/oa_pdf/13/9b/cmh-20-317.PMC4197183.pdf
Chemotherapy induced liver abnormalities: An imaging perspective http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.317S-phase of the cell cycle by substituting structural analogues of  purines and pyrimidines in place of naturally occurring bases.,Non-OADS,/arxiv_data1/oa_pdf/13/9b/cmh-20-317.PMC4197183.pdf
320 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.317tem to fight off the cancer.,Non-OADS,/arxiv_data1/oa_pdf/13/9b/cmh-20-317.PMC4197183.pdf
"Chemotherapy induced liver abnormalities: An imaging perspective http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.317in both metastatic breast and colon cancer, but it has also been  reported in metastatic pancreatic cancer after gemcitabine and  oxaliplatin therapy.26 Pseudocirrhosis is defined by morphology changes in the liver  parenchyma that mimics liver cirrhosis, and can cause retracted  tumor tissue and scarring (Fig.",Non-OADS,/arxiv_data1/oa_pdf/13/9b/cmh-20-317.PMC4197183.pdf
"322 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.317ring, the liver parenchyma can regenerate and this accounts for its  appearance.",Non-OADS,/arxiv_data1/oa_pdf/13/9b/cmh-20-317.PMC4197183.pdf
Chemotherapy induced liver abnormalities: An imaging perspective http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.317steatosis.,Non-OADS,/arxiv_data1/oa_pdf/13/9b/cmh-20-317.PMC4197183.pdf
324 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.317hepatotoxic to induce liver necrosis.33 CT findings of hepatic necro - sis include marked decrease of the enhancement of hepatic paren - chyma and cystic change when severe necrosis occurs (Fig.,Non-OADS,/arxiv_data1/oa_pdf/13/9b/cmh-20-317.PMC4197183.pdf
"Chemotherapy induced liver abnormalities: An imaging perspective http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.317CONCLUSION  Cancer chemotherapy may be toxic to the liver, and recognition  of patterns of liver injury is crucial to the clinician and radiologist.",Non-OADS,/arxiv_data1/oa_pdf/13/9b/cmh-20-317.PMC4197183.pdf
326 Clin Mol Hepatol Volume _20  Number _3  September 2014 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2014.20.3.3172003;123:100-102.,Non-OADS,/arxiv_data1/oa_pdf/13/9b/cmh-20-317.PMC4197183.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Although definitions of the term vary, a frequently cited  definition of cancer survivor is the following: An individual is  considered a cancer survivor from the time of diagnosis,  through the balance of his or her life.",Non-OADS,/arxiv_data1/oa_pdf/17/18/jbc-17-189.PMC4197348.pdf
"In terms of the value of a quali - tative approach, which is discussed in detail in the section  “Qualitative approach toward understanding of breast cancer  survivorship, ” we believed this would be a pragmatic first step  to choose focused topics from among a wide range of survi -A Review of Breast Cancer Survivorship Issues from Survivors’ Perspectives Jihyoung Cho*, So-Y oun Jung1,*, Jung Eun Lee2, Eun-Jung Shim3, Nam Hyoung Kim4, Zisun Kim5, Guiyun Sohn6,  Hyun Jo Y oun7, Ku Sang Kim8, Hanna Kim6,9, Jong Won Lee6, Min Hyuk Lee10 Department of Surgery, Dongsan Medical Center, Keimyung University School of Medicine, Daegu; 1Breast Cancer Center, National Cancer Center, Goyang;  2Department of Food and Nutrition, Sookmyung Women’s University, Seoul; 3Department of Psychology, Pusan National University School of Medicine,  Busan; 4Department of Advertising and Branding, Kaywon University of Art and Design, Uiwang; 5Department of Surgery, Soonchunhyang University  College of Medicine, Bucheon; 6Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul; 7Department of Surgery,  Chonbuk National University Medical School, Jeonju; 8Department of Surgery, Ajou University School of Medicine, Suwon, Korea; 9Saint Louis University  School of Medicine, St. Louis, Missouri, USA; 10Department of Surgery, Soonchunhyang University College of Medicine, Seoul, KoreaREVIEW ARTICLEJ Breast Cancer 2014 September; 17(3): 189-199  http://dx.doi.org/10.4048/jbc.2014.17.3.189 Despite the fact that more breast cancer survivors are currently  enjoying longer lifespans, there remains limited knowledge about  the factors and issues that are of greatest significance for these  survivors, particularly from their perspectives.",Non-OADS,/arxiv_data1/oa_pdf/17/18/jbc-17-189.PMC4197348.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.189vorship issues.,Non-OADS,/arxiv_data1/oa_pdf/17/18/jbc-17-189.PMC4197348.pdf
Focused Review of Breast Cancer Survivorship Issues191 http://dx.doi.org/10.4048/jbc.2014.17.3.189  http://ejbc.krSEXUAL WELL-BEING Sexuality is a basic and important domain of quality of life  (QoL) for humans.,Non-OADS,/arxiv_data1/oa_pdf/17/18/jbc-17-189.PMC4197348.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.189refer all potential patients to the appropriate reproductive en - docrinologist to ensure that the patients receive sufficient in - formation and to avoid treatment delays [38].,Non-OADS,/arxiv_data1/oa_pdf/17/18/jbc-17-189.PMC4197348.pdf
"Focused Review of Breast Cancer Survivorship Issues193 http://dx.doi.org/10.4048/jbc.2014.17.3.189  http://ejbc.krGenetic predisposition is, of course, one of the most impor - tant risk factors for breast cancer and accounts for 5% to 10%  of all breast cancers [49].",Non-OADS,/arxiv_data1/oa_pdf/17/18/jbc-17-189.PMC4197348.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.189guidelines from the U.S. Department of Health and Human  Services of 10 metabolic equivalent-hours/week for 18 to 48  months postdiagnosis had a lower risk of death [73].,Non-OADS,/arxiv_data1/oa_pdf/17/18/jbc-17-189.PMC4197348.pdf
"Focused Review of Breast Cancer Survivorship Issues195 http://dx.doi.org/10.4048/jbc.2014.17.3.189  http://ejbc.krinstance, in a large-scale qualitative study, identifying psycho - logical, physical, and contextual and environmental barriers,  Hefferon et al.",Non-OADS,/arxiv_data1/oa_pdf/17/18/jbc-17-189.PMC4197348.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.189survivor’s life, including the physical, psychological, social,  economic, and existential or spiritual aspects [113], a compre - hensive and multidisciplinary approach should be considered  for breast cancer survivorship research.",Non-OADS,/arxiv_data1/oa_pdf/17/18/jbc-17-189.PMC4197348.pdf
Focused Review of Breast Cancer Survivorship Issues197 http://dx.doi.org/10.4048/jbc.2014.17.3.189  http://ejbc.krterval to definitive breast surgery on clinical presentation and survival  in early-stage invasive breast cancer.,Non-OADS,/arxiv_data1/oa_pdf/17/18/jbc-17-189.PMC4197348.pdf
Epub 2013 Mar 4. http://dx.doi.org/10.1097/ COC.0b013e318280d79f.,Non-OADS,/arxiv_data1/oa_pdf/17/18/jbc-17-189.PMC4197348.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.18945.,Non-OADS,/arxiv_data1/oa_pdf/17/18/jbc-17-189.PMC4197348.pdf
Focused Review of Breast Cancer Survivorship Issues199 http://dx.doi.org/10.4048/jbc.2014.17.3.189  http://ejbc.krintroduction to qualitative methods in health and health services re - search.,Non-OADS,/arxiv_data1/oa_pdf/17/18/jbc-17-189.PMC4197348.pdf
Focused Review of Breast Cancer Survivorship Issues  http://ejbc.krAppendix 1.,Non-OADS,/arxiv_data1/oa_pdf/17/18/jbc-17-189.PMC4197348.pdf
" Jihyoung Cho, et al.http://ejbc.kr  Appendix 2.",Non-OADS,/arxiv_data1/oa_pdf/17/18/jbc-17-189.PMC4197348.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Breast cancer is a common malignancy and the second lead - ing cause of death in women [1].",Non-OADS,/arxiv_data1/oa_pdf/89/0e/jbc-17-200.PMC4197349.pdf
"Downregulation of siRNA-Mediated Suppression of Synuclein γ Inhibits MDA-MB-231 Cell  Migration and Proliferation by Downregulating the Phosphorylation of AKT  and ERK Jingsong He*, Ni Xie1,*, Jianbo Y ang2, Hong Guan3, Weicai Chen, Huisheng Wu, Zishan Yuan, Kun Wang, Guojin Li,   Jie Sun, Limin Yu Department of Breast Surgery and 1Biobank, The First Affiliated Hospital of Shenzhen University, Second People’s Hospital of Shen Zhen, Shen Zhen, China;  2Department of Laboratory Medicine and Pathology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA;3Department of Pathology,  The First Affiliated Hospital of Shenzhen University, Second People’s Hospital of Shen Zhen, Shen Zhen, ChinaORIGINAL ARTICLEJ Breast Cancer 2014 September; 17(3): 200-206  http://dx.doi.org/10.4048/jbc.2014.17.3.200 Purpose:  Synuclein- γ (SNCG), which was initially identified as  breast cancer specific gene 1, is highly expressed in advanced  breast cancers, but not in normal or benign breast tissue.",Non-OADS,/arxiv_data1/oa_pdf/89/0e/jbc-17-200.PMC4197349.pdf
The Effects of SNCG siRNA on Human Breast Cancer 201 http://dx.doi.org/10.4048/jbc.2014.17.3.200  http://ejbc.krSNCG expression sensitizes breast cancer cells to antimicrotu - bule agent-induced cytotoxicity [12-14].,Non-OADS,/arxiv_data1/oa_pdf/89/0e/jbc-17-200.PMC4197349.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.200lution, for 30 minutes in dark at 37°C; cells were then analyzed  by flow cytometry (Beckman Coulter, Brea, USA).",OADS,/arxiv_data1/oa_pdf/89/0e/jbc-17-200.PMC4197349.pdf
The Effects of SNCG siRNA on Human Breast Cancer 203 http://dx.doi.org/10.4048/jbc.2014.17.3.200  http://ejbc.krE PI103 102 101 100 100 101 102 103 Annexin V-FITC F PI103 102 101 100 100 101 102 103 Annexin V-FITC D PI103 102 101 100 100 101 102 103 Annexin V-FITCA PI103 102 101 100 100 101 102 103 Annexin V-FITC B PI103 102 101 100 100 101 102 103 Annexin V-FITC C PI103 102 101 100 100 101 102 103 Annexin V-FITC Figure 4.,Non-OADS,/arxiv_data1/oa_pdf/89/0e/jbc-17-200.PMC4197349.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.200Figure 5.,Non-OADS,/arxiv_data1/oa_pdf/89/0e/jbc-17-200.PMC4197349.pdf
"The Effects of SNCG siRNA on Human Breast Cancer 205 http://dx.doi.org/10.4048/jbc.2014.17.3.200  http://ejbc.krp-AKT and p-ERK levels (Figure 6), while there were no sig - nificant differences in the expression levels of AKT and ERK  among the four groups.",Non-OADS,/arxiv_data1/oa_pdf/89/0e/jbc-17-200.PMC4197349.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.200clein promotes cancer cell survival and inhibits stress- and chemothera - py drug-induced apoptosis by modulating MAPK pathways.,Non-OADS,/arxiv_data1/oa_pdf/89/0e/jbc-17-200.PMC4197349.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Breast cancer is one of the most common cancers in women  and a major cancer death in women.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/jbc-17-207.PMC4197350.pdf
"Efp is a downstream target of estro - gen receptor and mediates estrogen-induced cell growth,  which implies possible involvement in the development of The Role and Regulatory Mechanism of 14-3-3 Sigma in Human Breast Cancer SeungSang Ko*, Ji Y oung Kim1,*, Joon Jeong2, Jong Eun Lee3, Woo Ick Y ang4, Woo Hee Jung4 Department of Surgery, Cheil General Hospital & Women’s Health Care Center, Catholic Kwandong University College of Medicine, Seoul;  1Department of  Pathology, CHA Gangnam Medical Center, CHA University, Seoul; Departments of  2Surgery, 3Anatomy, and 4Pathology, Y onsei University College of  Medicine, Seoul, KoreaORIGINAL ARTICLEJ Breast Cancer 2014 September; 17(3): 207-218  http://dx.doi.org/10.4048/jbc.2014.17.3.207 Purpose:  14-3-3 sigma ( σ) is considered to be an important tu - mor suppressor and decreased expression of the same has  been reported in many malignant tumors by hypermethylation at  its promoter or ubiquitin-mediated proteolysis by estrogen-   responsive ring finger protein (Efp).",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/jbc-17-207.PMC4197350.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.207human breast cancers.,Non-OADS,/arxiv_data1/oa_pdf/d7/f2/jbc-17-207.PMC4197350.pdf
"Efp and 14-3-3 Sigma in Breast Cancer209 http://dx.doi.org/10.4048/jbc.2014.17.3.207  http://ejbc.krdone with NovaRed (Vector Laboratories), and then the slides  were counterstained with hematoxylin.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/jbc-17-207.PMC4197350.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.207for the methylated primer, and 72°C for 30 seconds; and 1 cycle  of 72°C for 4 minutes.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/jbc-17-207.PMC4197350.pdf
"Efp and 14-3-3 Sigma in Breast Cancer211 http://dx.doi.org/10.4048/jbc.2014.17.3.207  http://ejbc.krtive group frequently showed high nuclear grade, high histo - logic grade, and p53 positive cells.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/jbc-17-207.PMC4197350.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.207pression ( p= 0.009).,Non-OADS,/arxiv_data1/oa_pdf/d7/f2/jbc-17-207.PMC4197350.pdf
"Efp and 14-3-3 Sigma in Breast Cancer213 http://dx.doi.org/10.4048/jbc.2014.17.3.207  http://ejbc.krhormone receptor-positive group was more frequently hyper - methylated (45/71 cases, 63.4%) than the triple-negative group  (17/28 cases, 60.7%), but the difference was not statistically sig - nificant (Table 6).",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/jbc-17-207.PMC4197350.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.207σ showed that 14-3-3 σ expression was significantly associated  with an increased risk of recurrence and disease-related death  (p= 0.011 and p= 0.022), while Efp was not.",OADS,/arxiv_data1/oa_pdf/d7/f2/jbc-17-207.PMC4197350.pdf
"Efp and 14-3-3 Sigma in Breast Cancer215 http://dx.doi.org/10.4048/jbc.2014.17.3.207  http://ejbc.krlignant with the loss of 14-3-3 σ expression in 8%, 35%, and  77% of usual ductal hyperplasia, ductal carcinoma in situ  (DCIS), and invasive ductal carcinoma (IDC) lesions, respec -tively, which indicates the role of 14-3-3 σ as a tumor suppres - sor in breast carcinogenesis [20].",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/jbc-17-207.PMC4197350.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.207in hyperplasia without atypia, 38% in atypical hyperplasia,  83% in DCIS, and 96% in IDC [10].",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/jbc-17-207.PMC4197350.pdf
Efp and 14-3-3 Sigma in Breast Cancer217 http://dx.doi.org/10.4048/jbc.2014.17.3.207  http://ejbc.krprognosis was in contrast to the previously known function of  14-3-3 σ as a tumor suppressor.,Non-OADS,/arxiv_data1/oa_pdf/d7/f2/jbc-17-207.PMC4197350.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.207hofstede C, et al.",OADS,/arxiv_data1/oa_pdf/d7/f2/jbc-17-207.PMC4197350.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Cancer is a major health problem and one of the main  causes of mortality worldwide [1].",Non-OADS,/arxiv_data1/oa_pdf/d3/62/jbc-17-219.PMC4197351.pdf
"Carotenoids are yellow-orange pigments that are found in all Antiproliferatory Effects of Crab Shell Extract on Breast Cancer Cell Line  (MCF7) Leila Rezakhani, Zahra Rashidi, Pegah Mirzapur, Mozafar Khazaei Fertility and Infertility Research Center, Kermanshah University of Medical Sciences, Kermanshah, IranORIGINAL ARTICLEJ Breast Cancer 2014 September; 17(3): 219-225  http://dx.doi.org/10.4048/jbc.2014.17.3.219 Purpose:  Breast cancer is the most common type of cancer in  women.",Non-OADS,/arxiv_data1/oa_pdf/d3/62/jbc-17-219.PMC4197351.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.219higher plants and some animals.,Non-OADS,/arxiv_data1/oa_pdf/d3/62/jbc-17-219.PMC4197351.pdf
Antiproliferatory Crab Shell effect on MCF7  Cell Line221 http://dx.doi.org/10.4048/jbc.2014.17.3.219  http://ejbc.krNO assay NO was measured using the Griess staining method.,OADS,/arxiv_data1/oa_pdf/d3/62/jbc-17-219.PMC4197351.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.219MCF7 apoptosis   The apoptosis index of MCF7 cells treated with crab shell  extract showed an increase from control to experimental  groups in order of concentration, exhibiting a significant dif - ference with 400 ( p< 0.050), and 800 and 1,000 µg/mL ( p<  0.001) doses (Figure 4A, B).",Non-OADS,/arxiv_data1/oa_pdf/d3/62/jbc-17-219.PMC4197351.pdf
"Antiproliferatory Crab Shell effect on MCF7  Cell Line223 http://dx.doi.org/10.4048/jbc.2014.17.3.219  http://ejbc.kr24, 48, and 72-hour periods [19] and 100–1,000 µg/mL doses  [20] are used to analyze the effects of natural compounds on  cancer cell lines.",Non-OADS,/arxiv_data1/oa_pdf/d3/62/jbc-17-219.PMC4197351.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.219time caused cell growth to decline but viability did not fall be - low 50%, which could be because raw extract was used in the  present study unlike the previous study that used distinct and  pure compounds.",Non-OADS,/arxiv_data1/oa_pdf/d3/62/jbc-17-219.PMC4197351.pdf
"Antiproliferatory Crab Shell effect on MCF7  Cell Line225 http://dx.doi.org/10.4048/jbc.2014.17.3.219  http://ejbc.krnitric oxide synthase, and hypoxia-inducible factor 1alpha expression,  resulting in reduced angiogenesis.",Non-OADS,/arxiv_data1/oa_pdf/d3/62/jbc-17-219.PMC4197351.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION The Gail model is one of the most widely used breast cancer  risk assessment tools.",Non-OADS,/arxiv_data1/oa_pdf/dc/a4/jbc-17-226.PMC4197352.pdf
"As such, it is necessary to devel - op a breast cancer risk assessment tool especially for Asian Validation of Risk Assessment Models for Predicting the Incidence of Breast  Cancer in Korean Women Jun Won Min, Myung-Chul Chang, Hae Kyung Lee1, Min Hee Hur1, Dong-Y oung Noh2, Jung Han Y oon3, Y ongsik Jung4,  Jung-Hyun Y ang5, Korean Breast Cancer Society Department of Surgery, Dankook University College of Medicine, Cheonan; 1Department of Surgery, Cheil General Hospital and Women’s Healthcare  Center, Kwandong University College of Medicine, Seoul; 2Department of Surgery, Seoul National University College of Medicine, Seoul; 3Department of  Surgery, Chonnam National University Hwasun Hospital, Hwasun; 4Department of Surgery, Ajou University School of Medicine, Suwon; 5Department of  Surgery, Konkuk University School of Medicine, Seoul, KoreaORIGINAL ARTICLEJ Breast Cancer 2014 September; 17(3): 226-235  http://dx.doi.org/10.4048/jbc.2014.17.3.226 Purpose:  The Gail model is one of the most widely used tools to  assess the risk of breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/dc/a4/jbc-17-226.PMC4197352.pdf
Validation of Korean Breast Cancer Risk Assessment Program227 http://dx.doi.org/10.4048/jbc.2014.17.3.226  http://ejbc.krwomen.,Non-OADS,/arxiv_data1/oa_pdf/dc/a4/jbc-17-226.PMC4197352.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.226After construction of the log-relative risks, all three models  followed the procedure presented below.",OADS,/arxiv_data1/oa_pdf/dc/a4/jbc-17-226.PMC4197352.pdf
Validation of Korean Breast Cancer Risk Assessment Program229 http://dx.doi.org/10.4048/jbc.2014.17.3.226  http://ejbc.krTable 2.,Non-OADS,/arxiv_data1/oa_pdf/dc/a4/jbc-17-226.PMC4197352.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.226cer were expected and 161 were observed.,OADS,/arxiv_data1/oa_pdf/dc/a4/jbc-17-226.PMC4197352.pdf
Validation of Korean Breast Cancer Risk Assessment Program231 http://dx.doi.org/10.4048/jbc.2014.17.3.226  http://ejbc.krpatients aged 45 –49.,Non-OADS,/arxiv_data1/oa_pdf/dc/a4/jbc-17-226.PMC4197352.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.226years or more.,Non-OADS,/arxiv_data1/oa_pdf/dc/a4/jbc-17-226.PMC4197352.pdf
"Validation of Korean Breast Cancer Risk Assessment Program233 http://dx.doi.org/10.4048/jbc.2014.17.3.226  http://ejbc.krDISCUSSION In this study, we have validated the modified Gail model  (model 2), Asian American Gail model, and Korean model  using a dataset of Korean breast cancer screening patients.",Non-OADS,/arxiv_data1/oa_pdf/dc/a4/jbc-17-226.PMC4197352.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.226participant permission would need to be conducted.,Non-OADS,/arxiv_data1/oa_pdf/dc/a4/jbc-17-226.PMC4197352.pdf
http://www.kosis.kr/.,Non-OADS,/arxiv_data1/oa_pdf/dc/a4/jbc-17-226.PMC4197352.pdf
Validation of Korean Breast Cancer Risk Assessment Program235 http://dx.doi.org/10.4048/jbc.2014.17.3.226  http://ejbc.krof the Gail et al.,Non-OADS,/arxiv_data1/oa_pdf/dc/a4/jbc-17-226.PMC4197352.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Breast cancer is the most common cancer in women world - wide and the leading cause of cancer death among women.",Non-OADS,/arxiv_data1/oa_pdf/a5/80/jbc-17-236.PMC4197353.pdf
"Tabriz is the capital of East Azerbaijan Prov - ince, with a population of over 1.5 million people, and is the  largest, most populous, and industrialized city in the North  West of Iran; according to recent reports from the National  Center for Cancer Registration, the incidence of breast cancer Risk Factors for Breast Cancer in Iranian Women: A Hospital-Based Case- Control Study in Tabriz, Iran Mina Hosseinzadeh, Jamal Eivazi Ziaei1, Nader Mahdavi2, Parvaneh Aghajari3, Maryam Vahidi3, Alaviehe Fateh4,   Elnaz Asghari3 Department of Nursing, Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz; 1Hematology and Oncology Research  Center, Tabriz University of Medical Sciences, Tabriz; 2Department of Public Health, Maragheh University of Medical Science, Maragheh; 3Department of  Nursing, Tabriz Medical University, Tabriz; 4Department of Genetics, Tabriz University, Tabriz, IranORIGINAL ARTICLEJ Breast Cancer 2014 September; 17(3): 236-243  http://dx.doi.org/10.4048/jbc.2014.17.3.236 Purpose:  Breast cancer is the most common cancer in women  worldwide and the leading cause of cancer death among wom - en.",Non-OADS,/arxiv_data1/oa_pdf/a5/80/jbc-17-236.PMC4197353.pdf
"Risk Factors of Breast Cancer in Tabriz, Iran237 http://dx.doi.org/10.4048/jbc.2014.17.3.236  http://ejbc.kris higher in East Azerbaijan than in neighboring provinces [2].",Non-OADS,/arxiv_data1/oa_pdf/a5/80/jbc-17-236.PMC4197353.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.236Table 1.,Non-OADS,/arxiv_data1/oa_pdf/a5/80/jbc-17-236.PMC4197353.pdf
"Risk Factors of Breast Cancer in Tabriz, Iran239 http://dx.doi.org/10.4048/jbc.2014.17.3.236  http://ejbc.krstandard deviation, and OR with 95% CI were calculated.",OADS,/arxiv_data1/oa_pdf/a5/80/jbc-17-236.PMC4197353.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.236Table 1 shows the distribution of variables, ORs, and 95%  CIs from the univariate regression analysis of general risk fac - tors, while Table 2 shows the corresponding data for repro - ductive risk factors.",OADS,/arxiv_data1/oa_pdf/a5/80/jbc-17-236.PMC4197353.pdf
"Risk Factors of Breast Cancer in Tabriz, Iran241 http://dx.doi.org/10.4048/jbc.2014.17.3.236  http://ejbc.kr(OR, 3.09; 95% CI, 1.39–6.90) showed a statistically significant  association with breast cancer in the multivariate logistic re - gression model; therefore, they were considered to be risk fac - tors.",Non-OADS,/arxiv_data1/oa_pdf/a5/80/jbc-17-236.PMC4197353.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.236in postmenopausal women, physical activity throughout the  lifetime reduced the risk of breast cancer; in the present study,  we did not examine premenstrual and postmenopausal wom - en separately.",Non-OADS,/arxiv_data1/oa_pdf/a5/80/jbc-17-236.PMC4197353.pdf
"Risk Factors of Breast Cancer in Tabriz, Iran243 http://dx.doi.org/10.4048/jbc.2014.17.3.236  http://ejbc.krtraining in the field are now required to promote a healthy  diet, a change of unhealthy eating patterns, and methods for  coping with stress.",Non-OADS,/arxiv_data1/oa_pdf/a5/80/jbc-17-236.PMC4197353.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Sentinel lymph node biopsy (SLNB) is currently recognized  as the basic surgical method for axillary nodal staging in clini - cally axillary node-negative breast cancer patients [1].",Non-OADS,/arxiv_data1/oa_pdf/48/65/jbc-17-244.PMC4197354.pdf
"The purpose of this study was to investigate the frequency of  the axillary arch among patients with breast cancer who under - go SLNB and to determine whether the presence of the axil -Clinical Significance of the Axillary Arch in Sentinel Lymph Node Biopsy Won Ho Kil, Jeong Eon Lee, Seok Jin Nam Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaORIGINAL ARTICLEJ Breast Cancer 2014 September; 17(3): 244-249  http://dx.doi.org/10.4048/jbc.2014.17.3.244 Purpose:  The axillary arch is an anomalous muscle that is not in - frequently encountered during axillary sentinel lymph node biop - sy (SLNB) of breast cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/48/65/jbc-17-244.PMC4197354.pdf
Clinical Significance of the Axillary Arch in Sentinel Lymph Node Biopsy245 http://dx.doi.org/10.4048/jbc.2014.17.3.244  http://ejbc.krlary arch affects the rate of intraoperative SLN identification.,Non-OADS,/arxiv_data1/oa_pdf/48/65/jbc-17-244.PMC4197354.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.244surgery was performed in 793 patients (74.2%), and mastec- tomies were performed in 276 patients (25.8%).",OADS,/arxiv_data1/oa_pdf/48/65/jbc-17-244.PMC4197354.pdf
"Clinical Significance of the Axillary Arch in Sentinel Lymph Node Biopsy247 http://dx.doi.org/10.4048/jbc.2014.17.3.244  http://ejbc.krgroup with the axillary arch and the group without the axillary  arch; the group with the axillary arch showed a 12.7% (10/79)  SLNB failure rate, while the group without the axillary arch  showed a 1.4% (14/990) failure rate.",Non-OADS,/arxiv_data1/oa_pdf/48/65/jbc-17-244.PMC4197354.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.244tients in the high axillary group (Figure 2); the low axillary  and the combined group accounted for 13 patients (19%) and  10 patients (14%), respectively.",OADS,/arxiv_data1/oa_pdf/48/65/jbc-17-244.PMC4197354.pdf
Clinical Significance of the Axillary Arch in Sentinel Lymph Node Biopsy249 http://dx.doi.org/10.4048/jbc.2014.17.3.244  http://ejbc.krREFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/48/65/jbc-17-244.PMC4197354.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION The axillary lymph node status is the most significant prog - nostic factor in patients with breast cancer [1-4].",Non-OADS,/arxiv_data1/oa_pdf/3d/83/jbc-17-250.PMC4197355.pdf
"The aim of  this study was to evaluate the clinical utility of using a combi - nation of ICG with PB dye versus using blue dye alone for SLN  detection in patients with breast cancer undergoing SLNB.Use of Fluorescence Imaging in Combination with Patent Blue Dye versus  Patent Blue Dye Alone in Sentinel Lymph Node Biopsy in Breast Cancer  Meng Tong, Wenbin Guo, Wei Gao Department of Surgery, Breast Center, Dalian Central Hospital of Dalian Medical University, Dalian, ChinaORIGINAL ARTICLEJ Breast Cancer 2014 September; 17(3): 250-255  http://dx.doi.org/10.4048/jbc.2014.17.3.250 Purpose:  Near-infrared fluorescence imaging with indocyanine  green (ICG) has the potential to improve sentinel lymph node  (SLN) mapping in breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/3d/83/jbc-17-250.PMC4197355.pdf
Sentinel Lymph Node Biopsy in Breast Cancer 251 http://dx.doi.org/10.4048/jbc.2014.17.3.250  http://ejbc.kr Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/3d/83/jbc-17-250.PMC4197355.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.250The Fisher exact test, chi-square test, and Student t-test were  used to compare data between the two groups.",OADS,/arxiv_data1/oa_pdf/3d/83/jbc-17-250.PMC4197355.pdf
Sentinel Lymph Node Biopsy in Breast Cancer 253 http://dx.doi.org/10.4048/jbc.2014.17.3.250  http://ejbc.krence in this improvement between the two groups ( p= 0.296).,Non-OADS,/arxiv_data1/oa_pdf/3d/83/jbc-17-250.PMC4197355.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.250larly beneficial in difficult cases where SLNs were not readily  identified by using the dye method.,Non-OADS,/arxiv_data1/oa_pdf/3d/83/jbc-17-250.PMC4197355.pdf
Sentinel Lymph Node Biopsy in Breast Cancer 255 http://dx.doi.org/10.4048/jbc.2014.17.3.250  http://ejbc.krcance of sentinel lymph node micrometastases in human breast cancer.,Non-OADS,/arxiv_data1/oa_pdf/3d/83/jbc-17-250.PMC4197355.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Whole-breast irradiation (WBI) has become one of the key  components in breast conserving therapy.",Non-OADS,/arxiv_data1/oa_pdf/31/eb/jbc-17-256.PMC4197356.pdf
"Therefore, it is important to develop external-beam radiation  techniques that are more conformal.Accelerated Partial Breast Irradiation with Intensity-Modulated Radiotherapy  Is Feasible for Chinese Breast Cancer Patients  Zhenyu He*, Sangang Wu1,*, Juan Zhou2, Fengyan Li, Jiayan Sun, Qin Lin, Huanxin Lin, Xunxing Guan Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation  Center of Cancer Medicine, Guangzhou; Departments of 1Radiation Oncology and 2Obstetrics and Gynecology, Xiamen Cancer Center, The First Affiliated  Hospital of Xiamen University, Xiamen, ChinaORIGINAL ARTICLEJ Breast Cancer 2014 September; 17(3): 256-264  http://dx.doi.org/10.4048/jbc.2014.17.3.256 Purpose:  Several accelerated partial breast irradiation (APBI)  techniques are being investigated in patients with early-stage  breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/31/eb/jbc-17-256.PMC4197356.pdf
APBI with IMRT 257 http://dx.doi.org/10.4048/jbc.2014.17.3.256  http://ejbc.krIntensity-modulated radiotherapy (IMRT) is one of the  most rapidly growing therapeutic approaches in recent years.,Non-OADS,/arxiv_data1/oa_pdf/31/eb/jbc-17-256.PMC4197356.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.256depth, width and height of the cavity.",Non-OADS,/arxiv_data1/oa_pdf/31/eb/jbc-17-256.PMC4197356.pdf
APBI with IMRT 259 http://dx.doi.org/10.4048/jbc.2014.17.3.256  http://ejbc.krthe irradiation dose received by 5% of the PTV-EV AL volume  and D95 represents the irradiation dose received by 95% of the  PTV-EV AL.,OADS,/arxiv_data1/oa_pdf/31/eb/jbc-17-256.PMC4197356.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.256Table 2.,Non-OADS,/arxiv_data1/oa_pdf/31/eb/jbc-17-256.PMC4197356.pdf
"APBI with IMRT 261 http://dx.doi.org/10.4048/jbc.2014.17.3.256  http://ejbc.krgery to test the toxicity, efficacy, and cosmetic outcomes of the  procedure.",Non-OADS,/arxiv_data1/oa_pdf/31/eb/jbc-17-256.PMC4197356.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.256mainly erythema, breast edema, pigmentation, pain in the ir - radiated location, and subcutaneous fibrosis; no reactions of  grade 2 or higher were identified.",Non-OADS,/arxiv_data1/oa_pdf/31/eb/jbc-17-256.PMC4197356.pdf
APBI with IMRT 263 http://dx.doi.org/10.4048/jbc.2014.17.3.256  http://ejbc.krCONFLICT OF INTEREST The authors declare that they have no competing interests.,Non-OADS,/arxiv_data1/oa_pdf/31/eb/jbc-17-256.PMC4197356.pdf
http://ctep.cancer.gov/protocolDevelopment/ electronic_applications/docs/ctcaev3.pdf.,Non-OADS,/arxiv_data1/oa_pdf/31/eb/jbc-17-256.PMC4197356.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.256(a phase II trial).,Non-OADS,/arxiv_data1/oa_pdf/31/eb/jbc-17-256.PMC4197356.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Atypical ductal hyperplasia (ADH) of the breast is associat - ed with a 4- to 5-fold increased risk of malignancy.",Non-OADS,/arxiv_data1/oa_pdf/3c/5b/jbc-17-265.PMC4197357.pdf
"Inyoung Y oun, Min Jung Kim1, Hee Jung Moon1, Eun-Kyung Kim1 Department of Radiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul; 1Department of Radiology, Research Institute  of Radiological Science, Y onsei University College of Medicine, Seoul, KoreaORIGINAL ARTICLEJ Breast Cancer 2014 September; 17(3): 265-269  http://dx.doi.org/10.4048/jbc.2014.17.3.265 Purpose:  The purpose of our study was to evaluate the under­ estimation rate of atypical ductal hyperplasia (ADH) on vacuum­ assisted breast biopsy (VABB), and to examine the correlation  between residual microcalcifications and the underestimation  rate of ADH.",Non-OADS,/arxiv_data1/oa_pdf/3c/5b/jbc-17-265.PMC4197357.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.265METHODS  Between June 2008 and January 2013, 570 cases of 528 pa - tients in our institution underwent V ABB for the presence of  microcalcifications on mammograms.",Non-OADS,/arxiv_data1/oa_pdf/3c/5b/jbc-17-265.PMC4197357.pdf
No Residual Microcalcifications of ADH after Stereotactic Biopsy 267 http://dx.doi.org/10.4048/jbc.2014.17.3.265  http://ejbc.krmalignant groups are presented in Table 3.,Non-OADS,/arxiv_data1/oa_pdf/3c/5b/jbc-17-265.PMC4197357.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.265Among the patients classified as having BI-RADS category 4A  lesions, three out of nine patients without residual calcifica - tions (33.3%) were upgraded, whereas only one out of 11 pa - tients with residual calcifications (9.1%) was upgraded.",Non-OADS,/arxiv_data1/oa_pdf/3c/5b/jbc-17-265.PMC4197357.pdf
"No Residual Microcalcifications of ADH after Stereotactic Biopsy 269 http://dx.doi.org/10.4048/jbc.2014.17.3.265  http://ejbc.krcalcifications on post-V ABB mammograms still require sub - sequent surgery owing to the possibility of underestimation  [5,8,14].",Non-OADS,/arxiv_data1/oa_pdf/3c/5b/jbc-17-265.PMC4197357.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Contrast-enhanced magnetic resonance (MR) imaging of  the breast has high sensitivity (90%–99%) for invasive cancers  [1,2].",Non-OADS,/arxiv_data1/oa_pdf/37/2b/jbc-17-270.PMC4197358.pdf
"Although the  freehand technique is feasible, the use of the compression grid Initial Experience with Magnetic Resonance-Guided Vacuum-Assisted Biopsy  in Korean Women with Breast Cancer Hye Na Jung, Boo-Kyung Han, Eun Y oung Ko, Jung Hee Shin Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaORIGINAL ARTICLEJ Breast Cancer 2014 September; 17(3): 270-278  http://dx.doi.org/10.4048/jbc.2014.17.3.270 Purpose:  The aim of this study is to describe our initial experience  with magnetic resonance (MR)-guided biopsy and to determine  the malignancy rate of additional lesions identified by MR only in  Korean women with breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/37/2b/jbc-17-270.PMC4197358.pdf
Malignancy Rate of MR-Only Identified Lesions in Koreans with Breast Cancers 271 http://dx.doi.org/10.4048/jbc.2014.17.3.270  http://ejbc.krsystem is much easier and results in a shorter procedure time  due to more predictable needle placement [16].,Non-OADS,/arxiv_data1/oa_pdf/37/2b/jbc-17-270.PMC4197358.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.270ning was performed with a minimum repetition time and  echo time (4.4/1.6 ms for the axial images; 3.6/1.4 ms for the  sagittal images), a 12-flip angle, a 25–34 cm field of view, 1.5  mm sections with no gap, and a matrix size of 376–492 × 309– 492 for the axial images and 312 × 312 for the sagittal images.",Non-OADS,/arxiv_data1/oa_pdf/37/2b/jbc-17-270.PMC4197358.pdf
Malignancy Rate of MR-Only Identified Lesions in Koreans with Breast Cancers 273 http://dx.doi.org/10.4048/jbc.2014.17.3.270  http://ejbc.krstylet.,Non-OADS,/arxiv_data1/oa_pdf/37/2b/jbc-17-270.PMC4197358.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.270MR imaging findings and histologic correlation Twenty-one MR-guided biopsies were performed.,OADS,/arxiv_data1/oa_pdf/37/2b/jbc-17-270.PMC4197358.pdf
Malignancy Rate of MR-Only Identified Lesions in Koreans with Breast Cancers 275 http://dx.doi.org/10.4048/jbc.2014.17.3.270  http://ejbc.krfor one that was 3.2 cm in size.,Non-OADS,/arxiv_data1/oa_pdf/37/2b/jbc-17-270.PMC4197358.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.270The patients with nine benign and one high-risk lesion  who did not undergo subsequent surgery received follow-up  care consisting of an annual mammography and semiannual  US; the mean follow-up period was 32.1 months (range, 15– 44 months).",Non-OADS,/arxiv_data1/oa_pdf/37/2b/jbc-17-270.PMC4197358.pdf
Malignancy Rate of MR-Only Identified Lesions in Koreans with Breast Cancers 277 http://dx.doi.org/10.4048/jbc.2014.17.3.270  http://ejbc.krOur study has several limitations.,Non-OADS,/arxiv_data1/oa_pdf/37/2b/jbc-17-270.PMC4197358.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.270biopsy.,Non-OADS,/arxiv_data1/oa_pdf/37/2b/jbc-17-270.PMC4197358.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Traditionally, Korea has been composed of a single ethnic  group and, until very recently, has had little or no experience  with large-volume immigration.",Non-OADS,/arxiv_data1/oa_pdf/84/f7/jbc-17-279.PMC4197359.pdf
"Furthermore, communication problems, a lack of  health insurance, the burden of medical costs, and differences  in social conditions could reduce accessibility to medical ser - vices [5,6].Breast Cancer Screening Knowledge and Perceived Health Beliefs among  Immigrant Women in Korea Jiyoung Kim, Se Kyung Lee1, Jeonghui Lee2, Min-Y oung Choi2, Seung Pil Jung3, Min Kook Kim1, Sangmin Kim1,  Seok Jin Nam1, Jeong Eon Lee1, Won Ho Kil1 Department of Surgery, Jeju National University Hospital, Jeju; 1Division of Breast and Endocrine Surgery, Department of Surgery, Samsung Medical Center,  Sungkyunkwan University School of Medicine, Seoul; 2Department of Surgery, Hanyang University School of Medicine, Seoul; 3Department of Surgery,  Korea University Hospital, Korea University College of Medicine, Seoul, KoreaORIGINAL ARTICLEJ Breast Cancer 2014 September; 17(3): 279-286  http://dx.doi.org/10.4048/jbc.2014.17.3.279 Purpose:  Recently, through international marriage, immigrant  women have rapidly increased throughout Korea.",Non-OADS,/arxiv_data1/oa_pdf/84/f7/jbc-17-279.PMC4197359.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.279Previous studies have compared differences in mammogra - phy screening rates and health beliefs between specific ethnic  immigrant groups [7-9].,Non-OADS,/arxiv_data1/oa_pdf/84/f7/jbc-17-279.PMC4197359.pdf
"Knowledge and Perception of Breast Cancer 281 http://dx.doi.org/10.4048/jbc.2014.17.3.279  http://ejbc.krhad an effect on breast cancer screening behavior and screen - ing knowledge, beliefs, and perceptions.",Non-OADS,/arxiv_data1/oa_pdf/84/f7/jbc-17-279.PMC4197359.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.279Japanese women ( p< 0.001).,Non-OADS,/arxiv_data1/oa_pdf/84/f7/jbc-17-279.PMC4197359.pdf
"Knowledge and Perception of Breast Cancer 283 http://dx.doi.org/10.4048/jbc.2014.17.3.279  http://ejbc.kr0.001), having a job (OR, 2.30; 95% CI, 1.13–4.69; p= 0.022),  and better Korean listening/speaking ability (good vs. poor;  OR, 4.57; 95% CI, 1.61–12.96; p= 0.002) were associated with  greater mammography participation.",Non-OADS,/arxiv_data1/oa_pdf/84/f7/jbc-17-279.PMC4197359.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.279sociated with knowledge, positive beliefs or attitudes, and per - ceived benefits after adjusting for confounding variables.",Non-OADS,/arxiv_data1/oa_pdf/84/f7/jbc-17-279.PMC4197359.pdf
Knowledge and Perception of Breast Cancer 285 http://dx.doi.org/10.4048/jbc.2014.17.3.279  http://ejbc.krthese factors and breast cancer screening and to determine the  best systematic approach to multicultural families’ preventive  care problems.,Non-OADS,/arxiv_data1/oa_pdf/84/f7/jbc-17-279.PMC4197359.pdf
http://www.kosis.kr.,Non-OADS,/arxiv_data1/oa_pdf/84/f7/jbc-17-279.PMC4197359.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.279Cancer Screening Survey (KNCSS), 2004-2011.",Non-OADS,/arxiv_data1/oa_pdf/84/f7/jbc-17-279.PMC4197359.pdf
Knowledge and Perception of Breast Cancer   http://ejbc.krAppendix 1.,Non-OADS,/arxiv_data1/oa_pdf/84/f7/jbc-17-279.PMC4197359.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION  Metaplastic breast cancer (MpBC) is an extremely rare breast  cancer subtype constituting 0.25% to 1% of all breast cancers  [1].",Non-OADS,/arxiv_data1/oa_pdf/0f/77/jbc-17-287.PMC4197360.pdf
"Subse -Combined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor  Targeted Therapy in Metaplastic Breast Cancer Harboring a PIK3CA  Mutation Rishi Agarwal, Kimberly Koenig1, Eric Rohren1, Vivek Subbiah1 Department of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, USA; 1MD Anderson Cancer Center, Houston, USACASE REPORTJ Breast Cancer 2014 September; 17(3): 287-290  http://dx.doi.org/10.4048/jbc.2014.17.3.287 Metaplastic breast cancer (MpBC) is an extremely rare breast  cancer subtype, characterized by a heterogeneous phenotype.",Non-OADS,/arxiv_data1/oa_pdf/0f/77/jbc-17-287.PMC4197360.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.287quently, the patient declined further chemotherapy and under - went a left modified radical mastectomy followed by chest wall  radiation.",Non-OADS,/arxiv_data1/oa_pdf/0f/77/jbc-17-287.PMC4197360.pdf
"Targeted Therapy in Metaplastic Breast Cancer289 http://dx.doi.org/10.4048/jbc.2014.17.3.287  http://ejbc.krplete resolution of the disease in most of the sites on a PET  scan, with corresponding anatomic improvement observed on  a CT scan (Figures 1-3).",Non-OADS,/arxiv_data1/oa_pdf/0f/77/jbc-17-287.PMC4197360.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.287have been reported in MpBC.,OADS,/arxiv_data1/oa_pdf/0f/77/jbc-17-287.PMC4197360.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Chyle leakage has been known to result from damage to the  thoracic duct or its branches during neck or thoracic surgery  [1].",Non-OADS,/arxiv_data1/oa_pdf/0b/d2/jbc-17-291.PMC4197361.pdf
"SPECT/CT examination was performed to further as - sess the focal uptake located superior and inferior to the chyle Postmastectomy/Axillary Node Dissection Chyloma: The Additional Value of  SPECT/CT Lymphoscintigraphy Sue Ping Thang, Aaron Kian Ti Tong, David Chee Eng Ng Department of Nuclear Medicine and PET, Singapore General Hospital, Singapore, SingaporeCASE REPORTJ Breast Cancer 2014 September; 17(3): 291-294  http://dx.doi.org/10.4048/jbc.2014.17.3.291 After mastectomy and axillary node dissection, chylous leakage  is rare.",Non-OADS,/arxiv_data1/oa_pdf/0b/d2/jbc-17-291.PMC4197361.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.291Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/0b/d2/jbc-17-291.PMC4197361.pdf
"Postmastectomy/Axillary Node Dissection Chyloma: Value of SPECT/CT Lymphoscintigraphy 293 http://dx.doi.org/10.4048/jbc.2014.17.3.291  http://ejbc.krDISCUSSION A postmastectomy chyle leakage with axillary clearance is  rare because of the anatomical distance between the thoracic  duct and the operation site, with a reported incidence of  < 0.5% [4-6].",Non-OADS,/arxiv_data1/oa_pdf/0b/d2/jbc-17-291.PMC4197361.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.291management because of its low associated morbidity and to  prevent delays in further oncological treatment [8].,Non-OADS,/arxiv_data1/oa_pdf/0b/d2/jbc-17-291.PMC4197361.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Mastitis is a common disease with both infectious and non - infectious causes.",Non-OADS,/arxiv_data1/oa_pdf/aa/cb/jbc-17-295.PMC4197362.pdf
"Several small  lymph nodes less than 1 cm in short diameter were visible in Recurrent Bilateral Breast Abscess Due to Nontuberculous Mycobacterial  Infection Hyunkyung Y oo, Sang Hyun Choi1, Y oun Jeong Kim, Sei Joong Kim2, Y oung Up Cho2, Suk Jin Choi3 Department of Radiology, Inha University Hospital, Inha University College of Medicine, Incheon; 1Korea Health Promotion Foundation, Seoul;  Departments of  2Surgery and 3Pathology, Inha University Hospital, Inha University College of Medicine, Incheon, KoreaCASE REPORTJ Breast Cancer 2014 September; 17(3): 295-298  http://dx.doi.org/10.4048/jbc.2014.17.3.295 Since recurrent bilateral breast infection due to nontuberculous  mycobacterium (NTM) is rare, its diagnosis is easily overlooked;  in addition, complete recovery is often difficult to achieve.",Non-OADS,/arxiv_data1/oa_pdf/aa/cb/jbc-17-295.PMC4197362.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.295the left axilla level I.,Non-OADS,/arxiv_data1/oa_pdf/aa/cb/jbc-17-295.PMC4197362.pdf
Recurrent Breast Abscess Due to NTM297 http://dx.doi.org/10.4048/jbc.2014.17.3.295  http://ejbc.krbreast with thickening of the overlying skin.,Non-OADS,/arxiv_data1/oa_pdf/aa/cb/jbc-17-295.PMC4197362.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.295complex species are suspected as the source of infection, tar - geted antibacterial therapy is recommended [11].",Non-OADS,/arxiv_data1/oa_pdf/aa/cb/jbc-17-295.PMC4197362.pdf
http://www.med.ucla.edu/modules/wf - section/article.php?articleid=567.,Non-OADS,/arxiv_data1/oa_pdf/aa/cb/jbc-17-295.PMC4197362.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Dear Editor, Simpson [1] has conducted a thorough review of the litera - ture with regard to the educational utility of simulations in  teaching history and physical examination skills in diagnosing  breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/cd/6e/jbc-17-299.PMC4197363.pdf
"Many  early studies simply compared an intervention (simulation) Simulations in Breast Cancer: The Next Steps Kieran Walsh BMJ Learning, London, UKCOMMENTARYJ Breast Cancer 2014 September; 17(3): 299-300  http://dx.doi.org/10.4048/jbc.2014.17.3.299 Journal of         BreastCancer Correspondence to:  Kieran Walsh BMJ Learning, BMA House, Tavistock Square, London WC1H 9JR, UK Tel: +44-0207-383-6550, Fax: +44-0207-383-6242 E-mail: kmwalsh@bmj.com Received:  July 25, 2014 Accepted:  September 4, 2014",Non-OADS,/arxiv_data1/oa_pdf/cd/6e/jbc-17-299.PMC4197363.pdf
300  Kieran Walsh http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2014.17.3.299plus the traditional method of learning to the traditional  method of learning alone.,Non-OADS,/arxiv_data1/oa_pdf/cd/6e/jbc-17-299.PMC4197363.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests : The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/2f/e2/srep06621.PMC4197414.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6621 | DOI: 10.1038/srep06621 5",Non-OADS,/arxiv_data1/oa_pdf/2f/e2/srep06621.PMC4197414.pdf
The cutoff point for the MAGE-A9 expression score thatwas statistically significant in terms of survival was set using the X-tile software program (The Rimm Lab at Yale University; http://www.tissuearray.org/rimmlab) as described previously 28.,OADS,/arxiv_data1/oa_pdf/58/4b/srep06625.PMC4197415.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests : The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/60/77/srep06628.PMC4197416.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/0b/45/srep06627.PMC4197419.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6629 | DOI: 10.1038/srep06629 7",Non-OADS,/arxiv_data1/oa_pdf/84/67/srep06629.PMC4197420.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests : The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/5f/c4/srep06553.PMC4197434.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6553 | DOI: 10.1038/srep06553 7",Non-OADS,/arxiv_data1/oa_pdf/5f/c4/srep06553.PMC4197434.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/39/23/srep06338.PMC4197449.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/39/23/srep06338.PMC4197449.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/Diet, in ﬂammation and hospitalization A Galas et al 1174 European Journal of Clinical Nutrition (2014) 1168 –1174 © 2014 Macmillan Publishers Limited",Non-OADS,/arxiv_data1/oa_pdf/a6/13/ejcn2014120a.PMC4197458.pdf
"This is an open access article licensed under the  terms of the Creative Commons Attribution Non -Commercial License (http://creativecommons.org/lic - enses/by -nc/3.0/) which permits unrestricted, non -commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d1/48/TOCMJ-8-88.PMC4197526.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/ 2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/84/69/evr022.PMC4197744.pdf
"This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is  properly cited and the reuse is restricted to noncommercial purposes.",Non-OADS,/arxiv_data1/oa_pdf/b1/7f/prm-19-235.PMC4197750.pdf
"This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is  properly cited and the reuse is restricted to noncommercial purposes.",Non-OADS,/arxiv_data1/oa_pdf/7b/af/prm-19-241.PMC4197751.pdf
"<https://papyrus.bib.umontreal.ca/xmlui/handle/1866/8342> (Accessed August 8, 2013).",Non-OADS,/arxiv_data1/oa_pdf/7b/af/prm-19-241.PMC4197751.pdf
"<http://nationalpaincentre.mcmaster.ca/opioid/> (Accessed October 4, 2013).",Non-OADS,/arxiv_data1/oa_pdf/7b/af/prm-19-241.PMC4197751.pdf
"This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.",Non-OADS,/arxiv_data1/oa_pdf/cf/3e/prm-19-251.PMC4197752.pdf
<https://cacoo.com/> 42.,Non-OADS,/arxiv_data1/oa_pdf/a8/e4/prm-19-257.PMC4197753.pdf
"This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.",Non-OADS,/arxiv_data1/oa_pdf/73/0c/prm-19-267.PMC4197754.pdf
"<http://tinyurl.com/po6qwl4> (Accessed March 3, 2014).",Non-OADS,/arxiv_data1/oa_pdf/73/0c/prm-19-267.PMC4197754.pdf
"<http://paininchildhealth.dal.ca/> (Accessed January 21, 2014).8.",Non-OADS,/arxiv_data1/oa_pdf/73/0c/prm-19-267.PMC4197754.pdf
"<http://paininchildhealth.dal.ca/pich-curriculum/> (Accessed January 21, 2014).",Non-OADS,/arxiv_data1/oa_pdf/73/0c/prm-19-267.PMC4197754.pdf
"<http://tinyurl.com/scitech2012> (Accessed January 21, 2014).",Non-OADS,/arxiv_data1/oa_pdf/73/0c/prm-19-267.PMC4197754.pdf
"<http://painresearchforum.org/forums/discussion/16374-promoting-culture-evidence-conversation-christopher-eccleston> (Accessed 11 March, 2014).",Non-OADS,/arxiv_data1/oa_pdf/73/0c/prm-19-267.PMC4197754.pdf
KC11OISI0688)  and has also been registered with the Clinical Research Information Service of South Korea (http://cris.nih.go.kr; no.,Non-OADS,/arxiv_data1/oa_pdf/dd/c4/prm-19-275.PMC4197755.pdf
"This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.",Non-OADS,/arxiv_data1/oa_pdf/83/f2/prm-19-e124.PMC4197756.pdf
"<http://www.emotionalavailability.com/> (Accessed September 1, 2012).",Non-OADS,/arxiv_data1/oa_pdf/83/f2/prm-19-e124.PMC4197756.pdf
"This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.",Non-OADS,/arxiv_data1/oa_pdf/a1/dd/prm-19-e139.PMC4197758.pdf
"<http://nationalpaincentre.mcmaster.ca/documents/LowerBackPainGuidelineNov2011.pdf> (Accessed September 1, 2013).",Non-OADS,/arxiv_data1/oa_pdf/d4/31/prm-19-e146.PMC4197759.pdf
Additional information Supplementary Information accompanies this paper at http://www.nature.com/ naturecommunications Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.,Non-OADS,/arxiv_data1/oa_pdf/03/1e/ncomms6066.PMC4197815.pdf
"Reprints and permission information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article: Antonelli, R. et al.",Non-OADS,/arxiv_data1/oa_pdf/03/1e/ncomms6066.PMC4197815.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6066 14 NATURE COMMUNICATIONS | 5:5066 | DOI: 10.1038/ncomms6066 | www.nature.com/naturecommunications &2014 Macmillan Publishers Limited.",Non-OADS,/arxiv_data1/oa_pdf/03/1e/ncomms6066.PMC4197815.pdf
"Third, long-term datastorage, an essential component of goodscientific practice, easily turns into anabsurd exercise when detailed and standard-ized annotations (metadata) are missing.Many institutions worldwide are thereforeconsidering electronic note-keeping tosupport good scientific practice (http://lib.guides.umd.edu/ELN, http://academictech.doit.wisc.edu/ideas/el ectronic-lab-notebooks).",Non-OADS,/arxiv_data1/oa_pdf/0f/14/embr0015-0631.PMC4197872.pdf
The metadata can immediately beused as Supplementary Material for publish-ing and enable future inclusion into databasesas appropriate (http://www.antibodypedia.com).,OADS,/arxiv_data1/oa_pdf/0f/14/embr0015-0631.PMC4197872.pdf
"In thiscontext, it is important to note that SLC12A5 is among the 4.5% most intolerant human genes (http://chgv.org/GenicIntolerance/)with regard to genic variation, and therefore, mutations in SLC12A5 are good candidates to contribute to disease phenotypes.",Non-OADS,/arxiv_data1/oa_pdf/6a/2c/embr0015-0723.PMC4197883.pdf
Spine lengths from cultured neurons wereanalyzed on acquired stacks of images using NeuronJ software(http://rsb.info.nih.gov/ij/).,OADS,/arxiv_data1/oa_pdf/6a/2c/embr0015-0723.PMC4197883.pdf
Supplementary information for this article is available online: http://embor.embopress.org Acknowledgements We thank the patients and their families for participating in our research.,Non-OADS,/arxiv_data1/oa_pdf/6a/2c/embr0015-0723.PMC4197883.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial   License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution,   and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1d/51/glu155.PMC4197903.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/.0/),whichpermitsnon-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ee/27/jit232.PMC4197907.pdf
http://www.healthmetricsandevaluation.,Non-OADS,/arxiv_data1/oa_pdf/ee/27/jit232.PMC4197907.pdf
http://www.who.int/entity/immunization_monitoring/data/coverage_estimates_series.xls .,OADS,/arxiv_data1/oa_pdf/ee/27/jit232.PMC4197907.pdf
http://api.worldbank.org/ dataﬁles/SH.STA.BRTC.ZS_Indicator_MetaData_en_EXCEL.xls .,OADS,/arxiv_data1/oa_pdf/ee/27/jit232.PMC4197907.pdf
http://databank.world bank.org/databank/download/WDIandGDF_csv.zip .,Non-OADS,/arxiv_data1/oa_pdf/ee/27/jit232.PMC4197907.pdf
http://eventdata.psu.edu/data.dir/atrocities.html .,Non-OADS,/arxiv_data1/oa_pdf/ee/27/jit232.PMC4197907.pdf
"Global health observatory data re- pository, 2011 .http://apps.who.int/ghodata .",Non-OADS,/arxiv_data1/oa_pdf/ee/27/jit232.PMC4197907.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/07/f3/1940.PMC4197945.pdf
"Af- ter six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http:// creativecommons.org/licenses/by-nc/4.0/.5Present address: Biochemistry Department, University of Wisconsin- Madison, Madison, Wisconsin 53706, USA Corresponding author: yuhnung.jan@ucsf.edu Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.239962.114.",Non-OADS,/arxiv_data1/oa_pdf/07/f3/1940.PMC4197945.pdf
2011) of ImageJ FiJI (http://fiji.sc).,Non-OADS,/arxiv_data1/oa_pdf/07/f3/1940.PMC4197945.pdf
The class III spiked protrusions were manually counted using the Cell Counter ImageJ plugin (http://rsbweb.nih.gov/ij/plugins/cell-counter.html).,OADS,/arxiv_data1/oa_pdf/07/f3/1940.PMC4197945.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/ee/cc/1885.PMC4197946.pdf
Article and publication date are online at http://www.genesdev.org/ cgi/doi/10.1101/gad.246819.114.,Non-OADS,/arxiv_data1/oa_pdf/ee/cc/1885.PMC4197946.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/27/63/1957.PMC4197947.pdf
Corresponding author: david_livingston@dfci.harvard.edu Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.241620.114.,Non-OADS,/arxiv_data1/oa_pdf/27/63/1957.PMC4197947.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/e1/ff/1879.PMC4197948.pdf
[Keywords : Wnt; mouse; Bcl9; Pygopus; lens induction; Pax6] Corresponding author: basler@imls.uzh.ch Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.246140.114.,Non-OADS,/arxiv_data1/oa_pdf/e1/ff/1879.PMC4197948.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/72/1e/1917.PMC4197949.pdf
"Af- ter six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http:// creativecommons.org/licenses/by-nc/4.0/.Corresponding author: zyuan@hsph.harvard.edu Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.245910.114.",Non-OADS,/arxiv_data1/oa_pdf/72/1e/1917.PMC4197949.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/83/c5/1929.PMC4197950.pdf
"Af- ter six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http:// creativecommons.org/licenses/by-nc/4.0/.Corresponding author: mark.onaitis@dm.duke.edu Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.243717.114.",Non-OADS,/arxiv_data1/oa_pdf/83/c5/1929.PMC4197950.pdf
Reads were mapped to human genome assembly GRCh37/hg19 using Bowtie via the Galaxy online analysis toolkit (http://galaxyproject.org) (Goecks et al.,OADS,/arxiv_data1/oa_pdf/83/c5/1929.PMC4197950.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/b7/45/1900.PMC4197951.pdf
"A f t e rs i xm o n t h s ,i ti sa v a i l a b l e under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http:// creativecommons.org/licenses/by-nc/4.0/.Corresponding author: lynne_maquat@urmc.rochester.edu Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.245506.114.",Non-OADS,/arxiv_data1/oa_pdf/b7/45/1900.PMC4197951.pdf
More detailed analysis suggested that TPP1 directly promotes telomerase activity at the telomere through the so- /C2112014 Karlseder This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/83/48/1857.PMC4197952.pdf
[Keywords : embryonic stem cells; human genome engineering; shelterin; telomerase; telomere maintenance] Correspondence: karlseder@salk.edu Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.250316.114.,Non-OADS,/arxiv_data1/oa_pdf/83/48/1857.PMC4197952.pdf
"This article, published in Genes &Development , is available under a Creative Commons License (Attribution-NonCom- mercial 4.0 International), as described at http://creativecommons.org/ licenses/by-nc/4.0/.",Non-OADS,/arxiv_data1/oa_pdf/eb/85/1859.PMC4197953.pdf
[Keywords : CRISPR; Cas9; development; genome editing; genome engi- neering; RNA-guided nuclease]Corresponding author: wildonger@wisc.edu Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.248252.114.,Non-OADS,/arxiv_data1/oa_pdf/eb/85/1859.PMC4197953.pdf
(A com- prehensive list is available at http://www.geewisc.wisc.edu.,Non-OADS,/arxiv_data1/oa_pdf/eb/85/1859.PMC4197953.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/05/42/1735.PMC4197959.pdf
"[Keywords : histone demethylase; KDM2A; mechanism; substrate specificity] Corresponding authors: jat@scripps.edu, yang_shi@hms.harvard.edu Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.249755.114.",Non-OADS,/arxiv_data1/oa_pdf/05/42/1735.PMC4197959.pdf
Thirty to 52 under- replicated (UR) regions 90–570 kb in length have been /C2112014 Yarosh and Spradling This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after thefull-issue publication date (see http://genesdev.cshlp.org/site/misc/ terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/b9/7a/1840.PMC4197960.pdf
"After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.Corresponding author: spradling@ciwemb.edu Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.245811.114.",Non-OADS,/arxiv_data1/oa_pdf/b9/7a/1840.PMC4197960.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/42/89/1758.PMC4197961.pdf
"After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http:// creativecommons.org/licenses/by-nc/4.0/.Corresponding authors: pateld@mskcc.org, ogozani@stanford.edu Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.246561.114.",Non-OADS,/arxiv_data1/oa_pdf/42/89/1758.PMC4197961.pdf
Corresponding author: nakamura.gast@tmd.ac.jp Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.245233.114.,Non-OADS,/arxiv_data1/oa_pdf/35/89/1752.PMC4197962.pdf
Article and publication date are online at http://www.genesdev.or g/cgi/doi/10.1101/gad.245829.114.,Non-OADS,/arxiv_data1/oa_pdf/ce/4e/1786.PMC4197963.pdf
"Tags were assigned to features using HTSeq-count (http://www-huber.embl.de/users/anders/HTSeq/doc/overview.html), and dif-ferential gene expression was determined using DESeq (Anders and Huber 2010).",OADS,/arxiv_data1/oa_pdf/ce/4e/1786.PMC4197963.pdf
Read counting was performed using HTSeq-count 0.5.3p9 (http://www-huber.embl.de/users/ anders/HTSeq/doc/overview.html) with custom Python scriptsprovided by the DEXSeq.,OADS,/arxiv_data1/oa_pdf/ce/4e/1786.PMC4197963.pdf
Another important mechanism that ensures the exclu- sive localization of centromeres is the control of CENP-Aprotein levels via ubiquitin-mediated proteolysis (Collins /C2112014 Deyter and Biggins This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/48/c7/1815.PMC4197964.pdf
"After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http:// creativecommons.org/licenses/by-nc/4.0/.Corresponding author: sbiggins@fhcrc.org Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.243113.114.",Non-OADS,/arxiv_data1/oa_pdf/48/c7/1815.PMC4197964.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/0d/fb/1800.PMC4197965.pdf
Corresponding author: lowes@mskcc.org Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.244368.114.,Non-OADS,/arxiv_data1/oa_pdf/0d/fb/1800.PMC4197965.pdf
"Thelist of genes was obtained from DrugBank (version 2.5; http://www.drugbank.ca) and was manually curated, excluding ambig- uous or redundant targets.",OADS,/arxiv_data1/oa_pdf/0d/fb/1800.PMC4197965.pdf
"E3 ligases can also simply mono-ubiquitinate lysine residues of a protein, an event thatsignals further regulation of the protein (Hicke and Dunn /C2112014 Pant and Lozano This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).",Non-OADS,/arxiv_data1/oa_pdf/e8/bb/1739.PMC4197966.pdf
Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.247452.114.,Non-OADS,/arxiv_data1/oa_pdf/e8/bb/1739.PMC4197966.pdf
"Phase I trials have been carried out with RG7112, a nutlin-3 analog, in patients with solid tumors or leukemia (http://www.clinicaltrials.gov, NCT0062387 and NCT00559533).",Non-OADS,/arxiv_data1/oa_pdf/e8/bb/1739.PMC4197966.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/7d/3f/1827.PMC4197967.pdf
"Corresponding authors: ramesh_shiv dasani@dfci.harvard.edu, xsliu@ jimmy.harvard.edu Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.240101.114.",Non-OADS,/arxiv_data1/oa_pdf/7d/3f/1827.PMC4197967.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e1/db/aabc-7-037.PMC4198066.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pAdvances and Applications in Bioinformatics and Chemistry 2014:7 37–44Advances and Applications in Bioinformatics and Chemistry Dove press submit your manuscript | www.dovepress.co m Dove press  37OriginAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AABC.S6893 4The hemagglutinin of the influenza A(H1N1)pdm09   is mutating towards stability Juan A Castelán-Vega Anastasia Magaña- Hernández Alicia Jiménez-Alberto rosa María ribas-Aparicio Departamento de Microbiología,   escuela nacional de Ciencias  Biológicas del instituto Politécnico  nacional, Mexico City, Mexico Correspondence: rosa María ribas- Aparicio   laboratorio de Producción y Control   de Biológicos, Departamento   de Microbiología, escuela nacional de  Ciencias Biológicas, instituto Politécnico  nacional, Prolongación de Carpio y Plan  de Ayala s/n, CP 11340 México, DF,  México   Tel +52 55 5729 6300   email rribas233@yahoo.co mAbstract:  The last influenza A pandemic provided an excellent opportunity to study the  adaptation of the influenza A(H1N1)pdm09 virus to the human host.",Non-OADS,/arxiv_data1/oa_pdf/e1/db/aabc-7-037.PMC4198066.pdf
"Material and methods HA influenza sequences A total of 7,479 full-length amino acid sequences of the  HA from the influenza A(H1N1)pdm09 virus were down - loaded from the OpenFlu database ( http://openflu.vital-it.",OADS,/arxiv_data1/oa_pdf/e1/db/aabc-7-037.PMC4198066.pdf
"Multiple-sequence alignments Each group of sequences was aligned with MAFFT version 7  (http://mafft.cbrc.jp/alignment/software /), using the progres - sive method (fast Fourier transform – normalized similarity  matrix [FFT -NS-1]) for a fast analysis.16 The consensus  sequence for each alignment was calculated with BioEdit  7.1.9.",OADS,/arxiv_data1/oa_pdf/e1/db/aabc-7-037.PMC4198066.pdf
"( http://www.mbio.ncsu.edu/bioedit/bioedit.html ).17  Positional frequencies were calculated, and a consensus was  considered when at least 51% of the amino acids were identi - cal at a given position.",OADS,/arxiv_data1/oa_pdf/e1/db/aabc-7-037.PMC4198066.pdf
effect of mutation on protein stability To determine the effect of the selected mutation on protein  stability we used the iStable server ( http://predictor.nchu.,OADS,/arxiv_data1/oa_pdf/e1/db/aabc-7-037.PMC4198066.pdf
Visualization of mutations Selected mutations were mapped in the structure of the HA  from the influenza A/California/4/2009 H1N1 virus (PDB:  3LZG) with PyMOL version 1.5.0.4 ( http://www.pymol.,Non-OADS,/arxiv_data1/oa_pdf/e1/db/aabc-7-037.PMC4198066.pdf
"Advances and Applications in Bioinformatics and Chemistry Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com /advances-and-applications-in-bioinformatics-and-chemistry-journalAdvances and Applications in Bioinformatics and Chemistry is an inter - national, peer-reviewed open-access journal that publishes articles in the  following fields: Computational biomodeling; Bioinformatics; Compu - tational genomics; Molecular modeling; Protein structure modeling and  structural genomics; Systems Biology; Computational Biochemistry; Computational Biophysics; Chemoinformatics and Drug Design; In silico  ADME/Tox prediction.",Non-OADS,/arxiv_data1/oa_pdf/e1/db/aabc-7-037.PMC4198066.pdf
Visit http://www.dovepress.com/testimonials.ph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/e1/db/aabc-7-037.PMC4198066.pdf
"Available from: http://www.pymol.org/citin g. Accessed  September 24, 2014.",Non-OADS,/arxiv_data1/oa_pdf/e1/db/aabc-7-037.PMC4198066.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/89/d3/clep-6-351.PMC4198151.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical Epidemiology 2014:6 351–357Clinical Epidemiology Dove press submit your manuscript | www.dovepress.co m Dove press  351Original rEsEarChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CLEP .S6568 1Quality of venous thromboembolism diagnoses  among prostate cancer patients in the Danish  national registry of Patients aska Drljevic1 Michael Borre2 Morten høyer3 Vera Ehrenstein4 Mary nguyen-n ielsen4 1Department of Pharmacology,   2Department of Urology,  3Department  of Oncology,  4Department of Clinical  Epidemiology, aarhus University  hospital, aarhus, Denmark Correspondence: aska Drljevic   Department of Pharmacology, aarhus  University hospital,  44 nørrebrogade,  aarhus  8000, Denmark   Tel +45 2849 0381  Email askadrlj@rm.d kBackground and aim:  It is well established that cancer patients have an increased risk of  venous thromboembolism (VTE).",Non-OADS,/arxiv_data1/oa_pdf/89/d3/clep-6-351.PMC4198151.pdf
Available from: http://www.laeger.dk/portal/page/portal/LAEGERDK/ UGESKRIFT_FOR_LAEGER/TIDLIGERE_NUMRE/2008/UFL_ EKCMA_2008_34/UFL_EKCMA_2008_34_53525.,Non-OADS,/arxiv_data1/oa_pdf/89/d3/clep-6-351.PMC4198151.pdf
"Available from: http://www.cancer.dk/Hjaelp +viden/ kraeftformer/ kraeftsygdomme /prostata/statistik +prostatakraef t. Accessed  August  5, 2014.",Non-OADS,/arxiv_data1/oa_pdf/89/d3/clep-6-351.PMC4198151.pdf
"Available from:  http://www.ssi.dk/~/media/Indhold/DK%20-%20dansk/Sundheds - data%20og%20it/NSF/Registre/Cancerregisteret/Cancerregisteret%20 2011.ash x. Accessed October  22, 2013.",OADS,/arxiv_data1/oa_pdf/89/d3/clep-6-351.PMC4198151.pdf
"Available from: http://www.ssi.dk/~/media/Indhold/DK%20-%20 dansk/Sundhedsdata%20og%20it/NSF/Registre/Dodsaarsagsregisteret/ D%C3%B8ds%C3%A5rsagsregisteret%202012.ash x. Accessed Octo - ber 22, 2013.",OADS,/arxiv_data1/oa_pdf/89/d3/clep-6-351.PMC4198151.pdf
Available  from: http://www.dst.dk/en/Statistik/emner/befolkning-og-befolknings - fremskrivning.aspx.,OADS,/arxiv_data1/oa_pdf/89/d3/clep-6-351.PMC4198151.pdf
"Available from: http://www.regioner.dk/sundhed/ kvalitet +og+forskning/den +danske +kvalitetsmode l. Accessed May  13,  2014.",OADS,/arxiv_data1/oa_pdf/89/d3/clep-6-351.PMC4198151.pdf
"Clinical Epidemiology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-epidemiology-journa lClinical Epidemiology is an international, peer-reviewed, open access  journal focusing on disease and drug epidemiology, identification of  risk factors and screening procedures to develop optimal preventative  initiatives and programs.",Non-OADS,/arxiv_data1/oa_pdf/89/d3/clep-6-351.PMC4198151.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/f0/b5/clep-6-343.PMC4198152.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical Epidemiology 2014:6 343–350Clinical Epidemiology Dove press submit your manuscript | www.dovepress.co m Dove press  343Original rEsEarChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/CLEP .S6239 2relationship between physical performance   and cognitive performance measures among   community-dwelling older adults huiloo Won1 Devinder Kaur ajit singh2 normah Che Din3 Manal Badrasawi4 Zahara abdul Manaf4 sin Thien Tan2 Chu Chiau Tai2 suzana shahar4 1nutrition science Program,   2Physiotherapy Program, 3health  Psychology Program, 4Dietetics  Program, Faculty of health   sciences, Universiti Kebangsaan   Malaysia, Kuala lumpur, Malaysia Correspondence: suzana shahar   Dietetics Programme, Faculty of   health sciences, Universiti Kebangsaan   Malaysia, Jalan raja Muda abdul aziz,   50300 Kuala lumpur, Malaysia   T el +60 3 9289 7607   Email suzana.shahar@gmail.co mPurpose:  Cognitive impairment is correlated with physical function.",Non-OADS,/arxiv_data1/oa_pdf/f0/b5/clep-6-343.PMC4198152.pdf
"Clinical Epidemiology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-epidemiology-journa lClinical Epidemiology is an international, peer-reviewed, open access  journal focusing on disease and drug epidemiology, identification of  risk factors and screening procedures to develop optimal preventative  initiatives and programs.",Non-OADS,/arxiv_data1/oa_pdf/f0/b5/clep-6-343.PMC4198152.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e8/49/ceg-7-395.PMC4198153.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical and Experimental Gastroenterology 2014:7 395–413Clinical and Experimental Gastroenterology Dove press submit your manuscript | www.dovepress.co m Dove press  395REviEwopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CEG.S4373 8The p53/microRNA connection   in gastrointestinal cancer Matjaz Rokavec Huihui Li Longchang Jiang Heiko Hermeking Experimental and Molecular  Pathology, institute of Pathology,   Ludwig-Maximilians-Universität  München, Munich, Germany Correspondence: Heiko Hermeking   Experimental and Molecular Pathology,   institute of Pathology,   Ludwig-Maximilians-University Munich,   Thalkirchner Strasse 36,   D-80337 Munich, Germany   Tel +49 89 2180 73 685   Fax +49 89 2180 73 697   Email heiko.hermeking@med.uni- muenchen.d eAbstract:  The protein encoded by the TP53  gene is one of the most important suppressors of  tumor formation, which is also frequently inactivated in gastrointestinal cancer.",Non-OADS,/arxiv_data1/oa_pdf/e8/49/ceg-7-395.PMC4198153.pdf
Available from: http://www.mirnarx.com /.,Non-OADS,/arxiv_data1/oa_pdf/e8/49/ceg-7-395.PMC4198153.pdf
"Clinical and Experimental Gastroenterology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-and-experimental-gastroenterology-journa lClinical and Experimental Gastroenterology is an international, peer- reviewed, open access journal, publishing all aspects of gastroenterology  in the clinic and laboratory, including: Pathology, pathophysiology  of gastrointestinal disease; Investigation and treatment of gastointes - tinal disease; Pharmacology of drugs used in the alimentary tract; Immunology/genetics/genomics related to gastrointestinal disease.",Non-OADS,/arxiv_data1/oa_pdf/e8/49/ceg-7-395.PMC4198153.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/e8/49/ceg-7-395.PMC4198153.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/09/37/cmar-6-397.PMC4198276.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pCancer Management and Research 2014:6 397–404Cancer Management and Research Dove press submit your manuscript | www.dovepress.co m Dove press  397Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CMAR.S3734 5Targeting the MeT receptor tyrosine kinase   in non-small cell lung cancer: emerging role   of tivantinib eberechi S Agwa Patrick C Ma Translational Hematology and  Oncology Research, Taussig Cancer  institute, Cleveland Clinic, Cleveland,   OH, USA Correspondence: Patrick C Ma   Translational Hematology and Oncology  Research, Taussig Cancer institute,  Cleveland Clinic, Cleveland,   OH 44195, USA   Tel +1 216 445 5545   Fax +1 216 636 2498   email map@ccf.or gAbstract:  MET receptor tyrosine kinase and its natural ligand, hepatocyte growth factor,  have been implicated in a variety of cancers, including non-small cell lung cancer (NSCLC).",Non-OADS,/arxiv_data1/oa_pdf/09/37/cmar-6-397.PMC4198276.pdf
Available from:  http://clinicaltrials.gov/ct2/show/NCT0107504 8.,Non-OADS,/arxiv_data1/oa_pdf/09/37/cmar-6-397.PMC4198276.pdf
Available from: http://files.shareholder.com/downloads/ ARQL/0x0x603004/d4d3b6d2-4ce1-467f-979b-43f4c2613e01 /.,Non-OADS,/arxiv_data1/oa_pdf/09/37/cmar-6-397.PMC4198276.pdf
Available from: http://www.marketwatch.com/story/10-q-arqule- inc-2013-05-0 8.,Non-OADS,/arxiv_data1/oa_pdf/09/37/cmar-6-397.PMC4198276.pdf
"Cancer Management and Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/cancer-management-and-research-journa lCancer Management and Research is an international, peer-reviewed  open access journal focusing on cancer research and the optimal use of  preventative and integrated treatment interventions to achieve improved  outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/09/37/cmar-6-397.PMC4198276.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/09/37/cmar-6-397.PMC4198276.pdf
"Available from: http://www.esmo.org/ Oncology-News/A-Phase-III-Study-of-Tivantinib-Plus-Erlotinib-Did- Not-Meet-a-Primary-Endpoint-in-Patients-with-Locally-advanced-or- Metastatic-Non-squamous-NSCL C. Accessed April 17, 2014.",Non-OADS,/arxiv_data1/oa_pdf/09/37/cmar-6-397.PMC4198276.pdf
Available from: http://clinicaltrials.gov/ct2/show/ NCT0137737 6.,Non-OADS,/arxiv_data1/oa_pdf/09/37/cmar-6-397.PMC4198276.pdf
"http://www.kyowa-kirin.com/news_releases/2012/pdf/ e20120830_01.pd f. Accessed April 17, 2014.",Non-OADS,/arxiv_data1/oa_pdf/09/37/cmar-6-397.PMC4198276.pdf
Available from: http://clinicaltrials.gov/ct2/show/NCT 01580735?term =Tivantinib +and+lung+cancer&rank =6.,Non-OADS,/arxiv_data1/oa_pdf/09/37/cmar-6-397.PMC4198276.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/07/47/cia-9-1661.PMC4198277.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2014:9 1661–1667Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  1661OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/CIA.S6760 2eiji Kondo1,2 Osamu Jinnouchi3 hiroki Ohnishi3  Ikuji Kawata3 seiichi nakano2 Masakazu goda1 Y oshiaki Kitamura1 Koji Abe1 hiroshi hoshikawa4 hidehiko Okamoto5  noriaki Takeda1 1Department of Otolaryngology,   University of Tokushima school  of Medicine, T okushima, Japan;   2Department of Otolaryngology,   Kochi national hospital, Kochi, Japan;   3Department of Otolaryngology,   Anan Kyoei hospital, Anan, Japan;   4Department of Otolaryngology,   Kagawa University school of Medicine,   Kagawa, Japan; 5Department of  sensori-Motor Integration, national  Institute for Physiological sciences,   Okazaki, Japan Correspondence: noriaki Takeda   Department of Otolaryngology,  University of Tokushima school   of Medicine, 3-18-15 Kuramoto,  Tokushima 770-8503, Japan   Tel +81 88 633 7169   Fax +81 88 633 7170   email takeda@tokushima-u.ac.j p Objective:  In the present study, an attempt was made to examine the effects of aural  stimulation  with ointment containing capsaicin on swallowing function in order to develop a novel and safe  treatment for non-obstructive dysphagia in elderly patients.",Non-OADS,/arxiv_data1/oa_pdf/07/47/cia-9-1661.PMC4198277.pdf
"Among neurological diseases or com - plications, stroke and dementia reflect high rates of both dysphagia and pneumonia.4 effects of aural stimulation with capsaicin  ointment on swallowing function in elderly  patients with non-obstructive dysphagiaJournal name: Clinical Interventions in Aging Journal Designation: Original Research Y ear: 2014 Volume: 9 Running head verso: Kondo et al Running head recto: Effects of aural capsaicin stimulation on swallowing function DOI: http://dx.doi.org/10.2147/CIA.S67602",Non-OADS,/arxiv_data1/oa_pdf/07/47/cia-9-1661.PMC4198277.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lDove pres s Clinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/07/47/cia-9-1661.PMC4198277.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/07/47/cia-9-1661.PMC4198277.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c2/80/copd-9-1069.PMC4198322.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of COPD 2014:9 1069–1079International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1069RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/COPD.S6801 1The effects of high intensity exercise during  pulmonary rehabilitation on ventilatory  parameters in people with moderate   to severe s table COPD: a systematic review Kristin Osterling1 Kimbly MacFadyen1 Robert Gilbert2 Gail Dechman1 1School of Physiotherapy, 2School of  Health Sciences, Dalhousie University,   Halifax, NS, Canada Correspondence: Kristin Osterling   4th Floor, Forrest Building, 5869  University Avenue, Halifax,   NS, B3H 4R2, Canada   Tel +1 902 494 2524   Fax +1 902 494 1941   email kristin.osterling@dal.c aObjective:  The objective of this systematic review was to determine whether people with  moderate to severe COPD who are participating in pulmonary rehabilitation and exercising  at high intensity demonstrate the changes in ventilatory parameters that are associated with  decreased dyspnea.",Non-OADS,/arxiv_data1/oa_pdf/c2/80/copd-9-1069.PMC4198322.pdf
"This systematic review was regis - tered during the preliminary search stage with PROSPERO  (CRD42014007117) on January 14, 2014 at http://www.crd.",OADS,/arxiv_data1/oa_pdf/c2/80/copd-9-1069.PMC4198322.pdf
Clinical Trials  Registry ( https://clinicaltrials.go v) was accessed to search for  any abstracts of newly completed or upcoming research stud - ies.,OADS,/arxiv_data1/oa_pdf/c2/80/copd-9-1069.PMC4198322.pdf
"Available from:  http://www.cochrane-handbook.or g. Accessed January 1, 2014.",OADS,/arxiv_data1/oa_pdf/c2/80/copd-9-1069.PMC4198322.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-copd-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/c2/80/copd-9-1069.PMC4198322.pdf
